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Background
Methyleugenol (Figure 1) is an alkenylbenzene that occurs naturally in various herbs such
as tarragon, basil, nutmeg and allspice (Smith et al., 2002). Methyleugenol is added to food
either directly as a flavoring substance or as a constituent of added essential oils (Smith et al.,
2002). Methyleugenol also occurs at low levels in oranges, bananas, and grapefruit juices
(Nijssen et al., 2008). The interest in the risk of methyleugenol as a food constituent came from
its widespread use in a variety of foods and beverages as well as its structural resemblance to
the known carcinogen safrole (Johnson et al., 2000). In addition, methyleugenol has been
reported to be DNA reactive and carcinogenic, inducing malignant tumors in multiple tissues of
rats and mice as well as inducing unscheduled DNA synthesis in rat liver (Ding et al., 201;
NTP, 2000; Smith et al., 2002). The safety of human exposure to methyleugenol at low dietary
intake levels has been assessed several times. In 1965, the Expert Panel of the Flavor and
Extract Manufacturers Association (FEMA) concluded that methyleugenol was GRAS
(Generally Recognized As Safe) under conditions of intended use as a flavoring substance in
food (Hall and Oser, 1965). In the FEMA evaluation, it was taken into account that there are
experimental data suggesting a non-linear relationship between dose and profiles of metabolism
and metabolic activation and that exposure due to use as a flavoring is relatively low (Smith et
al., 2002). In 2000, the carcinogenicity of methyleugenol was investigated in mice and rats by
the National Toxicology Program (NTP) (NTP, 2000). The NTP reported that methyleugenol is
Figure 1. Structure of methyleugenol
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carcinogenic in both rats and mice (NTP, 2000). In 2001, the FEMA Expert Panel reassessed
the available data for methyleugenol and confirmed that there is no considerable cancer risk
resulting from consumption of methyleugenol as flavoring substance and affirmed the GRAS
status of methyleugenol at the use levels as a flavoring substance (Smith et al., 2002). In 2001,
the Scientific Committee on Food (SCF) of the European Union published a scientific opinion
on methyleugenol in which it was concluded that methyleugenol is genotoxic and carcinogenic
and that reductions in exposure and restrictions in use levels are indicated (SCF, 2001). Based
on these findings, the use of methyleugenol as pure substance in foodstuffs has been prohibited
since September 2008 within the European Union (European Commission, 2008). A recent
evaluation, performed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA)
in 2008, has indicated that although evidence of carcinogenicity to rodents given high doses of
methyleugenol exists, further research is needed to assess the potential risk to human health at
relevant dietary exposure resulting from the presence of methyleugenol in foods and essential
oils and its use as flavoring agent (JECFA, 2008). The occurrence of these different expert
opinions in risk assessment of methyleugenol originates in part from the absence of scientific
agreement to support the unequivocal translation of carcinogenicity data of rodent animal
experiments obtained at high levels of exposure to the relevant human situation. Predicting the
cancer risk in humans at relevant dietary intake levels requires extrapolation of the animal
carcinogenicity data taking in consideration species, dose and interindividual variation.
Furthermore, it implies extrapolation from rat or mouse studies with high dose levels of the
pure compound to the human situation in which exposure at low dose levels occurs within the
context of a complex food matrix.
The aim of the present PhD project was to obtain quantitative insight into the consequences
of dose- and species-dependent effects and of interindividual differences and matrix effects for
the bioactivation and detoxification of methyleugenol by using physiologically based kinetic
(PBK) modeling.
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Chemical and physical properties of methyleugenol
Methyleugenol (4-allyl-1,2-dimethoxybenzene) has a molecular weight of 178.2 g/mol
(NTP, 2000). It is a colorless to pale yellow, oily liquid with a clove-carnation odor and a bitter
taste. It is soluble in most organic solvents like ethanol, ethyl ether, and chloroform (NTP,
2000). On the other hand, it is insoluble in water, glycol, and propylene glycol (NTP, 2000).
Methyleugenol evaporates readily at room temperature and darkens and thickens slowly when
exposed to air (Lide, 1998; Sax′s, 1992). Methyleugenol has a boiling point of 254.7 °C, a
melting point of – 4 °C, a refractive index of 1.532, and a density of 1.0396 at 20 °C (NTP,
2000).
Production, use, and human exposure to methyleugenol
Methyleugenol can be produced by methylation of eugenol (Opdyke, 1979) or by extraction
from natural sources. The annual production volume of methyleugenol in the USA is 77 kg/year
(Gavin et al., 2007). Methyleugenol is a naturally occurring constituent of the essential oils of a
number of plants (De Vincenzi et al., 2000). It is present, for instance, in the essential oils from
basil, pay, tea tree, citronella (Environment Canada, 2010), anise, nutmeg, mace, cinnamon
leaves (Fenaroli′s, 1975), pixuri seeds (Carlini et al., 1983), and laurel fruits and leaves (Farm
Chemical Handbook, 1992). Methyleugenol has also been detected in blackberry essence,
bananas, black pepper, and bilberries (WHO, 1981).  Human exposure to methyleugenol may
occur through the consumption of foods flavored with these aromatic plants and/or their
essential oil fractions. Methyleugenol is (or has been) used as a flavoring agent in jellies, baked
goods, nonalcoholic beverages, chewing gum, candy, pudding, relish, and ice cream (NTP,
2000). Some specified groups characterized by eating fresh pesto are exposed to high levels of
methyleugenol because fresh pesto is prepared from a large quantity of fresh sweet basil (Miele
et al., 2001). In addition some plant-based food supplements were recently shown to contain
relatively high levels of methyleugenol (van den Berg et al., 2011). Methyleugenol is also used
as a fragrance in perfumes (0.3% to 0.8%), creams and lotions (0.01% to 0.05%), soaps and
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detergents (0.02% to 0.2%) (Opdyke, 1979). One of the uses for methyleugenol is as an insect
repellant (Environment Canada, 2010). In 1982, methyleugenol was used in combination with
malathion to control an outbreak of oriental fruit flies in California (Hays and Laws, 1991).
Methyleugenol has also been used as an anesthetic in rodents (Carlini et al., 1981). The average
daily human intake of methyleugenol has been estimated by the SCF to be 13 mg/day,
corresponding to 0.217 mg/(kg bw)/day for a 60 kg person (SCF, 2001), while the FEMA
estimated the average daily intake of methyleugenol to be less than 0.01 mg/(kg bw)/day (Smith
et al., 2002). The estimation of the SCF was based on theoretical maximum use levels of
methyleugenol in various food categories and consumption data for these food categories,
whereas the intake estimation of the FEMA was based on production volume data for flavor use
(SCF, 2001; Smith et al., 2002).
Carcinogenicity of methyleugenol
The carcinogenicity of methyleugenol was demonstrated by Miller et al. (1983). In this
study male B6C3F1 mice were exposed to methyleugenol prior to weaning via intraperitoneal
injection. Each mouse was given 4.75 µmol methyleugenol. The outcomes of this study
revealed formation of liver tumors which means that methyleugenol was carcinogenic. In
another two-year carcinogenicity study (Johnson et al., 2000; NTP, 2000), male and female
F344/N rats and B6C3F1 mice were given by gavage methyleugenol doses of 37, 75, or 150
mg/(kg bw)/day suspended in 0.5% methylcellulose. In rats, methyleugenol induce liver
neoplasms including hepatoadenoma, hepatocarcinoma and hepatocholangioma (both sexes).
Also methyleugenol was observed to cause benign and malignant neuroendocrine tumors,
neuroendocrine cell hyperplasia, and atrophy of the glandular stomach (both sexes).
Furthermore, renal tubule hyperplasia, nephropathy and adenomacarcinoma were noticed in the
kidney of male rats. Moreover, fibroadenoma in the mammary gland, fibroma and fibrosarcoma
in subcutaneous tissue, malignant mesotheliomas and splenic fibrosis were observed in male
rats. Squamous cell papilloma or carcinoma (combined) were noticed in the forestomach of
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female rats. In mice, methyleugenol induce liver neoplasms including hepatoblastoma in both
sexes and neuroendocrine tumors of the glandular stomach in male. Based on the above
mentioned findings, it was concluded that methyleugenol is a multisite, multispecies carcinogen
and majorly exerts its effect in the liver as demonstrated in all exposed groups (NTP, 2000).
Genotoxicity of methyleugenol
Methyleugenol has been found to induce chromosomal recombination in yeast
(Saccharomyces cerevisiae) (Brennan et al., 1996; Schiestl et al., 1989) and cell transformation
in Syrian hamster embryo cells (Kerckaert et al., 1996; NTP, 2002). On the other hand, the
results of most standard in vitro genotoxicity assays including the Ames test indicated that
methyleugenol was not mutagenic (Brennan et al., 1996; Ding et al., 2011). In spite of this,
methyleugenol forms DNA adducts and induces unscheduled DNA synthesis in rat liver after in
vivo exposure (Ding et al., 2011). Furthermore, methyleugenol induced DNA adducts in
cultured human HepG2 hepatoma cells (Zhou et al., 2007). Moreover, methyleugenol caused
unscheduled DNA synthesis in primary hepatocytes obtained from mice and rats (Burkey et al.,
2000; Chan and Caldwell, 1992; Howes et al., 1990). The unscheduled DNA synthesis due to
exposure to methyleugenol required sulfotransferase mediated metabolite formation (Burkey et
al., 2000).
Pharmacokinetics of methyleugenol
Methyleugenol is rapidly absorbed, metabolized, and excreted after oral administration
(Johnson et al., 2000; Schecter et al., 2004). It was reported that the time for methyleugenol to
achieve the maximum concentrations in blood in rat and mice after dosing by oral gavage (37
mg/(kg bw) up to 300 mg/(kg bw)) was 5-15 min (Johnson et al., 2000). Also in a study where
nine volunteers were exposed to about 216 mg methyleugenol per volunteer via consumption of
ginger snap cookies (3.16 mg/g), the plasma peak concentration was reached quickly at 15 min
after exposure and the estimated  half-life of elimination was about 90 min (Schecter et al.,
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2004). Because the maximum blood concentration was achieved so quickly and long before the
stomach could have emptied, this might give an indication that methyleugenol may be absorbed
directly from the stomach and/or forestomach (Johnson et al., 2000).
The important metabolic pathways of methyleugenol include O-demethylation of the
methoxy moieties on the benzene ring, 2′,3′-epoxidation and 1′-hydroxylation of the allylic side
chain (Figure 2) (NTP, 2000; Solheim and Scheline, 1976). O-demethylation of the meta or
para methoxy substituents of methyleugenol yields the corresponding phenolic derivatives,
which may be excreted as sulfate or glucuronic acid conjugate (Smith et al., 2002). Epoxidation
of the side chain yields a 2′,3′-epoxide. This epoxide is detoxified by epoxide hydrolase to form
the dihydrodiol or via glutathione conjugation (Luo and Guenther, 1995). Hydroxylation at the
1'-position of methyleugenol is considered to represent the bioactivation pathway producing the
proximate carcinogenic metabolite 1′-hydroxymethyleugenol (Drinkwater et al., 1976; Miller et
al., 1983). In a next step 1′-hydroxymethyleugenol can be sulfonated by sulfotransferases to
form the ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol (Miller et al., 1983).
Incubations with microsomes from 13 human liver samples showed 37-fold difference in 1′-
hydroxylation of methyleugenol (Gardner et al., 1997). These results suggest that the risk to
humans ingesting methyleugenol is subject to marked interindividual variability. Incubations of
methyleugenol either with recombinant individual human cytochromes P450 or microsomes
from pooled human livers indicated that P450 1A2, 2A6, 2C9, 2C19, and 2D6 are able to
bioactivate methyleugenol to the proximate metabolite 1′-hydroxymethyleugenol (Jeurissen et
al., 2006). Based on the data reported by Jeurissen et al. (2006), P450 1A2 was shown to be the
most important enzyme involved in the bioactivation of methyleugenol to its proximate
carcinogenic metabolite 1′-hydroxymethyleugenol. Furthermore, kinetic results revealed a 5-
fold difference in the catalytic activities for 1′-hydroxylation of methyleugenol of microsomes
obtained from 15 human livers (Jeurissen et al., 2006). Recently, studies using Salmonella
typhimurium TA100 strains with expression of human SULT revealed that SULT1A1 and
SULT1E1 are the main liver sulfotransferase enzymes involved in activation of 1′-
hydroxymethyleugenol to DNA reactive metabolites (Herrmann et al., 2012).
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Figure 2. Suggested metabolic pathways of methyleugenol.
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In addition to conversion of 1′-hydroxymethyleugenol to its DNA reactive 1′-
sulfooxymethyleugenol metabolite other pathways facilitate detoxification of 1′-
hydroxymethyleugenol. These include glucuronidation by UDP-glucuronosyltransferases
(UGTs) and oxidation to 1′-oxomethyleugenol which may be chemically regenerating 1′ -
hydroxymethyleugenol, but may rather be efficiently detoxified by glutathione conjugation
(Phillips et al., 1981).
Approaches of cancer risk assessment
Since the occurrence of methyleugenol in botanical and botanical preparations present in
food cannot readily be eliminated or avoided, estimation of the cancer risk at low dose levels
will be necessary to indicate whether the presence of low concentrations of methyleugenol in
the daily regular diet is of concern from a public health point of view. International agreement
on how to evaluate the potential risk of genotoxic carcinogens that naturally occur in food is
absent. Many different scenarios were suggested for the risk assessment of chemicals that are
both genotoxic and carcinogenic. When the carcinogenicity is caused by a genotoxic
mechanism, it is assumed that there is no obvious threshold and any level of exposure carries
some degree of carcinogenic risk (COC, 2004). This approach, however, only identifies the
hazard and does not give a quantitative estimate of the cancer risk at intake levels relevant for
dietary human exposure (Dybing et al., 2008). EFSA reported that there are different
approaches that are currently available for assessing the risk of substances that are both
genotoxic and carcinogenic (EFSA, 2005). One of these approaches is linear extrapolation of
animal carcinogenicity data obtained at high dose levels to low dose levels which are relevant to
human intake. This approach requires definition of a point of departure to be derived from the
animal data at high dose levels from which the extrapolation can be performed to zero risk at
zero dose level. The point of departure may be the T25 which is the dose that increases the
tumor incidence by 25% (Barlow et al., 2006; Dybing et al., 2008). It may also be the so-called
Benchmark Dose 10 (BMD10) (the Benchmark Dose that gives a 10% extra cancer incidence) or
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its lower confidence bound (BMDL10) determined using the Benchmark Dose approach (BMD)
(EFSA, 2005; EPA, 2005). The BMD approach provides a useful tool for deriving a point of
departure within the observable dose range by fitting a curve to the dose-response data from an
animal bioassay and using this curve fit to estimate the intake level that corresponds to a fixed
tumor incidence. The simplest way to estimate the risk associated with the average dietary
human intake is to apply linear extrapolation from the BMD10 or T25 as the point of departure
to zero dose at zero risk. Based on this extrapolation a so-called virtual safe dose (VSD) can be
derived, corresponding to the dose that results in an additional cancer risk of one in a million
upon lifetime exposure, which is generally considered an acceptable risk by risk managers
(Rietjens et al., 2010). Extrapolating from animal tumor data at high doses using mathematical
modeling in order to obtain estimates of the risk to humans at low exposures has been much
debated, since it is not known whether or not the model chosen actually reflects the underlying
biological processes. In addition, numerical estimates may be misused or misinterpreted in
further risk management and risk communication if the uncertainties and inaccuracy connected
to the model may not be communicated (EFSA, 2005). Recently, EFSA considered the Margin
of Exposure (MOE) approach as a useful and pragmatic option for risk assessment of
substances that are both genotoxic and carcinogenic (EFSA, 2005).The MOE represents the
proportion between a reference point acquired from the dose–response data obtained from
experimental or epidemiological studies (BMDL10) and the human estimated daily intake (EDI).
In this approach there is no extrapolation or generation of possibly uncertain risk estimates
since it takes account of intake/exposure and the available data on the dose–response
relationship are used (EFSA, 2005). The magnitude of the MOE does not indicate a safe dose of
a chemical but indicates whether the estimated daily intake is (or is not) close to dose levels
actually causing increased tumor incidences in animal bioassays so that risk management
actions might (not) be required (Dybing et al., 2008). EFSA considered that, when the MOE is
higher than 10,000, the compound is considered to be of low priority for risk management
actions (EFSA, 2005). This margin of 10,000 takes into consideration the various uncertainties
in the MOE approach, such as interspecies differences and human variability in biokinetics and
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biodynamics, the shape of the dose-response curve below the experimental data, and human
interindividual variability in cell cycle control and DNA repair (Barlow et al., 2006; Dybing et
al., 2008; EFSA, 2005).
As outlined above, the MOE approach has been defined because the classical risk
assessment approaches used for assessing the risk of chemicals that are both genotoxic and
carcinogenic, like the linear extrapolation of cancer incidences, have problems when cancer
data obtained in animal bioassays are extrapolated to dose levels and cancer incidences orders
of magnitude below the experimental data obtained in animal bioassays, in order to model the
human situation. The presence of uncertainties in the shape of the dose-response curve at dose
levels relevant for dietary human intake, interspecies variations in metabolism and metabolic
activation and the great interindividual variability within the human population, as compared to
the variability in the inbred strains used for the rodent bioassays, make it difficult to perform
such extrapolations. Physiologically based kinetic (PBK) modeling can provide a method to
obtain a better mechanistic basis for extrapolations from data obtained in experimental animal
studies to the human situation (Andersen and Krishnan 1994; Clewell et al., 2001; Clewell et
al., 2002).
PBK models
The structure of the PBK model depends primarily on the aims for which the model is
developed and on the available data. The PBK models consist of many compartments which
represent the tissues of interest. Each compartment has its own physiological (e.g. blood flows),
physicochemical (e.g. partition coefficients) and biochemical (e.g. metabolic rates) parameters.
Target tissues are generally represented as individual compartment (e.g. liver, lung, or kidney)
while some non-target tissues are lumped together in one compartment (e.g. slowly perfused
tissues such as muscle and skin or richly perfused tissues such as brain and spleen). Depending
upon the available data, PBK models should include the target organ as a separate
compartment. The PBK model consists of mathematical equations for each relevant
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compartment describing absorption, distribution, metabolism and excretion (ADME) of the
chemical and/or its metabolites in that respective organ of interest. In this way PBK models
quantitatively describe actual physiological processes within the relevant tissues of the body
(Krishnan and Andersen, 2001). Solution of the PBK equations results in outcomes that are an
indication of, for example, the tissue concentration of a compound or its metabolite in any
tissue over time at a certain dose, allowing analyses of effects at both high but also more
realistic low dose levels (Rietjens et al., 2011). Furthermore, such PBK models can be
developed for different species, which facilitates interspecies extrapolation. In addition, by
incorporating equations and kinetic constants for metabolic conversions by individual human
samples and/or specific isoenzymes, modeling of interindividual variations and genetic
polymorphisms becomes feasible (Bogaards et al., 2000).
In cancer risk assessment strategies, PBK models can predict internal dose levels for
exposure regimens that have not been directly measured, by converting external exposure
values to an internal dose metric (e.g. the predicted plasma or tissue levels of a parent
compound or its reactive metabolites) in animal bioassays, as well as in human exposure
scenarios (Andersen and Krishnan, 1994). Such an internal dose metric is considered to be more
closely related to the toxic response than the applied external doses. Extrapolation of the cancer
risk from high to low doses and from animals to humans can be performed based on the internal
dose metrics rather than the applied external doses (Andersen and Krishnan, 1994).
Developing a PBK model
For the development of a PBK model for a specific compound, model parameters need to be
obtained. The physiological parameters included in the developed PBK models should
correspond to acceptable values for the specific species. The reference values of physiological
parameters (e.g. blood flow rates and tissue volumes) for adult animals and humans are
available in literature (Brown et al., 1997; Chiu et al., 2007 and references therein). Tissue-
blood partition coefficients can be used to model the steady state concentration of a chemical in
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the specific tissue compared with blood. Several methods were mentioned in the literature for
obtaining tissue-blood partition coefficients (Chiu et al., 2007). Tissue-blood partition
coefficients for nonvolatile chemicals might be obtained in vitro using radioactive chemicals in
ultrafiltration, equilibrium dialysis or vial equilibration procedures (Chiu et al., 2007 and
references therein) and can be obtained using in silico methods based on the octanol water
partition coefficients as well. Biochemical parameters required for PBK models, including
absorption rate and metabolic parameters, can be determined by fitting a model to data from in
vivo studies (Chiu et al., 2007). Alternatively, metabolic parameters might also be derived from
in vitro experiments with tissue fractions, primary cell cultures, or tissue slices of organs
involved in the metabolism of the compound. Some advantages of using in vitro metabolic
parameters to define PBK models, include the ability to separately define and analyze
individual metabolic processes, such as phase I metabolism and phase II metabolism, or
bioactivation and detoxification, and to compare contributions from individual conversions to
the overall metabolism across species and between individuals, when limited in vivo data are
available as is often the case for humans (Lipscomb and Poet, 2008).
Objective and outline of this thesis
The aim of the present PhD project was to build physiologically based kinetic (PBK)
models for methyleugenol for both rats and (individual) human subjects in order to obtain a
quantitative insight into dose-dependent effects, species differences, and interindividual
differences in bioactivation and detoxification of methyleugenol. For the development of these
models, metabolic parameters were determined in vitro using relevant tissue fractions. The
physiological parameters were obtained from the literature (Brown et al., 1997) and partition
coefficients were estimated from the octanol-water partition coefficient based on an in silico
method (DeJongh et al., 1997). The present chapter of this thesis presents an introduction to the
bioactivation, detoxification, genotoxicity and carcinogenicity of methyleugenol as well as a
short introduction to PBK modeling and the aim and content of the present thesis are given.
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Chapter 2 defines a PBK model for methyleugenol metabolism in male rat, elucidating dose-
dependent effects in bioactivation and detoxification of methyleugenol. In Chapter 3 a PBK
model for methyleugenol bioactivation and detoxification in human is defined of which the
outcomes were compared to those predicted by the PBK model for methyleugenol in male rat,
described in Chapter 2. Comparison of the two models allows evaluation of the occurrence of
species differences in metabolic activation and detoxification of methyleugenol. Whereas the
PBK model for methyleugenol metabolism in human describes the relative extent of
bioactivation in an average situation, interindividual differences can occur within the whole
population. The activity levels of the enzymes involved in these reactions can vary in the
human population due to genotype and lifestyle-based factors, which could influence the level
of bioactivation of methyleugenol between different human subjects to a level that is higher
than what would be observed in animal studies with inbred rodent strains. In Chapter 4, the
influence of possible effects of the dietary matrix and its ingredients on detoxification and
bioactivation of methyleugenol is investigated in some more detail. To this end the effects of
the basil flavonoid nevadensin (Figure 3) on the SULT mediated bioactivation and DNA adduct
formation of 1′-hydroxymethyleugenol is investigated by measuring the formation of
methyleugenol-DNA adducts in the human HepG2 cell line. In order to investigate possible in
vivo implications, the SULT inhibition by nevadensin is also integrated into the male rat and
human PBK models for bioactivation and detoxification of methyleugenol. Chapter 5 defines a
PBK model for methyleugenol metabolism in individual human subjects using individual
kinetic data for 1'-hydroxylation, epoxidation, and O-demethylation determined based on the
kinetic constants for individual P450 enzymes, using individual kinetic data for glucuronidation
of 1'-hydroxymethyleugenol based on kinetic constants for individual UGT enzyme, and using
kinetic data for oxidation and sulfonation based on kinetic constants for individual human liver
fractions. Based on the models obtained, the interindividual variation in the liver levels of 1'-
sulfooxymethyleugenol due to variation in these metabolic reactions can be evaluated. In a
second step, the individual models are combined with literature data on interindividual variation
in activity levels of the key enzymes involved in formation, detoxification, and bioactivation of
CHAPTER 1
21
1'-hydroxymethyleugenol, to model the maximum level of variability in the general population.
Chapter 6 presents a discussion of the results obtained in this thesis indicating on how these
results can be used in the risk assessment of methyleugenol. Finally, chapter 7 presents a
summary of the results of this study.
Figure 3. Structural formula of nevadensin
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Abstract
The present study defines a physiologically based kinetic (PBK) model for the
alkenylbenzene methyleugenol in rat based on in vitro metabolic parameters determined using
relevant tissue fractions, in silico derived partition coefficients, and physiological parameters
derived from the literature. The model was based on the model previously developed for the
related alkenylbenzene estragole and consists of eight compartments including liver, lung, and
kidney as metabolizing compartments, and separate compartments for fat, arterial blood, venous
blood, richly perfused and slowly perfused tissues. Evaluation of the model was performed by
comparing the PBK predicted concentration of methyleugenol in the venous compartment to
methyleugenol plasma levels reported in the literature, by comparing the PBK predicted dose-
dependent % of formation of 2-hydroxy-4,5-dimethoxyallylbenzene, 3-hydroxy-4-methoxy-
allylbenzene, and 1′-hydroxymethyleugenol glucuronide to the corresponding % of metabolites
excreted in urine reported in the literature, which were demonstrated to be in the same order of
magnitude. With the model obtained, the relative extent of bioactivation and detoxification of
methyleugenol at different oral doses was examined. At low doses, formation of 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol and methyleugenol-2′,3′-oxide leading to detoxification
appears to be the major metabolic pathways, occurring in the liver. At high doses, the model
reveals a relative increase in the formation of the proximate carcinogenic metabolite 1′-
hydroxymethyleugenol, occurring in the liver. This relative increase in formation of 1′-
hydroxymethyleugenol leads to a relative increase in formation of 1′-hydroxymethyleugenol
glucuronide, 1′-oxomethyleugenol, and 1′-sulfooxymethyleugenol the latter being the ultimate
carcinogenic metabolite of methyleugenol. These results indicate that the relative importance of
different metabolic pathways of methyleugenol may vary in a dose-dependent way, leading to a
relative increase in bioactiviation of methyleugenol at higher doses.
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Introduction
Methyleugenol is a naturally occurring constituent of the essential oils of a number of plants
(De Vincenzi et al., 2000). It is present in, for instance, basil, nutmeg, tarragon, star anise,
lemongrass, pimento and fennel (SCF, 2001). Human exposure to methyleugenol may occur
through the consumption of foods flavored with these aromatic plants and/or their essential oil
fractions. Miller et al. (1983) dosed mice with 4.75 µmol (846 µg) of methyleugenol
administered by intraperitoneal injections from 1 to 22 days after birth. Hepatic tumors were
found in 70% and 96% of the mice sacrificed after 13 months and between 13 and 18 months,
respectively. Moreover, methyleugenol was found to cause hepatocholangiomas and
hepatocholangiocarcinomas in male and female rats when administered daily at oral dose levels
higher than and including 150 mg/(kg bw)/day, five days per week for two years (NTP, 2000).
In 1965, the panel of the Flavor and Extract Manufacturers Association (FEMA) concluded that
methyleugenol was GRAS (Generally Recognized As Safe) under conditions of intended use as
a flavoring substance in food (Hall and Oser, 1965). In the FEMA evaluation it was taken into
account that there are experimental data suggesting a non-linear relationship between dose and
profiles of metabolism and metabolic activation and that exposure due to use as a flavoring is
relatively low (Smith et al., 2002). In 2000, the carcinogenicity of methyleugenol was
investigated in mice and rats by the National Toxicology Program (NTP) (NTP, 2000). The
NTP reported that methyleugenol is carcinogenic in both rats and mice (NTP, 2000). In 2001,
the FEMA Panel reassessed the available data for methyleugenol and confirmed that there is no
considerable cancer risk resulting from consumption of methyleugenol as flavoring substance
and affirmed the GRAS status of methyleugenol as a flavoring substance (Smith et al., 2002).
In 2001, the Scientific Committee on Food (SCF) of the European Union published a scientific
opinion on methyleugenol in which it was concluded that methyleugenol is genotoxic and
carcinogenic and that reductions in exposure and restrictions in use levels are indicated (SCF,
2001). Based on different methodologies the average daily intake of methyleugenol was
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estimated by the SCF to be 13 mg/day, corresponding to 0.217 mg/(kg bw)/day for a 60 kg
person (SCF, 2001), while the FEMA estimated the average daily intake of methyleugenol to be
less than 0.01 mg/(kg bw)/day (Smith et al., 2002). The estimation of the SCF is based on
theoretical maximum use levels of methyleugenol in various food categories and consumption
data for these food categories, whereas the intake estimation of the FEMA is based on
production volume data for flavor use (SCF, 2001; Smith et al., 2002).
Methyleugenol is unreactive by itself but undergoes metabolic activation to produce
electrophilic metabolites that act as the reactive genotoxic DNA binding intermediates (Gardner
et al., 1997; Miele et al., 2001). Figure 1 displays the different metabolic pathways of
methyleugenol. Important metabolic pathways include O-demethylation of the methoxy
moieties on the benzene ring, 2′,3′-epoxidation, and 1′-hydroxylation of the allylic side chain
(NTP, 2000; Solheim and Scheline, 1976). O-demethylation of the meta or para methoxy
substituents of methyleugenol yields the corresponding phenolic derivatives, which may be
excreted as sulfate or glucuronic acid conjugate (Smith et al., 2002). Epoxidation of the side
chain yields a 2′,3′-epoxide. This epoxide is detoxified by epoxide hydrolase to form the
dihydrodiol or via glutathione conjugation (Luo and Guenther, 1995). Hydroxylation at the 1'-
position of methyleugenol is considered to represent the bioactivation pathway producing the
proximate carcinogenic metabolite 1′-hydroxymethyleugenol (Drinkwater et al., 1976; Miller et
al., 1983). In a next step 1′-hydroxymethyleugenol can be sulfonated by sulfotransferases to
form the ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol (Miller et al., 1983).
In order to predict the degree of bioactivation and detoxification of methyleugenol at low
dose intake, it is important to take non-linear effects in kinetics into account when extrapolating
from high dose to low dose. The present study was undertaken to develop a physiologically
based kinetic (PBK) model which will be able to give insight in possible dose-dependent
differences and shifts in methyleugenol metabolism with emphasis on detoxification and
bioactivation pathways. Recently, physiologically based kinetic (PBK) models for the related
genotoxic and carcinogenic alkenylbenzene estragole were developed for male rat (Punt et al.,
2008) and human (Punt et al., 2009). These models were capable of elucidating dose dependent
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Figure 1. Suggested metabolic pathways of methyleugenol in male rat.
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differences in bioactivation and detoxification of estragole, based on in vitro metabolic
parameters. It can be expected that the PBK model thus developed for male rat (Punt et al.,
2008) can be used to develop a similar model for the related carcinogenic alkenylbenzenes
including methyleugenol, the model compound of the present study. The objectives of the
present study were to define the kinetics of relevant metabolic pathways of methyleugenol in
order to define a PBK model for methyleugenol in male rat and to investigate possible dose-
dependent shifts in detoxification and bioactivation of methyleugenol using the PBK model
thus obtained.
Materials and Methods
Chemical and reagents
Pooled liver, kidney, lung and small intestine microsomes from male Sprague Dawley rats
and pooled liver microsomes from female Sprague Dawley rats were purchased from BioPredic
International (Rennes, France). Pooled liver microsomes from male Fisher 344 and female
Fisher 344 rats were purchased from BD Gentest (Woburn, MA, USA). Dichloromethane, m-
chloroperbenzoic acid, potassium fluoride, potassium carbonate, hydrochloric acid (37%),
potassium dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, and acetic acid
were purchased from VWR Merck (Darmstadt, Germany). β-Glucuronidase and reduced β-
nicotinamide adenine dinucleotide phosphate (NADPH) were obtained from Roche Diagnostics
(Mannheim, Germany). Tris(hydroxymethyl) aminomethane was obtained from Gibco BRL
Life Technologies (Paisley, Scotland). Methyleugenol, eugenol, acetonitrile (chromatography
grade), methanol, dimethyl-sulfoxide (DMSO), ascorbic acid, glutathione (GSH), alamethicin,
and uridine 5′-diphosphoglucuronic acid (UDPGA) were purchased from Sigma-Aldrich
(Steinheim, Germany). 3′-Phosphoadenosine-5′-phosphosulfate (PAPS) was obtained from
Fluka (Buchs Switzerland).
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Synthesis of Phase I Metabolites
Caution: 1′-Acetoxymethyleugenol, 1′-hydroxymethyleugenol, 3-(3,4-dimethoxyphen-yl)-2-
propen-1-ol, methyleugenol-2′,3′-oxide, and 1′-oxomethyleugenol are carcinogenic and should
be handled carefully.
1′–Hydroxymethyleugenol was synthesized as described previously for 1′-hydroxysafrole
(Borchert et al., 1973; Jeurissen et al., 2004), using veratraldehyde as the starting material. Its
identity was confirmed by comparison of its MS spectral data to literature MS data (m/z 179,
161, 151, 139) (Solheim and Scheline, 1976). Based on GC and HPLC analysis the purity of 1'-
hydroxymethyleugenol was estimated to be more than 98 % (Jeurissen et al., 2006). 3-(3,4-
Dimethoxyphenyl)-2-propen-1-ol was synthesized, as described previously for 1′-
hydroxyestragole (Iyer et al., 2003), using 1′-acetoxymethyleugenol as the starting material.
The GC-MS analysis revealed that the method described resulted in formation of 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol instead of 1′-hydroxymethyleugenol. Structural confirmation
was obtained by comparison of its MS spectral data (m/z 176, 161, 151, 138) to those available
from literature (Solheim and Scheline, 1976). Based on HPLC analysis, the purity of 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol was about 98%. 1′-Acetoxymethyleugenol was synthesized
based on a method described by Iyer et al. (2003) for the synthesis of 1′-acetoxyestragole, using
methyleugenol as the starting material. The purity of 1′-acetoxymethyleugenol was determined
by HPLC as about 98%.
Methyleugenol-2′,3′-oxide was synthesized as described by Luo et al. (1992) using
methyleugenol instead of estragole. GC-MS analysis of the product confirmed the formation of
methyleugenol-2′,3′-oxide (m/z 194, 177, 165, 151, 138) (Solheim and Scheline, 1976). Further
confirmation for the formation of methyleugenol-2′,3′-oxide was obtained from monitoring the
hydrolysis of methyleugenol-2′,3′-oxide in incubations with male rat liver microsomes resulting
in formation of 3-(3,4-dimethoxyphenyl)propane-1,2-diol.
3-(3,4-Dimethoxyphenyl)propane-1,2-diol was synthesized as described in the literature
(Solheim and Scheline, 1976) and its formation was confirmed by comparing its retention time
and  UV spectra to those of the compound obtained from incubation of methyleugenol-2′,3′-
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oxide with male rat liver microsomes.
Synthesis of 3-hydroxy-4-methoxyallylbenzene was performed according to the method
described in the literature (Solheim and Scheline, 1976). Its identity was confirmed by
comparing its MS spectral data (m/z 149, 137, 131, 121) to MS data from literature (Solheim
and Scheline, 1976).
No reference compound was available for 2-hydroxy-4,5-dimethoxyallylbenzene. Its
formation in the incubation mixture of methyleugenol with rat liver microsomes was confirmed
comparing its MS spectral data (m/z 176, 151, 123, 107) to MS data from literature (Solheim
and Scheline, 1976).
GC-MS analysis
GC-MS analysis was performed to identify the phase I metabolites of methyleugenol
formed during the microsomal incubations. An incubation mixture of methyleugenol was
extracted with CH2Cl2. The organic layer was transferred into a new vial and the solution was
concentrated under a stream of nitrogen. Aliquots (2 µL) of the sample were injected on a
HP6890 gas chromatograph, equipped with a J&W MS-5 column (30 m x 0.25 mm, 0.25 µm
film) and an HP5973 mass selective detector. The GC was programmed for a 47 min run with a
temperature gradient from 50 to 250 °C at 5 °C /min. The inlet temperature was 260 °C, the
split ratio was 15:1 and the pressure of the helium carrier gas was 12.0 psi. The mass
spectrometer was run in the electron impact mode with electron energy at 70 eV with a mass
range of m/z 30 – 550 and a source temperature of 280 °C (Jeurissen et al., 2006).
Phase I Metabolism
Determination of the organs which are involved in the metabolism of methyleugenol was
performed as described by Punt et al. (2008) for estragole. The microsomal preparations of the
liver, lung, kidney, and small intestine from male Sprague Dawley rats were incubated with
methyleugenol in the presence of NADPH, and the formation of the metabolites was monitored
over time. The incubation mixtures had a final volume of 160 μL, containing (final
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concentrations) 3 mM NADPH, 1 mM ascorbic acid and 1 mg/mL microsomal protein in 0.2 M
Tris-HCl (pH 7.4). After pre-incubation at 37 °C for 1 min, the reactions were started by the
addition of the substrate methyleugenol added from a 100 times concentrated stock solution in
DMSO. The reactions were terminated by addition of 40 μL cold acetonitrile. Initial incubations
were performed at a substrate concentration of 1000 μM (final concentration) at several
incubation times and microsomal protein concentrations. Blank incubations were performed
without the cofactor NADPH.
The kinetic constants for the formation of different phase I metabolites of methyleugenol
were determined in liver, lung, and kidney microsomes, which were found to be capable of
metabolizing methyleugenol (see Results section). The incubation mixtures were as described
above. Incubations with male rat liver, lung, and kidney microsomes were carried out for 10
min at a substrate concentration that ranged from 50 to 1000 μM methyleugenol. All
incubations were started by addition of substrate from a 100 times concentrated stock solution
in DMSO and terminated by addition of 40 μL cold acetonitrile. Under the conditions specified,
the formation of the different methyleugenol metabolites was linear with time and microsomal
protein concentration for all the microsomal fractions. In the blank incubations performed
without NADPH low amounts of 3-(3,4-dimethoxyphenyl)-2-propen-1-ol were also formed.
Therefore the formation of 3-(3,4-dimethoxyphenyl)-2-propen-1-ol was corrected for the
amount of 3-(3,4-dimethoxyphenyl)-2-propen-1-ol formed in the blank incubations. In the
blank incubations performed without NADPH, low amounts of eugenol were also found. The
amounts of eugenol found in the blank incubations of both liver and kidney microsomes were
equal or more than the amount of eugenol found in incubation mixtures. Only the formation of
eugenol in lung microsomes was corrected for the amount of eugenol found in the blank
incubations.
Kinetic constants for formation of phase I metabolites were also determined in incubations
with liver microsomes obtained from female Sprague Dawley rats, and male and female Fisher
344 rats. As for the incubations with liver microsomes from male Sprague Dawley rats, the
formation of 3-(3,4-dimethoxyphenyl)-2-propen-1-ol was corrected for the amount of 3-(3,4-
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dimethoxyphenyl)-2-propen-1-ol formed in the blank incubations without cofactor.
HPLC analysis of Phase I metabolites
Before HPLC analysis of the samples, all incubations were centrifuged for 5 min at 16,000
g. Aliquots of 50 μL of the supernatant of each sample were analyzed on a Waters M600 HPLC
system (Waters, Milford, MA) equipped with an Alltima C18 5-µm column, 150 x 4.6 mm
(Grace Alltech, Breda, The Netherlands). Detection was performed between 200 and 350 nm
using a Waters 2996 photodiode array detector (Waters, Milford, MA).
For the analysis of phase I metabolites the gradient was made with ultrapure water and
acetonitrile. The flow rate was 1 mL/min and a gradient was applied from 0% to 15%
acetonitrile over 5 min and then increased to 17.5 % over 20 min after which the percentage
acetonitrile was increased to 35% over 15 min and kept at 35 % for 5 min. Then the percentage
of acetonitrile was increased to 100% over 10 min, and kept at 100% for 5 min. Quantification
of 1′-hydroxymethyleugenol was achieved by comparison of the peak areas of this metabolite in
the chromatograms obtained at a wavelength of 280 nm to the calibration curve of the
synthesized 1′-hydroxymethyleugenol obtained at the same wavelength. Because
methyleugenol-2′,3′-oxide and 3-(3,4-dimethoxyphenyl)propane-1,2-diol have the same UV
spectra as 1′-hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol and 2-hydroxy-
4,5-dimethoxyallylbenzene have the same UV spectrum as 1′-acetoxymethyleugenol, and the
unidentified metabolite eluting at a retention time of 44.9 min has almost the same UV spectra
as eugenol (data not shown) it was assumed that they have the same molar extinction coefficient
as 1′-hydroxymethyleugenol, 1′-acetoxymethyleugenol, and eugenol respectively.
Quantification of 3-(3,4-dimethoxyphenyl)propane-1,2-diol, reflecting formation of
methyleugenol-2′,3′-oxide in liver microsomes, was therefore achieved by comparison of the
peak area of 3-(3,4-dimethoxyphenyl)propane-1,2-diol in the chromatograms obtained at a
wavelength of 280 nm to the calibration curve for 1′-hydroxymethyleugenol obtained at the
same wavelength. In kidney microsomes, quantification of methyleugenol-2′,3′-oxide was
achieved by comparison of the peak area of methyleugenol-2′,3′-oxide in the chromatograms
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obtained at a wavelength of 280 nm to the calibration curve for 1′-hydroxymethyleugenol
obtained at the same wavelength. While quantification of 3-(3,4-dimethoxyphenyl)-2-propen-1-
ol and 2-hydroxy-4,5-dimethoxyallylbenzene was achieved by comparison of the peak area of
3-(3,4-dimethoxyphenyl)-2-propen-1-ol and 2-hydroxy-4,5-dimethoxyallylbenzene in the
chromatograms obtained at a wavelength of 280 nm to the calibration curve for 1′-
acetoxymethyleugenol. Quantification of the unidentified metabolite eluting at a retention time
of 44.9 min was achieved by comparison of the peak area of this metabolite in the
chromatograms obtained at a wavelength of 280 nm to the calibration curve for eugenol
obtained at the same wavelength.
Phase II metabolism
Glucuronidation of 1′-hydroxymethyleugenol to 1′-hydroxymethyleugenol glucuronide
Incubations with male Sprague Dawley rat liver microsomes were performed as described
by Punt et al. (2008) using 1′-hydroxymethyleugenol instead of 1′-hydroxyestragole to
determine the kinetic constants for glucuronidation of 1′-hydroxymethyleugenol. The
incubation mixture had a final volume of 200 μL, containing (final concentrations) 10 mM
UDPGA, and 1 mg/mL microsomal protein in 0.2 M Tris-HCl (pH 7.4) containing 10 mM
MgCl2. The incubation mixture was pre-treated with 0.025 mg/mL of the poreforming peptide
alamethicin from a 200 times concentrated stock in methanol on ice for 15 min to overcome
enzyme latency and obtain maximal glucuronidation activity (Fisher et al., 2000; Lin and
Wong, 2002). The reactions were started by the addition of the substrate 1′-
hydroxymethyleugenol from a 200 times concentrated stock solution in DMSO, after pre-
incubation at 37 °C for 1 min. The reactions were carried out for 10 min and terminated by
addition of 50 μL cold acetonitrile. Blank incubations were performed without the cofactor
UDPGA. Additional incubations were performed in which the samples obtained were treated
with β-glucuronidase to verify whether 1′-hydroxymethyleugenol glucuronide had indeed been
formed. For these incubations, 90 µL of sample (reaction mixture that has not been terminated
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by addition of acetonitrile) was added to 10 µL of 1 M potassium phosphate (pH 6.2). After the
addition of 2 µL of β-glucuronidase solution (0.3 units), the mixture was incubated for 1 hr at
37 °C.
The kinetic constants for the formation of 1′ -hydroxymethyleugenol glucuronide from 1′-
hydroxymethyleugenol were determined using liver microsomes. The incubation mixtures were
as described above. Incubations with male rat liver microsomes were carried out for 10 min at a
substrate concentration that ranged from 50 to 2000 μM 1′-hydroxymethyleugenol. All
incubations were started by addition of substrate from a 200 times concentrated stock solution
in DMSO and terminated by addition of 50 μL cold acetonitrile. Under the conditions specified,
the formation of 1′-hydroxymethyleugenol glucuronide was linear with time and microsomal
protein concentration. In the blank incubations performed without UDPGA no 1′-
hydroxymethyleugenol glucuronide was formed.
HPLC analysis of 1′-hydroxymethyleugenol glucuronide
HPLC analysis was used for quantification of 1′-hydroxymethyleugenol glucuronide using
an Alltima C18 5-µm column, 150 mm x 4.6 mm (Grace Alltech, Breda, The Netherlands)
coupled to Waters M600 HPLC system (Waters, Milford, MA). Elution was performed using a
gradient made with ultrapure water containing 0.1% (v/v) acetic acid and acetonitrile. The flow
rate was 1 mL/min and a gradient was applied from 10% to 25% acetonitrile over 30 min after
which the percentage acetonitrile was increased to 100% over 2 min, and kept at 100% for 1
min. Detection was performed at 280 nm using a Waters 2996 photodiode array detector
(Waters, Milford, MA). Because 1′-hydroxymethyleugenol glucuronide has the same UV
spectrum as 1′-hydroxymethyleugenol (data not shown) it was assumed that it has the same
molar extinction coefficient as 1′-hydroxymethyleugenol. Quantification of the 1′-
hydroxymethyleugenol glucuronide was therefore achieved by comparison of the peak area of
1′-hydroxymethyleugenol glucuronide in the chromatograms obtained at a wavelength of 280
nm to the calibration curve of 1′-hydroxymethyleugenol obtained at the same wavelength.
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LC-MS analysis of 1′-hydroxymethyleugenol glucuronide
The nature of 1′-hydroxymethyleugenol glucuronide was furthermore verified by LC-MS,
which was performed on an Agilent 1200 HPLC system coupled to a Bruker MicroTOF mass
spectrometer. Aliquots of 20 μL (injected volume) were separated on an Alltima C18 5-µm
column, 150 x 2.1 mm (Grace Alltech, Breda, The Netherlands). The gradient was made with
ultrapure water containing 0.1% (v/v) formic acid (eluent A) and acetonitrile with 0.1% (v/v)
formic acid (eluent B) and the flow rate was set to 0.2 mL/min. A linear gradient was applied
from 10% to 25% eluent B over 30 min after which the percentage of eluent B was increased to
100% over 2 min, and kept at 100% for 1 min. Mass spectrometric analysis was in the negative
electrospray mode using a spray voltage of capillary voltage of 4500 V, a capillary temperature
of 200 °C, and nitrogen as nebulizer gas at 8.0 L/min.
Oxidation of 1′-hydroxymethyleugenol to 1′-oxomethyleugenol
Formation of 1′-oxomethyleugenol was studied as described by Punt et al. (2009) for
formation of 1′-oxoestragole. Incubations were performed with male rat Sprague Dawley liver
microsomes, using NAD+ as cofactor and GSH to trap the reactive 1′-oxomethyleugenol. The
kinetic constants for formation of the 1′-oxomethyleugenol adduct with GSH, reflecting the
formation of 1′-oxomethyleugenol, were determined with male rat liver microsomes at substrate
concentrations that ranged from 10 to 1000 µM 1′-hydroxymethyleugenol. These incubation
mixtures had a final volume of 160 µL, containing (final concentrations) 3 mM NAD+, 10 mM
GSH, and 1 mg/mL microsomal protein in 0.2 M Tris-HCl (pH 7.4). The reactions were
terminated after 10 min by addition of 40 µL cold acetonitrile. Under these conditions the
formation of the glutathione adduct, 3′-(glutathione-S-yl)-1′-oxo-2′-3′-dihydromethyleugenol
(GS-1′-oxomethyleugenol), was linear with time and microsomal protein concentration.
HPLC analysis of GS-1′-oxomethyleugenol
The incubation mixture was centrifuged for 5 min at 16,000 g. HPLC analysis was used for
quantification of GS-1′-oxomethyleugenol using an Alltima C18 5-µm column, 150 mm x 4.6
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mm (Grace Alltech, Breda, The Netherlands) coupled to Waters M600 HPLC system. Detection
was performed at 280 nm using a Waters 2996 photodiode array detector. Quantification of GS-
1′-oxomethyleugenol was performed by means of a calibration curve obtained as described by
Punt et al. (2009). To this end 1′-oxomethyleugenol was synthesized from 1′-
hydroxymethyleugenol as described for 1′-oxosafrole by Fennell et al. (1984). A calibration
curve of GS-1′-oxomethyleugenol was prepared by incubating 40 µM 1′-oxomethyleugenol
with increasing concentrations of GSH, ranging from 2 to 10 µM in 0.2 M Tris-HCl (pH 7.4).
The reactions were incubated for 6 hr at 37 °C resulting in full conversion of all GSH added to
the incubations to GS-1′-oxomethyleugenol. The peak area of GS-1′-oxomethyleugenol in the
chromatograms of these incubations were related to the quantity of GSH used in the reactions,
thus providing a calibration curve for the GSH adduct of 1′ -oxomethyleugenol ultimately
quantifying the formation of 1′-oxomethyleugenol.
LC-MS analysis of GS-1′-oxomethyleugenol
Formation of GS-1'-oxomethyleugenol in the incubations was verified by LC-MS, which
was performed on an Agilent 1200 HPLC system coupled to a Bruker MicroTOF mass
spectrometer. Aliquots of 20 μL (injected volume) were separated on an Alltima C18 5-µm
column, 150 x 2.1 mm (Grace Alltech, Breda, The Netherlands). The gradient was made with
acetonitrile (eluent B) and ultrapure water (eluent A) both containing 0.1% (v/v) formic acid
and the flow rate was set to 0.2 mL/min. A linear gradient was applied from 0 to 25% eluent B
over 5 min and was kept at 25% for 5 min, after which the percentage of eluent B was increased
to 100% over 2 min. Mass spectrometric analysis was performed in positive electrospray mode
using a spray capillary voltage of 4500 V, a capillary temperature of 200 °C, and nitrogen as
nebulizer gas at 8.0 L/min. Full scan data (m/z 125– 500) were obtained to identify the main
protonated molecular ion present in the sample.
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Sulfonation of 1′-hydroxymethyleugenol to 1′-sulfooxymethyleugenol
The formation of 1′-sulfooxymethyleugenol was characterized in incubations of 1′-
hydroxymethyleugenol with liver S9 of male Sprague Dawley rats in the presence of GSH as
scavenger of the reactive carbo-cation formed upon decomposition of the unstable 1′-
sulfooxymethyleugenol. Using GSH as a scavenger of the carbo-cation of the alkenylbenzene is
considered a new method since determination of the sulfo-metabolite of 1′-hydroxyestragole
was performed previously based on incubation of the alkenylbenzene with 2′-deoxyguanosine
as a scavenger (Punt et al., 2007). The incubation mixture had a final volume of 100 µL
containing the following materials (final concentration): 10 mM GSH, 2 mg/mL S9, and 0.2
mM PAPS in 0.1 M potassium phosphate (pH 8.2). The incubation was started by addition of
the substrate 1′-hydroxymethyleugenol. The incubation mixture was incubated for 2 hr at 37 °C,
after which 25 µL of cold acetonitrile was added. Under these conditions the formation of the
glutathione adduct of the carbo-cation derived from 1′-sulfooxymethyleugenol was linear with
time and S9 protein concentration. The kinetic constants for the formation of 1′-
sulfooxymethyleugenol from 1′-hydroxymethyleugenol were determined using liver S9. The
incubation mixtures were as described above. Incubations with male rat liver S9 were carried
out for 2 hr at a substrate concentration that ranged from 50 to 1500 μM 1′-
hydroxymethyleugenol. All incubations were started by addition of substrate from a 200 times
concentrated stock solution in DMSO and terminated by addition of 25 μL cold acetonitrile.
Under the conditions specified, the formation of 1′-sulfooxymethyleugenol was linear with time
and S9 protein concentration. In the blank incubations performed without GSH formation of the
GSH adduct of the carbo-cation of 1′-sulfooxymethyleugenol was not observed.
HPLC analysis of the GSH adduct of 1′-sulfooxymethyleugenol
For the HPLC analysis of the incubations in which formation of 1′-sulfooxymethyleugenol
was investigated, the samples were centrifuged for 5 min at 16,000 g and 50 µL of the
supernatant of each sample was analyzed on an Alltima C18 5-µm column, 150 mm x 4.6 mm
(Grace Alltech, Breda, The Netherlands), coupled to a Waters 2695 alliance HPLC system. The
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gradient was made with acetonitrile and ultrapure water. The flow rate was 1 mL/min and the
percentage of ultrapure water was kept at 100 % for the first 5 min. Then a gradient was applied
from 0 to 10 % acetonitrile over 10 min, after which the percentage of acetonitrile was
increased to 30 % over 10 min and then increased to 80 % over 10 min and kept at 80 % for 2
min. Detection was performed at 270 nm using a Waters 2996 photodiode array detector
(Waters). Because the GSH adduct of 1′-sulfooxymethyleugenol has the same UV spectra as 1′-
acetoxymethyleugenol (data not shown) it was assumed that it has the same molar extinction
coefficient as 1′-acetoxymethyleugenol. Quantification of the GSH adduct of 1′-
sulfooxymethyleugenol was therefore achieved by comparison of the peak area of the GSH
adduct of 1′-sulfooxymethyleugenol in the chromatograms obtained at a wavelength of 270 nm
to the calibration curve of 1′-acetoxymethyleugenol obtained at the same wavelength.
LC-MS analysis of the GSH adduct of 1′-sulfooxymethyleugenol
The nature of 1′-sulfooxymethyleugenol was verified by LC-MS, which was performed on
an Agilent 1200 HPLC system coupled to a Bruker MicroTOF mass spectrometer. Aliquots of
20 μL (injected volume) were separated on an Alltima C18 5-µm column, 150 x 2.1 mm
(Alltech, Breda, The Netherlands). The gradient was made with ultrapure water containing
0.1% (v/v) formic acid (eluent A) and acetonitrile with 0.1% (v/v) formic acid (eluent B) and
the flow rate was set to 0.2 mL/min. The percentage of eluent B was kept at 0% for 5 minutes
after which a linear gradient was applied from 0% to 10% eluent B over 10 min and a
subsequent increase to 30% in another 10 minutes, after which the percentage of eluent B was
increased to 80% over 10 min, and kept at 80% for 2 min. Mass spectrometric analysis was in
the negative electrospray mode using a spray voltage of capillary voltage of 4500 V, a capillary
temperature of 200 °C, and nitrogen as nebulizer gas at 8.0 L/min.
Data analysis
The apparent maximum velocity (Vmax(app)) and apparent Michaelis-Menten constant (Km(app))
for the formation of the different phase I metabolites of methyleugenol and metabolites of 1′-
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hydroxymethyleugenol were determined by fitting the data to the standard Michaelis-Menten
equation v=Vmax/(1+(Km/[S])), with [S] being the substrate concentration, using the LSW data
analysis toolbox (version 1.1.1, MDL Information Systems, Inc.).
PBK model methyleugenol
The PBK model for methyleugenol was developed based on the PBK model previously
defined for the detoxification and bioactivation of the related alkenylbenzene estragole (Punt et
al., 2008). The aim behind developing a PBK model is to estimate the formation of different
methyleugenol metabolites in male rat tissues (liver, kidney, and lung) at different oral doses of
methyleugenol. Figure 2 presents a schematic overview of the PBK model. The final model is
composed of separate compartments for liver, lung and kidney tissues, which were found to be
involved in the metabolism of methyleugenol (see Results section). Since the partition
coefficient of methyleugenol in fat tissue was found to be relatively high, a separate fat
compartment was included in the developed model. All other tissues such as adrenal, brain, and
heart were lumped into a richly perfused tissue group, while tissues such as bone, muscle, and
skin were lumped into slowly perfused tissue group (Ramsey and Anderson, 1984).
The uptake of methyleugenol from the gastrointestinal tract was modeled as a first-order
process, assuming direct entry from the intestine to the liver compartment, and an absorption
rate constant (Ka) value similar to that of estragole which was 1.0 hr-1 (Punt et al., 2008).
Based on the results of phase I incubations (see Results section), it was found that
methyleugenol-2′,3′-oxide, 1′-hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol,
2-hydroxy-4,5-dimethoxyallylbenzene, 3-hydroxy-4-methoxyallylbenzene and a relatively minor
unidentified metabolite with retention time of 44.9 min (denoted M6), were formed in liver
tissues, while eugenol and 3-hydroxy-4-methoxyallylbenzene were formed in lung tissues and
methyleugenol-2′,3′-oxide was formed in kidney tissues (See Results section).
Based on these results the mass balance equations for methyleugenol in the metabolizing
tissues are described as follows:
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Figure 2. Representation of the conceptual model for a physiologically based pharmacokinetic model for
methyleugenol.
Liver:
dALME/dt = dUptakeME/dt
+ QL*(CAME- CLME/PLME)
– Vmax,L_MEO* CLME/PLME / (Km,L_MEO + CLME/PLME)
– Vmax,L_1′HME* CLME/PLME / (Km,L_1′HME+CLME/PLME)
– Vmax,L_3DMPOH* CLME/PLME / (Km,L_3DMPOH+ CLME/PLME)
– Vmax,L_2HDME* CLME/PLME / (Km,L_2HDME+ CLME/PLME)
– Vmax,L_3HMA* CLME/PLME / (Km,L_3HMA+ CLME/PLME)
– Vmax,L_M6* CLME/PLME / (Km,L_M6 + CLME/PLME)
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dUptakeME/dt = – dAGIME/dt = Ka*AGIME
AGIME (0) = Oral dose
CLME = ALME/VL
Lung:
dALuME/dt = QC*(CVME-CLuME/PLuME)
– Vmax,Lu_1EU* CLuME/PLuME /(Km,Lu_1EU+CLuME/PLuME)
– Vmax,Lu_3HMA* CLuME/PLuME /(Km,Lu_3HMA+ CLuME/PLuME)
CLuME = ALuME/VLu
Kidney:
dAKME/dt = QK*(CAME-CKME/PKME)
– Vmax,K_MEO*CVK/(Km,K_MEO+ CKME/PKME)
CKME = AKME/VK
where UptakeME is the amount of methyleugenol taken up from the gastrointestinal tract (µmol),
AGIME (µmol) is the amount of methyleugenol remaining in the gastrointestinal tract, ATiME is
the amount of methyleugenol in a tissue (Ti = L (liver), K (kidney) or Lu (lung)) (µmol), CTiME
is the methyleugenol concentration in a tissue (µmol/L), CAME is the methyleugenol
concentration in the arterial blood (µmol/L), CVME is the methyleugenol concentration in the
venous blood (µmol/L), QTi is the blood flow rate to a tissue (L/hr), QC is the cardiac output
(L/hr), VTi is the volume of a tissue, PTiME is the tissue/blood partition coefficient of
methyleugenol in a tissue, and Vmax,Ti_M and Km, Ti_M are the maximum rate of formation and the
Michaelis-Menten constant for the formation of the different phase I metabolites in a tissue:
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methyleugenol-2′,3′-oxide(MEO),1′-hydroxymethyleugenol(1′HME),3-(3,4-dimethoxyphenyl)-
2-propen-1-ol (3DMPOH), 2-hydroxy-4,5-dimethoxyallylbenzene (2HDME), eugenol (1EU),
the unidentified metabolite with retention time of 44.9 min (M6) and 3-hydroxy-4-
methoxyallylbenzene (3HMA). In case of methyleugenol-2′,3′-oxide, 3-(3,4-dimethoxyphenyl)-
2-propen-1-ol, 2-hydroxy-4,5-dimethoxyallylbenzene, M6 (44.9 min) and 3-hydroxy-4-
methoxyallylbenzene only formation of these metabolites is taken into account and no further
reactions with these metabolites were modeled. Formation of 1′-hydroxymethyleugenol in the
liver, but not in lung and kidney, was followed up by phase II reactions, since 1′-hydroxylation
of methyleugenol was found to occur only in the liver (see Results section). To describe the
disposition of 1′-hydroxymethyleugenol and its phase II metabolites a near quantitative
intrahepatic conversion of 1′-hydroxymethyleugenol by phase II enzymes was assumed. This
assumption was based on the findings that the overall catalytic efficiency for the phase II
reaction was higher than the catalytic efficiency for the formation of 1′-hydroxymethyleugenol.
For this reason only intra-organ distribution of 1′-hydroxymethyleugenol was modeled and no
distribution of this metabolite over the body was taken into account. This simplification of the
model reduced the number of parameters considerably, but might lead to an overestimation of
the contributions of the phase II reactions (Filser et al., 2001). The mass balance equation for
1′-hydroxymethyleugenol in the liver is as follows:
Liver:
dAL1′HME/dt =  + Vmax,L_1′HME*CLME/PLME/(Km,L_1′HME+CLME/PLME)
– Vmax,L_1′OME*CL1′HME/PL1′HME/(Km,L_1′OME+CL1′HME/PL1′HME)
– Vmax,L_1′HMEG*CL1HME/ PL1′HME/(Km,L_1′HMEG+CL1′HME/PL1′HME)
– Vmax,L_1′HMES*CL1′HME/ PL1′HME/(Km,L_1′HMES+CL1′HME/PL1′HME)
CL1′HME = AL1′HME / VL
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where AL1′HME is the amount of 1′-hydroxymethyleugenol in the liver (µmol), CL1′HME is the 1′-
hydroxymethyleugenol concentration in the liver (µmol/L), PL1′HME is the liver/blood partition
coefficient of 1′-hydroxymethyleugenol, and Vmax,L_M and Km,L_M are the maximum rate of
formation and the Michaelis-Menten constant for the formation of the phase II metabolites: 1′-
oxomethyleugenol (1′OME), 1′-hydroxymethyleugenol glucuronide (1′HMEG), and 1′-
sulfooxymethyleugenol (1′HMES) in the liver. The kinetic constants for the formation of phase
I metabolites from methyleugenol and phase II metabolites from 1′-hydroxymethyleugenol
were determined in vitro in the present study. The Vmax values for the different phase I and
phase II metabolic pathways in the liver, expressed as nmol/min/(mg microsomal protein), were
scaled to the liver using a microsomal protein yield of 35 mg/(g liver) (Medinsky et al., 1994).
The Vmax values for the different phase I metabolic pathways in the lung and kidney were scaled
accordingly using a microsomal protein yield of 20 mg/(g lung) and 7 mg/(g kidney),
respectively (Beierschmitt and Weiner, 1986; Medinsky et al., 1994). The Vmax values for
sulfonation of 1′-hydroxymethyleugenol, expressed as nmol/min/ (mg S9 protein), were scaled
to the liver using an S9 protein yield of 143 mg/(g liver), which corresponds to the sum of the
cytosolic protein yield of 108 mg/(g liver) and the microsomal protein yield of 35 mg/(g liver)
reported in the literature (Medinsky et al., 1994). Furthermore this scaling factor was verified as
described by Punt et al. (2008). The physiological parameters used in the methyleugenol model
were obtained from Brown et al. (1997). Partition coefficients were estimated from the log Kow
based on a method of DeJongh et al. (1997) (Table 1). Log Kow values were estimated with
KOWWIN™ version 1.67 using the EPI Suite™ software package version 4.0 and amounted to
3.03 for methyleugenol and 1.49 for 1'-hydroxymethyleugenol. Model equations were coded
and numerically integrated in Berkeley Madonna 8.0.1 (Macey and Oster, UC Berkeley, CA,
USA), using the Rosenbrock's algorithm for stiff systems.
Sensitivity analysis
To identify the key parameters to which the model output is most sensitive, a sensitivity
analysis was performed. Normalized sensitivity coefficients (SC) were determined according to
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the following equation: SC = (C' − C) / (P' − P) *(P / C), where C is the initial value of model
output, C' is the modified value of the model output resulting from an increase in parameter
value, P is the initial parameter value, and P' is the modified parameter value (Evans and
Andersen, 2000; Garg and Balthasar, 2007; Tardif et al., 2002). Based on the literature a 5%
increase in parameter values was chosen, to analyze the effect of a change in parameter on the
formation of 1′-hydroxymethyleugenol, 1′-hydroxymethyleugenol glucuronide, 1′-
oxomethyleugenol and 1′-sulfooxymethyleugenol expressed as % of the dose over a 24 hr
period of time (Evans and Andersen, 2000). Each parameter was analyzed individually, keeping
the other parameters to their initial values.
Table 1. Parameters used in the physiologically based kinetic model for methyleugenol in rat.
Physiological parametersa Tissue: blood partition coefficientsb
body weight (kg) 0.25
percentage of body weight methyleugenol
liver 3.4 liver 2.3
lungs 0.5 lung 2.3
kidney 0.7 kidney 2.3
fat 7.0 fat 69.5
rapidly perfused 4.4 rapidly perfused 2.3
slowly perfused 67.6 slowly perfused 0.8
arterial blood 1.85 1′-hydroxymethyleugenol
venous blood 5.55 liver 1.1
cardiac output  (L/hr) 5.4
percentage of cardiac output
liver 25.0
kidney 14.1
fat 7.0
rapidly perfused 36.9
slowly perfused 17.0
a Brown et al. (1997)
b DeJongh et al.(1997)
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Results
Formation of Phase I metabolites
Figure 3 presents the HPLC chromatograms of incubations of methyleugenol with male rat
liver, lung, and kidney microsomes in the presence of NADPH as cofactor. The results obtained
reveal that liver, lung, and kidney microsomes were all capable of metabolizing methyleugenol
to different types of metabolites at varying rates. The HPLC chromatogram of incubations of
methyleugenol with liver microsomes (Figure 3A) reveals formation of six metabolites of
methyleugenol which were identified as 3-(3,4-dimethoxyphenyl)propane-1,2-diol (RT = 15.9
min), 1′-hydroxymethyleugenol (RT = 32.1 min), 3-(3,4-dimethoxyphenyl)-2-propen-1-ol (RT
= 34.2 min), 2-hydroxy-4,5-dimethoxyallylbenzene (RT = 35.1 min), methyleugenol-2′,3′-oxide
(RT = 40.8 min), an unidentified metabolite eluting at a retention time of 44.9 min denoted M6,
and 3-hydroxy-4-methoxyallylbenzene (RT = 52.7 min). 3-(3,4-Dimethoxyphenyl)propane-1,2-
diol, 1′-hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, and methyleugenol-
2′,3′-oxide were identified based on the similarities of their retention times and UV spectra to
those of chemically synthesized reference compounds. Further identification of 1′-
hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, and methyleugenol-2′,3′-oxide
was performed by GC-MS providing mass spectral characteristics identical to those reported in
the literature (Solheim and Scheline, 1976) (Table 2). No reference compound was available for
2-hydroxy-4,5-dimethoxyallylbenzene but this metabolite was identified by analyzing a
dichloromethane extract of a microsomal incubation by GC-MS. The mass spectral data of the
metabolite were found to match those described for 2-hydroxy-4,5-dimethoxyallylbenzene in
the literature (Solheim and Scheline, 1976) (Table 2).
Incubating methyleugenol-2′,3′-oxide with male rat liver microsomes in the absence of any
cofactor revealed that in these incubations methyleugenol-2′,3′-oxide is completely hydrolyzed
to 3-(3,4-dimethoxyphenyl)propane-1,2-diol within the time frame of the incubation. Hydrolysis
is not observed in the blank incubations without microsomes, which indicates that the conversion
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Figure 3. HPLC chromatograms of incubations of methyleugenol (1 mM) with: A. Sprague Dawley male rat liver
microsomes (1 mg/mL), B. Sprague Dawley male rat lung microsomes (1 mg/mL), C. Sprague Dawley male rat kidney
microsomes, in the presence of NADPH (3 mM) as cofactor, and vitamin C (1 mM) as antioxidant.
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Table 2. Retention times and relative abundance of M+ and prominent fragments of methyleugenol and its
metabolites.
Compound  name Retention
time (min)
M+ Prominent fragments (m/e)
Relative abundance
methyleugenol
3-hydroxy-4-methoxyallylbenzene
1′-hydroxymethyleugenol
3-(3,4-dimethoxyphenyl)-2-propen-1-ol
2-hydroxy-4,5-dimethoxyallylbenzene
methyleugenol-2′,3′-oxide
17.7
16.6
22.6
25.3
23.1
26.6
178
164
194
194
194
194
163  151  147  107
149  137  131  121
176  161  151  139
176  161  151  138
179  151  123  107
177 165  151 138
is most likely catalyzed by epoxide hydrolases present in the microsomal preparation
(Guenthner and Luo, 2001; Luo et al., 1992; Luo and Guenthner, 1995,). Because the peak area
of 3-(3,4-dimethoxyphenyl)propane-1,2-diol resulting from hydrolyzing methyleugenol-2′,3′-
oxide with liver microsomes was equal to the peak area of methyleugenol-2′,3′-oxide present at
the start of the incubation (i.e. equal to the amount of methyleugenol-2′,3′-oxide in the blank
incubation without microsomes), the peak area of 3-(3,4-dimethoxyphenyl)propane-1,2-diol
was used for quantification of methyleugenol-2′,3′-oxide formation with liver microsomes.
Small amounts of methyleugenol-2′,3′-oxide, formed in the liver microsomal preparation, were
not converted to 3-(3,4-dimethoxyphenyl)propane-1,2-diol (<10% of 3-(3,4-dimethoxyphenyl)-
propane-1,2-diol) and they were neglected. We found that the synthesis of 3-hydroxy-4-
methoxyallylbenzene was accompanied with formation of eugenol, its isomer. HPLC analysis
of the product resulting from chemical synthesis indicated that two monodemethylated isomers
were formed in equal amounts and it was not possible to separate them by distillation as
reported by Solheim and Scheline (1976). The HPLC chromatogram of commercially available
eugenol revealed that eugenol had a retention time of 52.1 min. A hexane extract of the
synthesized isomer mixture was injected onto the HPLC and the chromatogram obtained
revealed two peaks, one with a RT of 52.1 min and the other with a RT of 52.7 min. From this
it can be concluded that the isomer at RT 52.7 min was 3-hydroxy-4-methoxyallylbenzene and
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that in the incubation of rat liver microsomes with methyleugenol, eugenol was not formed as a
major metabolite. Additional evidence for the formation of 3-hydroxy-4-methoxyallylbenzene
was obtained by analyzing a dichloromethane extract of the microsomal incubations by GC-
MS. The mass spectra obtained revealed the same mass spectrum that had been found by
Solheim and Scheline, (1976) for 3-hydroxy-4-methoxyallylbenzene (Table 2). The metabolite
denoted M6 eluting at 44.9 min was only a minor metabolite and therefore has not been
identified in the present work.
In the chromatogram of incubations with male rat lung microsomes two metabolites of
methyleugenolwere identified, corresponding to eugenol and 3-hydroxy-4-methoxyallylbenzene,
both resulting from O-demethylation (Figure 3B). In the chromatogram of incubations with
male rat kidney microsomes one metabolite of methyleugenol was identified, corresponding to
methyleugenol-2′,3′-oxide which did not convert to 3-(3,4-dimethoxyphenyl)propane-1,2-diol
as observed in incubations with liver microsomes (Figure 3C). A peak corresponding to 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol was observed in the incubations with both lung and kidney
microsomes. However, because the area of this peak was equal to the area of the same peak in
the blank incubations without NADPH, it was concluded that 3-(3,4-dimethoxyphenyl)-2-
propen-1-ol is not formed in incubations with both lung and kidney microsomes. Also a peak
corresponding to eugenol was observed in the incubations with both lung and kidney
microsomes. In kidney microsomal incubations, this peak was equal to the same peak in the
blank without NADPH. On the other hand, in lung microsomal incubation, there was a
formation for eugenol and it was corrected to the amount found in the blank incubation without
NADPH.
The presence of eugenol in blank incubations can be justified by noting that methyleugenol
used in the current study was synthesized from eugenol; the HPLC chromatogram of DMSO
methyleugenol standard showed that traces amounts of eugenol were present with
methyleugenol. In every addition of methyleugenol to the incubation mixture, eugenol was
added in minor traces.
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Kinetics of formation of Phase I Metabolites
Male rat liver, lung and kidney microsomes were incubated with increasing methyleugenol
concentrations to determine the kinetic parameters for the formation of the various phase I
metabolites of methyleugenol. Figures 4A-F show the rate of formation of 1′-
hydroxymethyleugenol, methyleugenol-2′,3′-oxide measured as 3-(3,4-dimethoxyphenyl)-
propane-1,2-diol, 3-hydroxy-4-methoxyallylbenzene, M6, 3-(3,4-dimethoxyphenyl)-2-propen-
1-ol, and 2-hydroxy-4,5-dimethoxyallylbenzene, respectively, all in incubations with male rat
liver microsomes with increasing methyleugenol concentrations. Table 3 summarizes the
apparent Km and Vmax values obtained from these plots. The results obtained with male rat liver
microsomes reveal that 1′-hydroxymethyleugenol is the most abundant metabolite formed,
followed by methyleugenol-2′,3′-oxide measured as 3-(3,4-dimethoxyphenyl)propane-1,2-diol,
3-(3,4-dimethoxyphenyl)-2-propen-1-ol, M6, and 2-hydroxy-4,5-dimethoxyallylbenzene. O-
demethylation was shown to be the least important metabolic route in these incubations. The
apparent Vmax for O-demethylation was about 25 times lower than the apparent Vmax for
formation of 1′-hydroxymethyleugenol, whereas the apparent Km was about 1.7 times lower.
Overall, the catalytic efficiency for the formation of the 3-hydroxy-4-methoxyallylbenzene (the
O-demethylated metabolite) by male rat liver microsomes, calculated as the apparent Vmax/Km,
was about 14.4 times lower than the catalytic efficiency for the formation of 1′-
hydroxymethyleugenol.
The results obtained with male rat lung microsomes reveal that 3-hydroxy-4-
methoxyallylbenzene and eugenol were formed, the two metabolites resulting from O-
demethylation, with 3-hydroxy-4-methoxyallylbenzene being the major metabolite (Figure 5A
and 5B). Table 3 summarizes the apparent Km and Vmax values obtained from these plots. The
apparent Vmax for 3-hydroxy-4-methoxyallylbenzene was about 3.2 times higher than the
apparent Vmax for formation of eugenol, whereas the apparent Km was about 1.7 times higher.
Overall, the catalytic efficiency for the formation of the 3-hydroxy-4-methoxyallylbenzene by
male rat lung microsomes, calculated as the apparent Vmax/Km, was about 2 times higher than
the catalytic efficiency for the formation of eugenol. Comparing the catalytic efficiencies for
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C. D.
E. F.
Figure 4. Formation rate of phase I metabolites in incubations with liver microsomes of male Sprague Dawley rats at
increasing concentrations (5 – 1000 µM) of methyleugenol indicating formation of A. 1′-hydroxymethyleugenol, B.
methyleugenol-2′,3′-oxide, C. 3-hydroxy-4-methoxyallylbenzene and D. M6  and at increasing concentrations (5 – 400
µM) of methyleugenol indicating formation of E. 3-(3,4-dimethoxyphenyl)-2-propen-1-ol and F. 2-hydroxy-4,5-
dimethoxyallylbenzene.
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Figure 5. Formation rate of the Phase I metabolites  in  incubations with lung microsomes of male Sprague Dawley rats
at increasing concentrations (5–600 µM) of methyleugenol indicating formation of A. eugenol and B. 3-hydroxy-4-
methoxyallylbenzene, and C. formation rate of methyleugenol-2′,3′-oxide in incubations with kidney microsomes of
male Sprague Dawley at increasing concentrations of  methyleugenol (5 – 600 µM).
the formation of phase I metabolites in the different organs that were scaled to the in vivo
situation (Table 3) reveals that in male rat conversion of methyleugenol to 3-hydroxy-4-
methoxyallylbenzene is most efficiently catalyzed in the lung compared to the liver. On the
other hand, formation of 1′-hydroxymethyleugenol, methyleugenol-2′,3′-oxide measured as 3-
(3,4-dimethoxyphenyl)propane-1,2-diol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, 2-hydroxy-
4,5-dimethoxyallylbenzene, and M6 is most efficiently catalyzed in the liver.
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Table 3. Kinetic parameters for phase I metabolism of methyleugenol in incubations with live microsomes
from male Sprague Dawley rat.
organ metabolite km(app)
a,b Vmax(app)
a,c
in vitro
catalytic efficiencyd
(Vmax(app)/Km(app))
scaled
Vmax,
in vivoe
in vivo
catalytic efficiencyf
(scaled Vmax, in
vivo/Km(app)
liver
methyleugenol-2′,3′-oxide 81 ± 15.5 1.84  ± 0.08 23 32.8g 0.4
1′-hydroxymethyleugenol 253  ± 90 3.26  ± 0.45 13 58.2g 0.23
3-(3,4-dimethoxyphenyl)-2-propen-1-ol 28  ± 2.3 0.68  ± 0.025 24 12.1g 0.43
2-hydroxy-4,5-dimethoxyallylbenzene 32 ± 1.1 0.27 ± 0.006 8.4 4.8g 0.15
3-hydroxy-4-methoxyallylbenzene 150 ± 55.5 0.13 ± 0.018 0.9 2.3g 0.015
M6 259 ± 16.4 0.44 ± 0.004 1.7 7.9g 0.03
lung
eugenol 19 ± 3 0.21± 0.03 11 0.32h 0.02
3-hydroxy-4-methoxyallylbenzene 33 ± 18.7 0.67  ± 0.077 20 1.01h 0.03
kidney methyleugenol-2′,3′-oxide 968 ± 230 0.31± 0.05 0.32 0.23i 0.00024
amean ± SD
b(µM)
c(nmol/min/mg microsomal protein)
d(µL/min/mg microsomal protein)
e(µmol/hr)
f (L/hr)
g Vmax (app) /(1000 nmol/µmol) * (60 min/hr) * (35 mg microsomal protein/ g liver) * (34 g liver/kg bw)* (0.25 kg bw)
hVmax (app ) /(1000 nmol/µmol) * (60 min/hr) * (20 mg microsomal protein/ g lung) * (5 g lung/kg bw)* (0.25 kg bw)
iVmax (app) /(1000 nmol/µmol) * (60 min/hr) * (7 mg microsomal protein/ g kidney) * (7 g kidney/kg bw)* (0.25 kg bw)
Formation of Phase II Metabolites
1′-Hydroxymethyleugenol glucuronide
HPLC analysis of an incubation of 1′-hydroxymethyleugenol with male rat liver
microsomes in the presence of UDPGA as a cofactor, conditions previously shown to result in
glucuronidation of 1′-hydroxyestragole to 1′-hydroxyestragole glucuronide (Punt et al., 2008),
revealed formation of one metabolite with RT of 19.3 min (chromatogram not shown).
Treatment of the sample with β-glucuronidase, resulted in complete disappearance of the peak
at 19.3 min accompanied by a comparable increase of the peak representing 1′-
hydroxymethyleugenol. This confirms that the metabolite corresponds to the glucuronosyl
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conjugate of 1′-hydroxymethyleugenol. Furthermore the spectrum of the metabolite, obtained
by LC-MS, reveals a deprotonated molecule at m/z 369, which corresponds to the theoretically
expected mass and confirms that the metabolite corresponds to 1′-hydroxymethyleugenol
glucuronide.
1′-Oxomethyleugenol
HPLC analysis of an incubation of 1′-hydroxymethyleugenol with male rat liver
microsomes using NAD+ as a cofactor, conditions previously shown to result in oxidation of 1′-
hydroxyestragole to 1′-oxoestragole (Punt et al., 2009), revealed formation of a metabolite with
RT of 11.4 min (chromatogram not shown). HPLC analysis of control incubations of 1′-
hydroxymethyleugenol in the absence of NAD+ revealed no appearance of the peak at RT of
11.4 min (chromatogram not shown). This argument was used as a confirmation for the
formation of the GSH adduct of 1'-oxomethyleugenol and thus of 1'-oxomethyleugenol in the
incubation with NAD+. Furthermore the spectrum of the metabolite, obtained by LC-MS,
reveals a deprotonated molecule at m/z 500, which corresponds to the theoretically expected
mass for the GSH adduct of 1′-oxomethyleugenol.
1′-Sulfooxymethyleugenol
HPLC analysis of an incubation of 1′-hydroxymethyleugenol with male rat liver S9 using
PAPS as a cofactor and GSH as a scavenger for the reactive carbo-cation derived from the
unstable 1′-sulfooxymethyleugenol metabolite revealed formation of a metabolite with RT of
12.9 min (chromatogram not shown). HPLC analysis of incubations of 1′-hydroxymethyleugenol
in the absence of GSH and in the presence of PAPS and liver S9 protein revealed no appearance
of the peak at 12.9 min (chromatogram not shown). This argument was used as a confirmation
for the formation of the GSH adduct of the carbo-cation of 1′-sulfooxymethyleugenol, and thus
an indirect detection of formation of 1′-sulfooxymethyleugenol in the complete incubation.
Furthermore the spectrum of the metabolite, obtained by LC-MS, reveals a deprotonated
molecule at m/z 484, which corresponds to the theoretically expected mass and confirms that
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the metabolite corresponds to the GSH adduct of the carbo-cation formed from 1'-
sulfooxymethyleugenol.
Kinetics of phase II metabolite formation
Figure 6A and 6B present the formation of 1′-hydroxymethyleugenol glucuronide and 1′-
oxomethyleugenol respectively, in incubations with microsomal preparations with male rat liver
and either UDPGA or NAD+ at increasing 1′-hydroxymethyleugenol concentrations. In
addition, Figure 6C presents the formation of the GSH conjugate of the carbo-cation of 1′-
sulfooxymethyleugenol in incubations with a rat liver S9 preparation, PAPS and increasing 1′ -
hydroxymethyleugenol concentrations. The kinetic parameters (Vmax and Km), obtained by
fitting the data to the standard Michaelis-Menten equation, are presented in Table 4. Comparing
the kinetic constants for glucuronidation to sulfonation and oxidation reveals that the apparent
Vmax for 1′-sulfooxymethyleugenol formation was about 12773 times lower than the apparent
Vmax for formation of 1′-hydroxymethyleugenol glucuronide, whereas the apparent Km was
about 8 times lower. Overall, the catalytic efficiency for the formation of the 1′-
sulfooxymethyleugenol by male rat liver proteins, calculated as the apparent Vmax/Km, was about
1750 times lower than the catalytic efficiency for the formation of 1′-hydroxymethyleugenol
glucuronide by male rat liver proteins. The apparent Vmax for 1′-oxomethyleugenol was about 10
times lower than the apparent Vmax for formation of 1′-hydroxymethyleugenol glucuronide,
whereas the apparent Km was about 4.4 times higher.  The catalytic efficiency for the formation
of the 1′-oxomethyleugenol by male rat liver microsomes was about 44 times lower than the
catalytic efficiency for the formation of 1′-hydroxymethyleugenol glucuronide by male rat liver
microsomes. Thus, based on these kinetic data it can be concluded that in male rat liver
glucuronidation may be the preferential pathway for conversion of 1′-hydroxymethyleugenol,
followed by oxidation to 1′-oxomethyleugenol and to a much lower extent by sulfonation to 1′-
sulfooxymethyleugenol.
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Figure 6. Formation rate of A. 1′-hydroxymethyleugenol glucuronide in incubations with liver microsomes of male
Sprague Dawley rat at increasing concentration of 1′-hydroxymethyleugenol (50 – 2000 µM), B. 1′-oxomethyleugenol
in incubations with liver microsomes of male Sprague Dawley rat at increasing concentration of 1′-
hydroxymethyleugenol (50 – 2000 µM), and C. 1′-sulfooxymethyleugenol in incubations with liver S9 of male Sprague
Dawley rat at increasing concentration of 1′-hydroxymethyleugenol (50 – 1500 µM).
Performance of the PBK model
With the kinetic constants obtained, all parameters of the PBK model were defined (Table 3
and Table 4) and the model as described in the Material and Method section was used for model
predictions. In a first step, predictions were made that allow investigating the performance of
the PBK model obtained. In an in vivo study performed by Solheim and Scheline (1976), rats
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Table 4. Kinetic parameters for the phase II metabolites of methyleugenol in incubations with liver
microsomes from male Sprague Dawley rat.
organ metabolite km(app)
a,b Vmax(app)
a,c
in vitro
catalytic efficiencyd
(Vmax(app)/Km(app))
scaled Vmax
in vivoe
in vivo
catalytic efficiencyf
(scaled Vmax, in
vivo/Km(app)
liver
1′-hydroxymethyleugenol
glucuronide
799 ± 192 28.1 ± 6.1 35 502g 0.63
1′-oxomethyleugenol 3534 ± 3038 2.83 ± 0.92 0.8 51g 0.014
1′-sulfooxymethyleugenol 102 ± 29.5 0.0022 ± 0.0054 0.02 0.16h 0.0016
a mean ± SD
b(µM)
c (nmol/min/(mg microsomal protein)
d(µl/min/(mg microsomal protein)
e (µmol/hr)
f (L/ hr)
gVmax (app) /(1000 nmol/µmol) * (60 min/hr) * (35 mg microsomal protein/ g liver) * (34 g liver/kg bw)* (0.25 kg bw)
hVmax (app) /(1000 nmol/µmol) * (60 min/hr) * (143 mg S9 protein/ g liver) * (34 g liver/kg bw)* (0.25 kg bw)
were given 200 mg/(kg bw) of methyleugenol. The results showed that 95% of the dose was
recovered in urine. In another study performed by NTP (NTP, 2000), male rats were given 118
mg/(kg bw) of methyleugenol, and the results showed that 100% of the dose was excreted in
urine collected over 24 hr. These data illustrate that the principal excretion pathway is through
urine and that biliary excretion is insignificant. Therefore evaluation of performance of the
PBK model could be done by comparison of plasma concentrations of methyleugenol and
urinary metabolite formation observed in vivo and predicted by the PBK model. The PBK
model-based predictions for concentrations of methyleugenol in venous blood at different time
points after dosing were compared to the reported plasma levels of methyleugenol in male
Fisher 344 rats exposed to a single oral gavage dose of 150 mg/(kg bw) (NTP, 2000). Figure 7
presents the results obtained and reveals that the PBK model predicted plasma concentrations of
methyleugenol are generally only 2-4 fold to up to at most one order of magnitude at the early
time points, higher than the actually measured ones. Also, the PBK model predicted accurately
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the percentage of methyleugenol converted to the 1′-hydroxymethyleugenol glucuronide
metabolite, after oral administration of 118 mg/kg of methyleugenol to male Fisher 344 rat. The
observed excreted amount of the 1′-hydroxymethyleugenol glucuronide metabolite in urine
collected over 24 hr was 20 % of the dose (NTP, 2000), while the PBK-based predicted amount
was 26 %. In another in vivo study, male rats received a dose of 200 mg/(kg bw) of
methyleugenol, the PBK model-based predictions for concentrations of 2-hydroxy-4,5-
dimethoxyallylbenzene and 3-hydroxy-4-methoxyallylbenzene were compared to the
corresponding metabolites in urine samples (collected over 24 hr). The PBK model predicted
accurately the percentage of methyleugenol converted to 3-hydroxy-4-methoxyallylbenzene to
amount to 3.6% of the dose whereas the actual measured level amounted to 4.0% of the dose.
The predicted formation of 2-hydroxy-4,5-dimethoxyallylbenezene is about 2.6-fold higher
(predicted to be 7.8% of the dose) than the actual measured level of formation (amounting to
3.0% of the dose) but remains within the same order of magnitude (Solheim and Scheline,
1976).
Figure 7. PBK predicted log10 concentrations of methyleugenol (nmol/ml) in venous blood of  male Sprague Dawley rat
(▬▬) compared to the reported log10 concentrations in (nmol/ ml) plasma blood of male Fisher 344 rat (•), both obtained
at an oral dose of 150 mg/(kg bw ) (NTP, 2000).
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Model predictions
The PBK model developed was used to predict the liver concentrations of methyleugenol
and 1′-hydroxymethyleugenol and conversion of 1′-hydroxymethyleugenol to 1′-
hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-sulfooxymethyleugenol in the
liver of male rat. Figure 8A presents the predicted time dependent concentration (µM) of
methyleugenol and 1′-hydroxymethyleugenol, the time dependent predicted levels (nmol/(g
liver)) of 1′-hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-
sulfooxymethyleugenol at a dose of 0.05 mg/(kg bw). This dose of 0.05 mg/(kg bw) was
selected to allow comparison with the outcomes obtained previously for the model of 1′-
estragole (Punt et al., 2008) and represents an exposure level in the range of estimated daily
exposure to these alkenylbenzenes (SCF, 2001). Since the model does not contain further
reactions for the phase II metabolites of 1′-hydroxymethyleugenol, the PBK model estimates
the total accumulated amounts of these 1′-hydroxymethyleugenol metabolites in liver over time
but not the actual time dependent concentrations present in the liver. For this reason the
estimated formation of 1′-sulfoxymethyleugenol does not represent the actual concentration of
this metabolite that would occur in the liver, but the total quantities that would theoretically be
formed in the liver over time. The model outcomes predict that 15 hr after dosing,
methyleugenol and 1′-hydroxymethyleugenol are completely metabolized and indicate a total
overall formation of 1.4 nmol/(g liver) of 1′-hydroxymethyleugenol glucuronide, 0.032 nmol/(g
liver) of 1′-oxomethyleugenol, and 0.0035 nmol/(g liver) of 1′-sulfooxymethyleugenol,
corresponding to 17.0%, 0.39%, and 0.042% of the dose respectively. Figure 8B presents the
predicted time-dependent concentration of methyleugenol and 1′-hydroxymethyleugenol, the
formation of 1′-hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-
sulfooxymethyleugenol after administration of 300 mg/(kg bw) methyleugenol, a dose which
was also selected to allow comparison with the outcomes of the estragole model (Punt et al.,
2008), and which represents a high level exposure in a range reported to result in induction of
hepatomas when administered on a daily basis (Abdo et al., 2001; NTP, 2000). At this dose,
the total conversion  of methyleugenol and 1′-hydroxymethyleugenol was predicted to take
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Figure 8. PBK model-predicted time dependent concentration (nmol/(g liver)) of methyleugenol, 1′-
hydroxymethyleugenol, and formation of 1′-hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-
sulfooxymethyleugenol following exposure to A. 0.05 mg/(kg bw), and B. 300 mg/(kg bw).
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Figure 9. The PBK model-predicted dose-dependent percentage of formation of phase I metabolites in Sprague Dawley
rat: methyleugenol 2′,3′-oxide (▬▬▬), 1′-hydroxymethyleugenol (▬ ▬ ▬), 3-(3,4-dimethoxyphenyl)-2-propen-1-ol (---), 2-
hydroxy-4,5-dimethoxyallylbenzene (▬ ● ▬ ● ▬), M6 (▬ ●● ▬ ●● ▬), and 3-hydroxy-4-methoxyallylbenzene (....).
longer than at a low dose of 0.05 mg/(kg bw), with methyleugenol and 1′-
hydroxymethyleugenol being almost completely metabolized after 20 hr. At a dose of 300
mg/(kg bw) the percentage of the dose that is ultimately converted into 1′-
hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-sulfooxymethyleugenol is
relatively higher than what is predicted at a dose of 0.05 mg/(kg bw). At this dose 14796
nmol/(g liver) of 1′-hydroxymethyleugenol glucuronide is formed, corresponding to 29.9% of
the dose. In the case of 1′-oxomethyleugenol and 1′-sulfooxymethyleugenol 346 and 29.3
nmol/(g liver) are formed, which correspond to 0.70 % and 0.06% of the dose respectively. The
results obtained also reveal that the observed relative increase in the percentage of the dose that
is ultimately converted into 1′-hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and
1′-sulfooxymethyleugenol can be justified by a change in phase I metabolism of methyleugenol.
Figure 9 presents a plot of the percentage of the methyleugenol dose that is converted into
the different phase I metabolites at different oral dose levels of methyleugenol. At low dose
levels of methyleugenol (0.05 mg/(kg bw)), approximately 31.0%, 17.6%, 11.4%, 32.9%, 2.3%
and 3.4% of the dose is metabolized to methyleugenol-2′,3′-oxide, 1′-hydroxymethyleugenol,
2-hydroxy-4,5-dimethoxyallylbenzene, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, M6, and 3-
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hydroxy-4-methoxyallylbenzene respectively, which makes epoxidation and 3′-hydroxylation
the major metabolic routes. As the dose increases to 300 mg/kg bw, approximately 32.8%,
30.8%, 7.4%, 19.8%, 4.1% and 3.5% of the dose is metabolized to methyleugenol-2′,3′-oxide,
1′-hydroxymethyleugenol, 2-hydroxy-4,5-dimethoxyallylbenzene, 3-(3,4-dimethoxyphenyl)-2-
propen-1-ol, M6, and 3-hydroxy-4-methoxyallylbenzene respectively. This relative decrease in
formation of 2-hydroxy-4,5-dimethoxyallylbenzene and 3-(3,4-dimethoxyphenyl)-2-propen-1-
ol, accompanied by an increase in the relative formation of the proximate carcinogen 1′-
hydroxymethyleugenol, M6, and 3-hydroxy-4-methoxyallylbenzene is a result of saturation of
both the 3′-hydroxylation on the allyl group and the hydroxylation at C2 of the benzene ring.
Figure 9 shows that an increase in the dose of methyleugenol is accompanied by a relative
increase of the amount of methyleugenol which is metabolized to the proximate carcinogenic
metabolite 1′-hydroxymethyleugenol. This increase in 1′-hydroxymethyleugenol lead to a
relative increase in the formation of phase II metabolites of 1′-hydroxymethyleugenol,
including the proximate carcinogen 1′-sulfooxymethyleugenol with the dose (Figure 10A, 10B,
and 10C). Under linear conditions for phase I metabolism (0.05-10 mg methyleugenol/(kg bw))
the PBK based predicted formation of phase I metabolites as % of the dose amounted to 31.0%,
17.6%, 2.3%, 32.9%, and 3.4% at a dose of 0.05 mg/(kg bw) and to 31.8%, 18.6%, 11.0%,
31.3%, 2.5%, and 3.5% at a dose of 10 mg/(kg bw) for methyleugenol-2′,3′-oxide, 1′-
hydroxymethyleugenol, 2-hydroxy-4,5-dimethoxyallylbenzene, 3-(3,4-dimethoxyphenyl)-2-
propen-1-ol, M6, and 3-hydroxy-4-methoxyallylbenzene respectively. Under saturating
conditions (300-4300 mg methyleugenol/(kg bw)) the PBK based predicted formation of phase
I metabolites, as % of the dose, amounted to 32.8%, 30.8%, 7.4%, 19.8%, 4.1%, and 3.5% at a
dose of 300 mg/(kg bw) and to 12.8%, 21.4%, 1.9%, 4.8%,  2.9%, and 1.3% at a dose of 4300
mg/(kg bw) for methyleugenol-2′,3′-oxide, 1′-hydroxymethyleugenol, 2-hydroxy-4,5-
dimethoxyallylbenzene, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, M6, and 3-hydroxy-4-
methoxyallylbenzene respectively.
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C.
Figure 10. The PBK model-predicted dose-dependent percentage of formation of phase II metabolites in the liver of
Sprague Dawley rat: A. 1′-hydroxymethyleugenol glucuronide, B. 1′-oxomethyleugenol, and C. 1′-
sulfooxymethyleugenol.
Sensitivity analysis
A sensitivity analysis was performed to determine the model parameters which affect the
formation of 1′-hydroxymethyleugenol, 1′-hydroxymethyleugenol glucuronide, 1′-
oxomethyeugenol, and 1′-sulfooxymethyleugenol as model outputs. These metabolites are only
formed in the liver. Figure 11A presents the parameters which have an effect on the formation
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of 1′-hydroxymethyleugenol. Formation of 1′-hydroxymethyleugenol primarily depends on the
kinetic constants for its formation (Vmax,L_1′HME, Km,L_1′HME) at both doses of 0.05 and 300
mg/(kg bw). To a small extent, the formation of 1′-hydroxymethyleugenol depends on the
kinetic constants of the other competing phase I metabolites formed in the liver. Figure 11B
presents the kinetic parameters which influence the formation of 1′-hydroxymethyleugenol
glucuronide. Glucuronidation of 1′-hydroxymethyleugenol primarily depends on the kinetic
constants for formation of 1′-hydroxymethyleugenol (Vmax,L_1′HME, Km,L_1′HME) and to a minor
extent on the kinetic constants for the formation of 3-(3,4-dimethoxyphenyl)-2-propen-1-ol
(Vmax,L_3DMPOH, Km,L_3DMPOH), methyleugenol-2′,3′-oxide (Vmax,L_MEO, Km,L_MEO), and 2-hydroxy-
4,5-dimethoxyallylbenzene (Vmax,L_2HDME, Km,L_2HDME). Figure 11C reveals that the formation of
1′-oxomethyleugenol depends on the formation constants of 1′-hydroxymethyleugenol
(Vmax,L_1′HME, Km,L_1′HME), but also on the kinetic constants for the formation of 1′-
hydroxymethyleugenol glucuronide (Vmax,L_1HMEG, Km,L_1′HMEG) and on the kinetic constants
(Vmax,L_1′OME, Km,L_1′OME) for the formation of 1′-oxomethyleugenol itself. Figure 11D reveals
that the formation of the ultimate carcinogen 1′-sulfooxymethyleugenol not only depends on the
kinetic constants for the formation of the proximate carcinogen 1′-hydroxymethyleugenol
(Vmax,L_1′HME, Km,L_1′HME), but also on the kinetic constants for formation of 1′-
hydroxymethyleugenol glucuronide (Vmax,L_1′HMEG, Km,L_1′HMG) and on the kinetic constant for
formation of 1′-sulfooxymethyleugenol itself (Vmax,L_1′HMES, Km,L_1′HMES). This indicates that
glucuronidation of 1′-hydroxymethyleugenol is an important competing metabolic pathway to
sulfonation due to its higher catalytic efficiency. Moreover the formation of 1′-
sulfooxymethyleugenol also depends on the liver microsomal protein yield (MPL) and liver S9
protein yield (S9PL).
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Figure 11. Sensitivity of the predicted formation of A. 1′-hydroxymethyleugenol, B. 1′-hydroxymethyleugenol
glucuronide, C. 1′-oxomethyleugenol, and D. 1′-sulfooxymethyleugenol to different model parameters. Gray bars
correspond to the normalized sensitivity coefficients at a dose of 0.05 mg/(kg bw) and black bars at a dose of 300
mg/(kg bw). VF = volume of fat tissue, PFME = fat/blood partition coefficient of methyleugenol, MPL = Liver
microsomal protein yield, S9PL = Liver S9 protein yield, Vmax and Km are the maximum rate of formation and the
Michaelis-Menten constant for the formation of the different metabolites (M) in liver: methyleugenol-2′,3′-oxide
(MEO), 1′-hydroxymethyleugenol (1′HME), 3-(3,4-dimethoxyphenyl)-2-propen-1-ol (3DMPOH), 2-hydroxy-4,5-
dimethoxyallylbenzene (2HDME), M6, 3-hydroxy-4-methoxyallylbenzene (3HMA), 1′-hydroxymethyleugenol
glucuronide (1′HMEG), 1′-oxomethyleugenol (1′OME), and 1′-sulfooxymethyleugenol (1′HMES) in liver tissue.
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Factors that could affect the PBK model outcome
Strain and gender differences
Strain and gender differences have been shown to affect the kinetics and metabolism of
drugs (Campbell, 1995). Since the PBK model was developed using data obtained from male
Sprague Dawley rat samples, the metabolic parameters were also determined using tissue
samples from female Sprague Dawley, and female and male Fisher 344 rats, in order to study
the impact of strain and gender differences on the PBK model outcomes. The kinetic parameters
of different strains and genders are presented in Table 5. Comparison of these kinetic
parameters reveals that there are no strain or gender differences in the formation of 1′-
hydroxymethyleugenol, 2-hydroxy-4,5-dimethoxyallylbenzene, 3-(3,4-dimethoxyphenyl)-2-
propen-1-ol, and 3-hydroxy-4-methoxyallylbenzene between male and female Sprague Dawley
rats and male and female Fisher 344 rats. Although some variation in Km and Vmax values for
these metabolic routes occurs, the overall catalytic efficiencies are about the same for the
different strains and genders. Only gender differences do occur in the formation of
methyleugenol-2′,3′-oxide. Methyleugenol-2′,3′-oxide formation was found to be more efficient
when measured for liver microsomes from male Sprague Dawley and Fisher 344 rats while it is
less efficient with female Sprague Dawley and Fisher 344 rat liver microsomes. The effect of
the differences in kinetic parameters on the outcome of the PBK model was studied by
determining the changes in the predicted formation of 1′-hydroxymethyleugenol. Figure 12
presents the PBK predicted formation of 1′-hydroxymethyleugenol as a percentage of the dose
over a 24 hr time-frame when kinetic constants of phase I metabolism by liver microsomes of
male or female Sprague Dawley rats, or male or female Fisher 344 rats, were applied, and all
other parameters were kept the same. It is observed that the formation of 1′-
hydroxymethyleugenol in female Sprague Dawley rats is 1.5 fold higher than in male Sprague
Dawley rats while no difference in the formation of 1′-hydroxymethyleugenol was found
between the different strains of the same sex. These results indicate that sex dependent
differences in phase I kinetics may influence the model outcome although they influence the
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Table 5. The kinetic parameters for liver metabolites (Vmax(app), Km(app), and catalytic efficiency
(Vmax(app)/Km(app))) of male Sprague Dawley, female Sprague Dawley, male Fisher 344 and female
Fisher 344 rats).
metabolite strain Vmax(app)a Km(app)
b catalytic efficiencyc
(Vmax(app)/Km(app))
methyleugenol-2′,3′-oxide
Male Sprague Dawley 1.84 81 22.7
Female Sprague Dawley 1.69 2184 0.77
Male Fisher 344 2.0 100 20.0
Female Fisher 344 0.96 1496 0.64
1'-hydroxymethyleugenol
Male Sprague Dawley 3.26 253 12.9
Female Sprague Dawley 1.39 90 15.4
Male Fisher 344 3.6 181 19.9
Female Fisher 344 1.79 69 25.9
2-hydroxy-4,5dimethoxyallyl-
benzene
Male Sprague Dawley 0.26 32 8.1
Female Sprague Dawley 0.18 22.3 8.1
Male Fisher 344 0.28 31.2 9.0
Female Fisher 344 0.17 31.4 5.4
3-(3,4-dimethoxyphenyl)-2-propen-
1-ol
Male Sprague Dawley 0.68 28 24.3
Female Sprague Dawley 0.44 17 25.9
Male Fisher 344 0.75 27.2 27.6
Female Fisher 344 0.48 23 20.9
M6
Male Sprague Dawley 0.44 259 1.7
Female Sprague Dawley 0.033 607 0.054
Male Fisher 344 0.30 86 3.5
Female Fisher 344 0.22 37 6.0
3-hydroxy-4-methoxyallylbenzene
Male Sprague Dawley 0.13 150 0.87
Female Sprague Dawley 0.11 261 0.42
Male Fisher 344 0.25 361 0.69
Female Fisher 344 0.12 216 0.56
a(nmol/min/(mg microsomal protein)
b(µM)
c(µL/ min/(mg microsomal protein)
formation of 1′-hydroxymethyleugenol and consequently its phase II metabolites to only a small
extent (2 fold at most). On the other hand, the strain dependent differences do not influence the
formation of 1′-hydroxymethyleugenol and its phase II metabolites.
Scaling factor of in vitro metabolic parameters to the in vivo situation
Scaling of in vitro metabolic parameters to the in vivo situation can also influence the model
outcome since the microsomal protein yield from different tissues used to scale the Vmax values
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to the in vivo situation were based on the values taken from the literature (Beierschmitt and
Weiner, 1986; Medinsky et al., 1994). The effect of changing microsomal protein yield on the
outcome of the PBK model was examined through monitoring the formation of 1′-
hydroxymethyleugenol. At doses of 0.05 mg/(kg bw), it was noted that decreasing the liver
microsomal protein yield by 4-times led to a decrease in the formation of 1′-
hydroxymethyleugenol from approximately 17.6% to 15.6%, while at 300 mg/(kg bw) the
decrease was approximately from 30.8% to 26.6%. Lowering the lung microsomal protein yield
4-times led to a small increase in the predicted formation of 1'-hydroxymethyleugenol from
17.6% to 18.0% and from 30.8% to 31.3% at 0.05 and 300 mg/(kg bw) doses, respectively. In
case of kidney, no influence was observed on the predicted formation of 1'-
hydroxymethyleugenol following changing the kidney microsomal protein yield at both 0.05
and 300 mg/kg bw doses. Also some uncertainty may exist in the in vitro derived apparent Km
values, which have been used for the in vivo apparent Km values. No indication can be given on
the level of uncertainty in these Km values (Punt et al., 2008). Based on the model, a 4-fold
increase in Km values for phase I metabolism in liver has however the same effects on the
estimated formation of the different phase I metabolites at a different oral dose as a 4-fold
decrease in scaling of Vmax values.
Figure 12. PBK model-predicted relative formation of 1′-hydroxymethyleugenol when using kinetic constants for phase
I metabolism by liver microsomes of male or female Sprague Dawley rats, or male or female Fisher 344 rats keeping all
other parameters the same. Gray bars correspond to the predicted formation of 1′-hydroxymethyleugenol as % of the
dose at a dose of 0.05 mg/(kg bw) and black bars at a dose of 300 mg/(kg bw).
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Discussion
The objective of the present study was to define a PBK model for methyleugenol in male
rat, based on in vitro metabolic parameters, which would allow evaluation of the dose-
dependent differences in bioactivation and detoxification at different oral doses of
methyleugenol. The PBK modeling approach has the advantage of giving insight in the organs
involved in metabolism of methyleugenol and how that affects the ultimate chances on
conversion to the ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol in the liver.
Through the model, the formation of the proximate carcinogenic metabolite (1′-
hydroxymethyleugenol) and the ultimate carcinogenic metabolite (1′-sulfooxymethyleugenol)
of methyleugenol in the liver of male rat can be predicted.
The developed model was evaluated by comparing the PBK model predicted concentration
of methyleugenol in venous blood to literature data on methyleugenol concentrations in plasma
of male Fisher 344 rats at different time points (NTP, 2000). At 0.25, 4, 6, 8, and 10 hr, the
outcomes of the PBK model were in the same order of magnitude as these literature results. At
time points of 1 and 2 hr, the PBK predicted venous blood concentration of methyleugenol was
somewhat overestimated. For instance at 2 hr, it was found that the predicted venous blood
concentration of methyleugenol was about 18 times higher than what is observed in the
literature. We should bear in mind that the present in vitro study was undertaken using tissue
fractions obtained from male Sprague Dawley rats while the in vivo study was performed using
male Fisher 344 rats (NTP, 2000). Also, differences in predicted and observed blood
concentrations of methyleugenol could be partly due to the fact that the model predicts whole
blood concentrations whereas the in vivo study covers plasma concentrations. This comparison
between whole blood and plasma concentrations can only be made based on the assumption that
the whole blood and plasma concentrations are equal. Furthermore, protein binding may
provide another explanation for the fact that the PBK predicted venous blood concentrations of
methyleugenol are somewhat higher than the observed blood concentrations. An additional
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evaluation of the model was performed by comparing the PBK predicted % of formation of
both 2-hydroxy-4,5-dimethoxyallylbenzene and 3-hydroxy-4-methoxyallylbenzene to the
literature date of urine samples (collected over 24 hr) of a male Wister rat given a single oral
dose of 200 mg/(kg bw) of methyleugenol. The PBK model predicted accurately the formation
of 3-hydroxy-4-methoxyallylbenzene while the PBK model based predicted formation of 2-
hydroxy-4,5-dimethoxyallylbenzene was only 2.6-fold higher than the reported literature value
and thus within the same order of magnitude (Solheim and Scheline, 1976). Additional
evaluation was performed by comparing the PBK model based predicted % of formation of 1′-
hydroxymethyleugenol glucuronide in urine (collected over 24 hr) of a male Fisher rat given a
single oral dose of 118 mg/(kg bw) of methyleugenol. The PBK model accurately predicted the
level of formation of the 1'-hydroxymethyleugenol glucuronide metabolite which was only 1.3-
fold higher than the observed in vivo value (NTP, 2000). The difference between the
experimental data and the literature data could be to some extent due to the strain dependent
differences in kinetics and scaling of in vitro metabolic data, although additional results of the
present study revealed that influences of species differences in especially phase I kinetics were
limited. The sensitivity analysis revealed that the influence of uncertainties in metabolic
parameters and scaling of in vitro metabolic parameters to the in vivo situation could affect the
outcomes of the PBK model. Overall it is important to stress that deviations within one order of
magnitude are generally considered acceptable within the present state-of-the-art of integrating
in vitro data and PBK modeling (Hissink et al., 1997; Lupfert and Reichel, 2005; Punt et al.,
2008; Quick and Shuler, 1999). This implies that conclusions derived from the present model
should preferably not be based on absolute outcomes but rather on comparison of different
conditions in a relative way as done in the present study. The PBK model developed in the
present study can be used to study dose-dependent bioactivation.
We have observed that increasing the dose is accompanied with increasing formation of the
reactive metabolite 1′-sulfooxymethyleugenol for methyleugenol. At a low dose of 0.05 mg/(kg
bw), which is relevant for dietary human intake, formation of methyleugenol-2′,3′-oxide and 3-
(3,4-dimethoxyphenyl)-2-propen-1-ol are the major metabolic routes amounting to 31.0 % and
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32.9% of the dose respectively. These metabolites are formed in the liver. Due to saturation of
these metabolic routes at higher doses, a relative increase in formation of the proximate
carcinogenic metabolite 1′-hydroxymethyleugenol occurs, resulting in a relative increase in
formation of 1′-sulfooxymethyleugenol as well. Formation of 1′-sulfooxymethyleugenol
increased from 0.042% of the dose at a dose of 0.05 mg/(kg bw) to 0.06% of the dose at a dose
of 300 mg/(kg bw).
Similar dose-dependent effects in bioactivation have previously been observed with the
PBK model developed for the related alkenylbenzene estragole (Punt et al., 2008). In case of
estragole, the formation of the ultimate carcinogenic metabolite 1′-sulfooxyestragole increased
from 0.08% of the dose at a dose of 0.05 mg/(kg bw) to 0.16% at a dose of 300 mg/(kg bw).
The underlying mechanism resulting in these dose-dependent effects on bioactivation of
estragole were, however, different than currently observed for methyleugenol. For estragole, the
dose-dependent effects in bioactivation were a result from a shift in phase I metabolism from O-
demethylation to 1′-hydroxylation with increasing doses of estragole. O-demethylation of
estragole is the major metabolic route at low doses, occurring mainly in the lung and kidney of
male rat. Due to saturation of the O-demethylation pathway in lung and kidney at higher doses,
formation of the proximate carcinogenic metabolite 1′-hydroxyestragole, occurring mainly in
the liver, becomes relatively more important leading to a relative increase in formation of 1′-
sulfooxyestragole as well. In case of methyleugenol, the dose-dependent effects in bioactivation
were a result from a shift in phase I metabolism from 3′-hydroxylation and hydroxylation of the
benzene ring to 1′-hydroxylation with increasing doses of methyleugenol. Due to saturation of
the 3′-hydroxylation and the hydroxylation of benzene ring pathways in liver at higher doses,
formation of the proximate carcinogenic metabolite 1′-hydroxymethyleugenol, occurring in the
liver, becomes relatively more important leading to a relative increase in formation of 1′-
sulfooxymethyleugenol.
Although the metabolic pathways of methyleugenol and the importance of different
metabolic routes have, so far, been considered to be similar to those for estragole (Smith et al.,
2010; Smith et al., 2002), the present study reveals some major differences in the metabolic
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conversion of these related compounds. An important difference is that the O-demethylation
route is not the major detoxification route of methyleugenol at low doses (predicted to account
for 3.4% of the dose at a dose of 0.05 mg/(kg bw)), whereas this has been observed to be the
major detoxification route at low doses for estragole (predicted to account for 56% of the dose
at a dose of 0.05 mg/kg bw) (Punt et al., 2008). With the previously developed PBK model for
estragole in male rat we observed that formation of this metabolite of estragole mainly occurred
in the lung tissue. Such a high level of extrahepatic metabolism of estragole in male rat is
possibly due to a relatively high systemic bioavailability (57%) of estragole and the capacity of
the lung to catalyze O-demethylation with a high affinity. In case of methyleugenol, the
efficiency by which lung tissue fractions catalyze O-demethylation was much lower than
observed for estragole (20 μL/min/(mg microsomal protein) for methyleugenol versus 1360
μL/min/(mg microsomal protein) for estragole (Punt et al., 2008)). This can explain the lower
level of conversion of methyleugenol via this metabolic pathway. The relative low level of O-
demethylation of methyleugenol is supported by in vivo data revealing that only 3.0% of the
dose is excreted via this metabolic route in male Wistar rats exposed to 200 mg/(kg bw),
whereas in case of estragole this metabolic route has been reported to account for 29-50% of the
dose in female Wistar rats exposed to a comparable oral dose of 500 mg/(kg bw) (Anthony et
al., 1987; Solheim and Scheline 1976). Altogether, the observed differences in metabolic
conversion between estragole and methyleugenol indicate the importance of evaluating the
metabolic fate of methyleugenol and consequences of dose-dependent effects in bioactivation
versus detoxification for the risk assessment of methyleugenol separate from estragole.
The relative increase in the formation of the proximate carcinogenic metabolite 1′-
hydroxymethyleugenol and the ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol in
the liver of male rat with increasing dose of methyleugenol implies a relative increase in
bioactivation of methyleugenol with the dose. This indicates that when extrapolating from high
dose animal experiments to low doses relevant for dietary human intake, it is important to take
into account non-linear effects in kinetics. In addition to dose-dependent effects, species
differences in metabolism and metabolic activation should also be taken into account in the
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extrapolation of animal carcinogenicity data to the human situation. To determine the overall
differences between humans and male rats in bioactivation of methyleugenol, it is of
importance to compare the relative extent of different metabolic pathways between these
species. To this end, now a similar PBK model for the human situation is being constructed.
Comparison of the results predicted by such a PBK model for the human to those predicted by
the rat model of the present study can provide further insight in species differences in
metabolism and metabolic activation of the alkenylbenzene methyleugenol.
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Abstract
This study defines a physiologically based kinetic (PBK) model for methyleugenol in
human based on in vitro and in silico derived parameters. With the model obtained,
bioactivation and detoxification of methyleugenol at different doses levels could be
investigated. The outcomes of the current model were compared with those of a previously
developed PBK model for methyleugenol in male rat. The results obtained reveal that formation
of 1′-hydroxymethyleugenol glucuronide, a major metabolic pathway in male rat liver, appears
to represent a minor metabolic pathway in human liver whereas in human liver a significantly
higher formation of 1′-oxomethyleugenol compared with male rat liver is observed.
Furthermore, formation of 1′-sulfooxymethyleugenol, which readily undergoes desulfonation to
a reactive carbo-cation that can form DNA or protein adducts, is predicted to be the same in the
liver of both human and male rat at oral doses of 0.0034 and 300 mg/(kg bw). Altogether
despite a significant difference in especially the metabolic pathways of the proximate
carcinogenic metabolite 1′-hydroxymethyleugenol between human and male rat, the influence
of species differences on the ultimate overall bioactivation of methyleugenol to 1′-
sulfooxymethyleugenol appears to be negligible. Moreover, the PBK model predicted the
formation of 1′-sulfooxymethyleugenol in the liver of human and rat to be linear from doses as
high as the benchmark dose (BMD10) down to as low as the virtual safe dose (VSD). This study
shows that kinetic data do not provide a reason to argue against linear extrapolation from the rat
tumor data to the human situation.
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Introduction
Methyleugenol is a natural constituent of the essential oils of a number of plants (De
Vincenzi et al., 2000).  It occurs in clove oil, allspice, cinnamon bark, walnuts, basil, nutmeg,
tarragon, star anise, lemongrass, pimento and fennel (SCF, 2001).  Methyleugenol is commonly
used as a flavoring agent, either natural or synthetic, in many food stuffs, for instance, candy,
cookies such as gingersnaps, ice cream, tomato ketchup and relish (Burdock, 1995; Leung,
1980). The use of methyleugenol as pure substance in food is momentarily limited to the US
since the European Union recently decided to prohibit the use of the compound (European
Commission, 2008). Botanical extracts containing methyleugenol are however still allowed and
in use. Methyleugenol was found to account for 2.6 %, 3.7 %, 13 % and 0.8 % of the volatile oil
of basil, bay (leaves), pimento (berry), and nutmeg, respectively (Smith et al., 2002). Moreover,
methyleugenol is used as a fragrance in some perfumes and toiletries at concentrations of 0.002-
0.3% (SRI International, 1990). Though the International Fragrance Research Association
(IFRA) has recently restricted the use of methyleugenol and established a limit of 2.5 µg/(kg
bw)/day (IFRA, 2009).  In 1965, the Expert Panel of the Flavor and Extract Manufacturers
Association (FEMA) concluded that methyleugenol was GRAS (Generally Recognized As
Safe) under conditions of intended use as a flavoring substance in food (Hall and Oser, 1965).
In the FEMA evaluation, it was taken into account that there are experimental data suggesting a
non-linear relationship between dose and profiles of metabolism and metabolic activation and
that exposure due to use as a flavoring is relatively low (Smith et al., 2002). Methyleugenol was
nominated for toxicological characterization and testing by the National Toxicology Program
(NTP) because it is widely used and it structurally resembles the known carcinogens safrole and
estragole (Miller et al., 1983; NTP, 1998). In 2000, the carcinogenicity of methyleugenol was
investigated in mice and rats by the National Toxicology Program (NTP) (NTP, 2000). The
NTP reported that methyleugenol is carcinogenic in both rats and mice (NTP, 2000).  It was
also shown that methyleugenol possesses a cytotoxic and genotoxic activity in rat hepatocytes
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(Burkey et al., 2000). In 2001, the FEMA Panel reassessed the available data for methyleugenol
and confirmed that there is no considerable cancer risk resulting from consumption of
methyleugenol as flavoring substance and affirmed the GRAS status of methyleugenol as a
flavoring substance given the low levels of exposure (Smith et al., 2002).  In 2001, the
Scientific Committee on Food (SCF) of the European Union published a scientific opinion on
methyleugenol in which it was concluded that methyleugenol is genotoxic and carcinogenic and
that reductions in exposure and restrictions in use levels are indicated (SCF, 2001).  On the
other hand, it is of interest to note that although methyleugenol forms DNA adducts (Gardner et
al., 1997; Phillips et al., 1984) and induces unscheduled DNA synthesis in rat liver (Chan and
Caldwell, 1992), it is negative in many in vitro genotoxicity assays and also did not induce
DNA damage  in liver, bone marrow, and bladder in a regular in vivo Comet assay in the
Fischer 344 rat following exposure to methyleugenol at dose level up to 2000 mg/(kg bw)/day
(Ding et al., 2011).  The average daily intake of methyleugenol was estimated by the SCF to be
13 mg/day, corresponding to 0.217 mg/(kg bw)/day for a 60 kg person (SCF, 2001), while the
FEMA, using a different methodology, estimated the average daily intake of methyleugenol to
be less than 0.01 mg/(kg bw)/day (Smith et al., 2002). The estimation of the SCF was based on
theoretical maximum use levels of methyleugenol in various food categories and consumption
data for these food categories, whereas the intake estimation of the FEMA was based on
production volume data for flavor use (SCF, 2001; Smith et al., 2002).
Methyleugenol is unreactive by itself but undergoes metabolic activation to produce an
electrophilic metabolite that acts as the reactive genotoxic DNA binding intermediate (Gardner
et al., 1997; Miele et al., 2001).  Figure 1 displays the different metabolic pathways of
methyleugenol. Important metabolic pathways include O-demethylation of the methoxy
moieties on the benzene ring, 2′,3′-epoxidation, and 1′-hydroxylation of the allylic side chain
(NTP, 2000; Solheim and Scheline, 1976). O-demethylation of the methoxy substituents of
methyleugenol yields the corresponding phenolic derivatives (3-hydroxy-4-methoxyallylbenzene
and eugenol), which may be excreted as sulfate or glucuronic acid conjugate (Smith et al.,
2002).  Epoxidation of the side chain yields a 2′,3′-epoxide (methyleugenol-2′,3′-oxide).  This
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epoxide (methyleugenol-2′,3′-oxide) is detoxified by epoxide hydrolase to form the dihydrodiol
(3-(3,4-dimethoxyphenyl)propane-1,2-diol) or via glutathione conjugation (Luo and Guenther,
1995). Hydroxylation at the 1'-position of methyleugenol is considered to represent the
bioactivation pathway producing the proximate carcinogenic metabolite 1′-
hydroxymethyleugenol (Drinkwater et al., 1976; Miller et al., 1983). In a next step 1′-
hydroxymethyleugenol can be sulfonated by sulfotransferases to form 1′-
sulfooxymethyleugenol which readily undergoes desulfonation to carbo-cation that can form
DNA adduct (Miller et al., 1983).
Recently, physiologically based kinetic (PBK) models were developed for methyleugenol in
male rat (Al-Subeihi et al., 2011) and for the related genotoxic and carcinogenic
alkenylbenzene estragole in male rat (Punt et al., 2008) and in human (Punt et al., 2009). These
models were capable of elucidating dose-dependent effects in bioactivation and detoxification
of methyleugenol and estragole, based on in vitro metabolic parameters. In addition to dose-
dependent effects, species differences in metabolism and metabolic activation can also occur.
For instance, Punt et al. (2007) previously demonstrated that male rats are more efficient in
sulfonation of 1′-hydroxyestragole than humans, and that male rats are far more efficient in
glucuronidation of 1′-hydroxyestragole than humans, whereas humans preferentially oxidize 1′-
hydroxyestragole to 1′-oxoestragole, a reaction hardly observed in male rats.
The objective of the present study was to develop a PBK model for methyleugenol in human
to determine the overall differences between humans and male rats in bioactivation and
detoxification of methyleugenol. To this end, the present study investigated the kinetics of
possible metabolic reactions of methyleugenol and 1′-hydroxymethyleugenol in incubations
with relevant human tissue fractions. The kinetic data obtained were used to build a PBK model
for methyleugenol metabolism in human to predict the relative extent of bioactivation and
detoxification of methyleugenol at dose levels relevant for dietary human intake. An evaluation
of the model defined was performed by comparing the predicted concentrations of
methyleugenol in whole blood to the levels of methyleugenol in serum blood of human
volunteers exposed to methyleugenol reported in the literature (Schecter et al., 2004). The
A PBK MODEL FOR METHYLEUGENOL IN HUMAN
88
Figure 1. Suggested metabolic pathways of methyleugenol in human.
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outcomes of the model were subsequently compared with those of the previously defined PBK
model for methyleugenol in male rat to evaluate the occurrence of species differences in
metabolic activation and detoxification of methyleugenol.
Materials and Methods
Chemical and reagents
Pooled mixed gender human liver microsomes, cytosol and S9 were purchased from BD
Gentest (Woburn, MA, USA). Pooled mixed gender kidney, lung and small intestine
microsomes were purchased from BioPredic International (Rennes, France). Hydrochloric acid
(37%), potassium dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, and acetic
acid were purchased from VWR International (Darmstadt, Germany). NADPH, NADP+,
NADH and NAD+ were obtained from Roche Diagnostics (Mannheim, Germany).
Methyleugenol, eugenol, methanol, dimethylsulfoxide (DMSO), ascorbic acid, alamethicin,
glutathione (GSH), and uridine 5′-diphosphoglucuronic acid (UDPGA) were purchased from
Sigma-Aldrich (Steinheim, Germany). Acetonitrile (UPLC/MS grade) was obtained from
Biosolve (Valkenswaard, Netherlands). 3′-Phosphoadenosine-5′-phosphosulfate (PAPS) was
obtained from Sigma Aldrich (Steinheim, Germany). 1′-Acetoxymethyleugenol, 1′-
hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, methyleugenol-2′,3′-oxide, 3-
(3,4-dimethoxyphenyl)propane-1,2-diol, 3-hydroxy-4-methoxyallylbenzene, and 1′-
oxomethyleugenol were synthesized and characterized as described previously (Al-Subeihi et
al., 2011).
Caution: 1′-acetoxymethyleugenol, 1′-hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-
propen-1-ol, methyleugenol-2′,3′-oxide, and 1′-oxomethyleugenol are carcinogenic and should
be handled carefully.
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In vitro incubations
Phase I Metabolism
Determination of the organs in human which are involved in the metabolism of
methyleugenol was performed as described for male rat (Al-Subeihi et al., 2011). In short, the
microsomal preparations of the liver, lung, kidney, and small intestine from human were
incubated with methyleugenol in the presence of NADPH, and the formation of the metabolites
was monitored over time. The incubation mixtures had a final volume of 160 μL, containing
(final concentrations) 3 mM NADPH, 1 mM ascorbic acid and 1 mg/mL microsomal protein in
0.2 M Tris-HCl (pH 7.4). After pre-incubation at 37 °C for 1 min, the reactions were started by
the addition of the substrate methyleugenol added from a 100 times concentrated stock solution
in DMSO. The reactions were terminated by addition of 40 μL cold acetonitrile. Initial
incubations were performed at a substrate concentration of 1000 μM (final concentration) at
several incubation times and microsomal protein concentrations. Blank incubations were
performed without the cofactor NADPH.
The kinetic constants for the formation of different phase I metabolites of methyleugenol
were determined in liver microsomes, which were found to be capable of metabolizing
methyleugenol (see Results section). The incubation mixtures were as described above.
Incubations with human microsomes were carried out for 10 min at a substrate concentration
that ranged from 25 to 800 μM methyleugenol. Under the conditions specified, the formation of
the different methyleugenol metabolites was linear with time and microsomal protein
concentration. In the blank incubations performed without NADPH low amounts of 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol and eugenol were formed. Therefore the formation of 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol and eugenol was corrected for the amount of these metabolites
already formed in the blank incubations.
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HPLC analysis of Phase I metabolites
Before HPLC analysis of the samples, all incubations were centrifuged for 5 min at 16,000
g. Aliquots of 50 μL of the supernatant of each sample were analyzed as previously described
(Al-Subeihi et al., 2011).
Quantification of 1′-hydroxymethyleugenol was achieved by comparison of the peak area of
this metabolite in the chromatograms obtained at a wavelength of 280 nm to the calibration
curve of the synthesized 1′-hydroxymethyleugenol obtained at the same wavelength. Because 3-
(3,4-dimethoxyphenyl)propane-1,2-diol has the same UV spectrum as 1′-hydroxymethyleugenol,
2-hydroxy-4,5-dimethoxyallylbenzene, and 3-(3,4-dimethoxyphenyl)-2-propen-1-ol have the
same UV spectrum as 1′-acetoxymethyleugenol (data not shown), it was assumed that they have
the same molar extinctioncoefficient as1′-hydroxymethyleugenol, and 1′-acetoxymethyleugenol,
respectively. Quantification of 3-(3,4-dimethoxyphenyl)-propane1,2-diol, reflecting formation
of methyleugenol-2′,3′-oxide in liver microsomes, was therefore achieved by comparison of the
peak area of the metabolite in the chromatograms obtained at a wavelength of 280 nm to the
calibration curve for 1′-hydroxymethyleugenol obtained at the same wavelength. The
quantification of 3-(3,4-dimethoxyphenyl)-2-propen-1-ol and 2-hydroxy-4,5-dimethoxyallyl-
benzene was achieved by comparison of their peak areas in the chromatograms obtained at a
wavelength of 280 nm to the calibration curve for 1′-acetoxymethyleugenol. Quantification of
eugenol in liver microsomes was achieved by comparison of the peak area of eugenol obtained
in the chromatograms to the calibration curve of eugenol (commercially available) obtained at
the same wavelength.
Phase II metabolism
Glucuronidation of 1′-hydroxymethyleugenol to 1′-hydroxymethyleugenol glucuronide
Incubations with pooled mixed gender human liver microsomes were performed as
described by Al-Subeihi et al. (2011). The incubation mixture had a final volume of 200 μL,
containing (final concentrations) 10 mM UDPGA, and 1 mg/mL microsomal protein in 0.2 M
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Tris-HCl (pH 7.4) containing 10 mM MgCl2. The incubation mixture was pre-treated with
0.025 mg/mL of the poreforming peptide alamethicin from a 200 times concentrated stock in
methanol on ice for 15 min to overcome enzyme latency and obtain maximal glucuronidation
activity (Fisher et al., 2000; Lin and Wong, 2002). The reactions were started by the addition of
the substrate 1′-hydroxymethyleugenol from a 200 times concentrated stock solution in DMSO,
after pre-incubation at 37 °C for 1 min. The reactions were carried out for 6 hr and terminated
by addition of 50 μL cold acetonitrile. Blank incubations were performed without the cofactor
UDPGA. Verification of the formation of 1′-hydroxymethyleugenol glucuronide was performed
by treatment of incubations with β-glucuronidase and analysis of samples by LC-MS as
described previously (Al-Subeihi et al., 2011).
The kinetic constants for the formation of 1′ -hydroxymethyleugenol glucuronide from 1′-
hydroxymethyleugenol were determined using pooled mixed gender human liver microsomes.
The incubation mixtures were as described above. Incubations with human liver microsomes
were carried out for 6 hr at a substrate concentration that ranged from 50 to 2000 μM 1′-
hydroxymethyleugenol. Under the conditions specified the formation of 1′-
hydroxymethyleugenol glucuronide was linear with time and microsomal protein concentration.
In the blank incubations performed without UDPGA no 1′-hydroxymethyleugenol glucuronide
was formed.
HPLC analysis was used for quantification of 1′-hydroxymethyleugenol glucuronide as
described previously (Al-Subeihi et al., 2011). Because 1′-hydroxymethyleugenol glucuronide
has the same UV spectrum as 1′-hydroxymethyleugenol (data not shown) it was assumed that it
has the same molar extinction coefficient as 1′-hydroxymethyleugenol. Quantification of 1′-
hydroxymethyleugenol glucuronide was therefore achieved by comparison of the peak area of
1′-hydroxymethyleugenol glucuronide in the chromatograms obtained at a wavelength of 280
nm to the calibration curve of 1′-hydroxymethyleugenol obtained at the same wavelength.
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Oxidation of 1′-hydroxymethyleugenol to 1′-oxomethyleugenol
Formation of 1′-oxomethyleugenol was studied as described by Al-Subeihi et al. (2011).
Incubations were performed with pooled mixed gender human liver microsomes or cytosol,
using NAD+, NADP, NADPH+ or NADPH as cofactor and GSH to trap the reactive 1′-
oxomethyleugenol. The kinetic constants for formation of the 1′-oxomethyleugenol adduct with
glutathione, reflecting the formation of 1′-oxomethyleugenol, were determined with human
liver microsomes or cytosol at substrate concentrations that ranged from 10 to 2000 µM or 50 to
2000 µM 1′-hydroxymethyleugenol, respectively. The incubation mixtures with microsomes
had a final volume of 160 µL, containing (final concentrations) 3 mM NAD+, 2 mM GSH, and
1 mg/mL microsomal protein in 0.2 M Tris-HCl (pH 7.4). The reactions were terminated after
10 min by addition of 40 µL cold acetonitrile. For cytosolic preparations, the incubation
mixtures had a final volume of 200 µL, containing (final concentrations) 3 mM NADP+, 2 mM
GSH, and 1 mg/mL cytosolic protein in 0.2 M Tris-HCl (pH 7.4). The reactions were
terminated after 10 min by addition of 50 µL cold acetonitrile. Under these conditions the
formation of the glutathione adduct, 3′-(glutathione-S-yl)-1′-oxo-2′-3′-dihydromethyleugenol
(GS-1′-oxomethyleugenol), was linear with time and either microsomal or cytosolic protein
concentration.
The incubation mixtures with either microsomal or cytosolic preparations were centrifuged
for 5 min at 16,000 g. HPLC analysis used for quantification of GS-1′-oxomethyleugenol
formed in microsomes was performed as described previously (Al-Subeihi et al., 2011). For the
HPLC analysis of the incubations in which formation of 1′-oxomethyleugenol in cytosol was
investigated a different HPLC method was used. For these samples 50 μL of the supernatants
were analyzed on an Alltima C18 5-μm column, 150 mm × 4.6 mm (Grace Alltech, Breda, The
Netherlands), coupled to a Waters 2695 Alliance HPLC system. The gradient was made with
acetonitrile and ultrapure water containing 0.1% acetic acid. The flow rate was 1 mL/min and
the gradient was applied from 0 to 10% acetonitrile over 10 min, after which the percentage of
acetonitrile was increased to 25% over 10 min and then increased to 100% over 5 min and kept
at 100% for 1 min. Detection was performed at 280 nm using a Waters 2996 photodiode array
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detector. Quantification of GS-1′-oxomethyleugenol formed in incubations with either
microsomes or cytosol was performed by means of a calibration curve obtained as described by
Al-Subeihi et al. (2011) and Punt et al. (2009).
Sulfonation of 1′-hydroxymethyleugenol to 1′-sulfooxymethyleugenol
The formation of 1′-sulfooxymethyleugenol was characterized in incubations of 1′-
hydroxymethyleugenol with human liver S9 in the presence of GSH as scavenger, as described
previously by Al-Subeihi et al. (2011). The incubation mixture had a final volume of 100 µL
containing the following materials (final concentration): 5 mM GSH, 2 mg/mL S9, and 0.2 mM
PAPS in 0.1 M potassium phosphate (pH 8.2). The incubation was started by addition of the
substrate 1′-hydroxymethyleugenol. The incubation mixture was incubated for 2 hr at 37 °C,
after which 25 µL of cold acetonitrile was added. Under these conditions the formation of the
glutathione adduct of carbo-cation derived from 1′-sulfooxymethyleugenol was linear with time
and S9 protein concentration. The kinetic constants for the formation of 1′ -
sulfooxymethyleugenol from 1′-hydroxymethyleugenol were determined using human liver S9.
The incubation mixtures were as described above. Incubations with human liver S9 were
carried out for 2 hr at a substrate concentration that ranged from 50 to 1500 μM 1′-
hydroxymethyleugenol. All incubations were started by addition of substrate from a 200 times
concentrated stock solution in DMSO and terminated by addition of 25 μL cold acetonitrile. In
the blank incubations performed without GSH formation of the GSH adduct of the carbo-cation
of 1′-sulfooxymethyleugenol was not observed. Before HPLC analysis of the samples, all
incubations were centrifuged for 5 min at 16,000 g. Aliquots of 50 μL of the supernatant of
each sample were analyzed and quantified as previously described (Al-Subeihi et al., 2011).
PBK model methyleugenol
The PBK model for methyleugenol was developed based on the PBK models previously
defined for the detoxification and bioactivation of methyleugenol in rat (Al-Subeihi et al.,
2011), and for the related alkenylbenzene estragole in rat (Punt et al., 2008) and in human (Punt
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et al., 2009). Figure 2 presents a schematic overview of the PBK model. The final model is
composed of separate compartments including liver which was the only organ found to be
involved in the metabolism of methyleugenol (see Results section). Since the partition
coefficient of methyleugenol in fat tissue was predicted to be relatively high (Table 1), a
separate fat compartment was included in the developed model. All other tissues such as
adrenal, brain, heart, kidney and lungs were lumped into a richly perfused tissue group, while
tissues such as bone, muscle, and skin were lumped into a slowly perfused tissue group
(Ramsey and Anderson, 1984). The uptake of methyleugenol from the gastrointestinal tract was
modeled as a first-order process, assuming direct entry from the intestine to the liver
compartment, and an absorption rate constant (ka) value similar to that of estragole, which was
1.0 hr-1 (Punt et al., 2008). Based on the results of phase I incubations (see Results section), it
Figure 2. Representation of the conceptual model for a physiologically based kinetic model for methyleugenol in
human.
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Table 1. Parameters used in the physiologically based kinetic model for methyleugenol in human.
Physiological parametersa Tissue:blood partition coefficientsb
body weight (kg) 63.8 methyleugenol
percentage of body weight
liver 2.6 liver 6.2
fat 21.4 fat 103
rapidly perfused 5 rapidly perfused 6.2
slowly perfused 51.7 slowly perfused 3.9
blood 7.9
cardiac output  (L/hr) 323 1'-hydroxymethyleugenol
percentage of cardiac output liver 1.4
liver 22.7
fat 5.2
rapidly perfused 47.3
slowly perfused 24.8
a Brown et al. (1997)
b DeJongh et al.(1997)
was found that metabolites of methyleugenol to be taken into account are methyleugenol-2′,3′-
oxide, 1′-hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, 2-hydroxy-4,5-
dimethoxyallylbenzene, eugenol and 3-hydroxy-4-methoxyallylbenzene. Based on these results
the mass balance equations for methyleugenol in the metabolizing tissues are described as
follows:
Liver:
dALME/dt = dUptakeME/dt
+ QL*(CAME- CLME/PLME)
– Vmax,L_MEO* CLME/PLME / (Km,L_MEO + CLME/PLME)
– Vmax,L_1′HME* CLME/PLME / (Km,L_1′HME+CLME/PLME)
– Vmax,L_3DMPOH* CLME/PLME / (Km,L_3DMPOH+ CLME/PLME)
– Vmax,L_2HDME* CLME/PLME / (Km,L_2HDME+ CLME/PLME)
– Vmax,L_3HMA* CLME/PLME / (Km,L_3HMA+ CLME/PLME)
– Vmax,L_1EU* CLME/PLME / (Km,L_1EU + CLME/PLME)
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dUptakeME/dt = – dAGIME/dt = ka*AGIME,
AGIME (0) = Oral dose
CLME = ALME/VL
where UptakeME is the amount of methyleugenol taken up from the gastrointestinal tract
(µmol), AGIME (µmol) is the amount of methyleugenol remaining in the gastrointestinal tract,
ALME is the amount of methyleugenol in the liver (µmol) and CLME is the methyleugenol
concentration in the liver (µmol/L). CAME is the methyleugenol concentration in the arterial
blood (µmol/L) which is considered to be equal to the methyleugenol concentration in the
mixed venous blood compartment. QL is the blood flow rate to the liver (L/hr), QC is the
cardiac output (L/hr), VL is the volume of the liver, PLME is the tissue/blood partition
coefficient of methyleugenol in the liver, and Vmax,L_M and Km,L_M are the maximum rate of
formation and the Michaelis-Menten constant for the formation of the different phase I
metabolites in the liver: methyleugenol-2′,3′-oxide, 1′-hydroxymethyleugenol, 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol, 2-hydroxy-4,5-dimethoxyallylbenzene, eugenol, and 3-
hydroxy-4-methoxyallylbenzene. In case of methyleugenol-2′,3′-oxide, 2-hydroxy-4,5-
dimethoxyallylbenzene, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, eugenol and 3-hydroxy-4-
methoxyallylbenzene, only formation of these metabolites is taken into account and no further
reactions with these metabolites were modeled. Formation of 1′-hydroxymethyleugenol in the
liver, but not in any other compartment, was followed up by phase II reactions, since 1′-
hydroxylation of methyleugenol was found to occur only in the liver (see Results section). To
describe the disposition of 1′-hydroxymethyleugenol and its phase II metabolites a near
quantitative intrahepatic conversion of 1′-hydroxymethyleugenol by phase II enzymes was
assumed. This assumption was based on the finding that the overall catalytic efficiency for the
phase II reactions was higher than the catalytic efficiency for the formation of 1′-
hydroxymethyleugenol. For this reason only intra-organ distribution of 1′-
hydroxymethyleugenol was modeled and no distribution of this metabolite over the body was
taken into account. This simplification of the model reduced the number of parameters
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considerably, but might lead to an overestimation of the contributions of the phase II reactions
(Filser et al., 2001). The mass balance equation for 1′-hydroxymethyleugenol in the liver is as
follows:
Liver:
dAL1′HME/dt =  + Vmax,L_1′HME*CLME/PLME/(Km,L_1′HME+CLME/PLME)
– Vmax,L_1′OME_mic*CL1′HME/PL1′HME/(Km,L_1′OME_mic+CL1′HME/PL1′HME)
– Vmax,L_1′OME_cyt*CL1′HME/PL1′HME/(Km,L_1′OME_cyt+CL1′HME/PL1′HME)
– Vmax,L_1′HMEG*CL1′HME/ PL1′HME/(Km,L_1′HMEG+CL1′HME/PL1′HME)
– Vmax,L_1′HMES*CL1′HME/ PL1′HME/(Km,L_1′HMES+CL1′HME/PL1′HME)
CL1′HME = AL1′HME / VL
where AL1′HME is the amount of 1′-hydroxymethyleugenol in the liver (µmol), CL1′HME is the 1′-
hydroxymethyleugenol concentration in the liver (µmol/L), PL1′HME is the liver/blood partition
coefficient of 1′HME, and Vmax,L_M and Km,L_M are the maximum rate of formation and the
Michaelis-Menten constant for the formation of phase II metabolites: 1′-oxomethyleugenol
formed by microsomal enzymes (1′OME_mic), 1′-oxomethyleugenol formed by cytosolic
enzymes (1′OME_cyt), 1′-hydroxymethyleugenol glucuronide, and 1′-sulfooxymethyleugenol
in the liver. The kinetic constants for the formation of phase I metabolites from methyleugenol
and the metabolites formed from 1′-hydroxymethyleugenol were determined in vitro in the
present study. The Vmax values for the different phase I and phase II metabolic reactions, in the
liver, expressed as nmol/min/(mg microsomal protein), were scaled to the liver using a
microsomal protein yield of 32 mg/(g liver) (Barter et al., 2007). The Vmax values for cytosolic
oxidation of 1′-hydroxymethyleugenol expressed as nmol/min/(mg cytosolic protein) was
scaled to the liver using a cytosolic protein yield of 80.7 mg/(g liver) (Cubitt et al., 2011). The
Vmax values for sulfonation of 1′ -hydroxymethyleugenol, expressed as nmol/min/(mg S9
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protein) was scaled to the liver using an S9 protein yield of 143 mg/(g liver) as previously
inferred by Punt et al. (2008, 2009). This scaling factor was verified by determining the
difference in various cytochrome P450 marker substrate activities between pooled human liver
S9 and pooled human liver microsomes as specified by the supplier. On average these P450
marker substrate activities where 4.7±2.5-fold lower in pooled human liver S9 compared with
pooled human liver microsomes. This indicates that the scaling factor from liver S9 to the liver
needs to be on average 4.7 times higher than the scaling factor from human liver microsomes to
the liver. This is in line with the 4.5-fold higher scaling factor for human liver S9 used in the
present study. On the whole, the different scaling factors were in line with what we have used in
our previous study for the human model for bioactivation and detoxification of the related
alkenylbenzene estragole (Punt et al., 2009), thus facilitating comparison.
The physiological parameters used in the methyleugenol model were obtained from Brown
et al. (1997). Partition coefficients were estimated from the log Kow based on a method of
DeJongh et al. (1997) (Table 1). Log Kow values were estimated with KOWWIN™ version 1.67
using the EPISuite™ software package version 4.0 and amounted to 3.03 for methyleugenol
and 1.49 for 1′-hydroxymethyleugenol. Model equations were coded and numerically integrated
in Berkeley Madonna 8.0.1 (Macey and Oster, UC Berkeley, CA, USA), using the
Rosenbrock's algorithm for stiff systems.
Sensitivity analysis
To identify the key parameters to which the model output is most sensitive, a sensitivity
analysis was performed at a methyleugenol dose of 0.0034 mg/(kg bw). In this sensitivity
analysis all model parameters were tested including physiological parameters, tissue blood
partitions coefficients, and kinetics parameters for formation of the different metabolites.
Normalized sensitivity coefficients (SC) were determined according to the following equation:
SC = (C' − C)/(P' − P) *(P/C), where C is the initial value of model output, C' is the modified
value of the model output resulting from an increase in parameter value, P is the initial
parameter value, and P' is the modified parameter value (Rietjens et al., 2011). Based on the
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literature a 5% increase in parameter values was chosen, to analyze the effect of a change in
parameter on the formation of 1′-hydroxymethyleugenol and 1′-sulfooxymethyleugenol
expressed as % of the dose over a 24 hr period of time (Evans and Andersen, 2000). Each
parameter was analyzed individually, keeping the other parameters to their initial values.
Results
Formation of Phase I metabolites
The results obtained from HPLC analysis of incubations of methyleugenol with mixed
gender human liver, lung, kidney, and intestine microsomes in the presence of NADPH as
cofactor reveal that only the liver microsomes were capable of metabolizing methyleugenol to
different types of metabolites at varying rates. The HPLC chromatogram of incubations of
methyleugenol with liver microsomes (Figure 3) reveals formation of six metabolites of
methyleugenol which were identified as 3-(3,4-dimethoxyphenyl)propane-1,2-diol  (RT = 15.9
min), 1′-hydroxymethyleugenol (RT = 32.1 min), 3-(3,4-dimethoxyphenyl)-2-propen-1-ol (RT
= 34.2 min), 2-hydroxy-4,5-dimethoxyallylbenzene (RT = 35.1 min), eugenol (RT = 52.1 min),
and 3-hydroxy-4-methoxyallylbenzene (RT = 52.7 min). 3-(3,4-dimethoxyphenyl)propane-1,2-
diol, 1′-hydroxymethyleugenol and 3-(3,4-dimethoxyphenyl)-2-propen-1-ol were identified
based on the similarities of their retention times and UV spectra to those of chemically
synthesized reference compounds. Eugenol was identified based on the similarities of its
retention time and UV spectra to that of commercially obtained eugenol. Further identification
of 1′-hydroxymethyleugenol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, and methyleugenol-2′,3′-
oxide was previously performed by GC-MS as described by Al-Subeihi et al. (2011). No
reference compound was available for 2-hydroxy-4,5-dimethoxyallylbenzene but this
metabolite was identified as previously described by Al-Subeihi et al. (2011).
Incubating methyleugenol-2′,3′-oxide with liver microsomes in the absence of any cofactor
revealed  that  methyleugenol-2′,3′-oxide is completely hydrolyzed to 3-(3,4-dimethoxyphenyl)-
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Figure 3. HPLC chromatogram of an incubation of methyleugenol (1 mM) with human liver microsomes (1 mg/ml) in
the presence of NADPH (3 mM) as cofactor, and vitamin C (1 mM) as antioxidant.
propane-1,2-diol (Al-Subeihi et al., 2011), which is formed upon hydrolysis of methyleugenol-
2′,3′-oxide by epoxide hydrolases present in the microsomal preparation (Guenthner and Luo,
2001; Luo et al., 1992; Luo and Guenthner, 1995).
3-hydroxy-4-methoxyallylbenzene was identified as previously described by Al-Subeihi et
al., (2011).
Kinetics of formation of Phase I Metabolites
Human liver microsomes were incubated with increasing methyleugenol concentrations to
determine the kinetic parameters for the formation of the various phase I metabolites of
methyleugenol. Figure 4 (A-F) shows the rate of formation of 1′ -hydroxymethyleugenol,
methyleugenol-2′,3′-oxide measured as 3-(3,4-dimethoxyphenyl)propane-1,2-diol, 3-hydroxy-
4-methoxyallylbenzene, 2-hydroxy-4,5-dimethoxyallylbenzene, 3-(3,4-dimethoxyphenyl)-2-
propen-1-ol, and eugenol, respectively. Table 2 summarizes the apparent Km and Vmax values
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Figure 4. Formation rate of phase I metabolites in incubations with human liver microsomes at increasing
concentrations (25 – 800 µM) of methyleugenol indicating formation of A. 1′-hydroxymethyleugenol, B.
methyleugenol-2′,3′-oxide, C. 3-hydroxy-4-methoxyallylbenzene, D. 2-hydroxy-4,5-dimethoxyallylbenzene, E. 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol, and F. at increasing concentrations (25 – 600 µM) of methyleugenol indicating
formation of eugenol.
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Table 2. Kinetic parameters for phase I metabolism of methyleugenol in incubations with human liver
microsomes.
metabolite Km(app)
a,b Vmax(app)
a,c
in vitro
catalytic
efficiencyd
(Vmax(app)/Km(app)
Scaled
Vmax(app),
in vivoe
in vivo
catalytic efficiencyf
(scaled Vmax(app),
in vivo/Km(app))
methyleugenol-2′,3′-oxide 23.7 ± 5 0.66  ± 0.11 27.8 1.27 54
1′-hydroxymethyleugenol 404  ± 195 1.38  ± 0.38 3.4 2.65 6.6
3-(3,4-dimethoxyphenyl)-2-propen-1-ol 161 ± 90 0.39  ± 0.08 2.4 0.75 4.7
2-hydroxy-4,5-dimethoxyallylbenzene 415 ± 84 0.10 ± 0.02 0.24 0.19 0.46
eugenol 13.6 ± 12.3 0.15 ± 0.02 11.0 0.29 21.3
3-hydroxy-4-methoxyallylbenzene 1097 ± 142 0.21 ± 0.02 0.2 0.40 0.36
a mean ± SD
bµM
cnmol/min/(mg microsomal protein)
d(µL/min/(mg microsomal protein)
eµmol/(hr(g liver)), calculated from the in vitro Vmax(app) based on a microsomal protein yield of  32 mg/(g liver)
fL/(hr(g liver))
obtained from these plots. The results reveal that 1′ -hydroxymethyleugenol is the most
abundant metabolite formed, followed by methyleugenol-2′,3′-oxide measured as 3-(3,4-
dimethoxyphenyl)propane-1,2-diol, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol, 3-hydroxy-4-
methoxyallylbenzene and eugenol. Formation of 2-hydroxy-4,5-dimethoxyallylbenzene was
shown to be the least important metabolic route in these incubations. The apparent Vmax for 2-
hydroxy-4,5-dimethoxyallylbenzene was about 14 times lower than the apparent Vmax for
formation of 1′-hydroxymethyleugenol, whereas the apparent Km was equal. Overall, the
catalytic efficiency for the formation of the 2-hydroxy-4,5-dimethoxyallylbenzene by human
liver microsomes, calculated as the apparent Vmax/Km, was about 14 times lower than the
catalytic efficiency for the formation of 1′-hydroxymethyleugenol.
Formation of 1′-hydroxymethyleugenol metabolites
1′-Hydroxymethyleugenol glucuronide
HPLC analysis of an incubation of 1′-hydroxymethyleugenol with human liver microsomes
in the presence of UDPGA as a cofactor, revealed formation of one metabolite with RT of 19.3
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min (chromatogram not shown). Treatment of the sample with β-glucuronidase, resulted in
complete disappearance of the peak at 19.3 min accompanied by a comparable increase of the
peak representing 1′-hydroxymethyleugenol. This confirms that the metabolite corresponds to
the glucuronosyl conjugate of 1′-hydroxymethyleugenol. Furthermore the spectrum of the
metabolite, obtained by LC-MS, reveals a deprotonated molecule at m/z 369, which corresponds
to the theoretically expected mass and confirms that the metabolite corresponds to 1′-
hydroxymethyleugenol glucuronide (Al-Subeihi et al., 2011).
1′-Oxomethyleugenol
HPLC analysis of an incubation of 1′-hydroxymethyleugenol with human liver microsomes
using NAD+ as a cofactor and GSH as a trapping agent for the reactive 1′-oxomethyleugenol,
revealed the formation of a metabolite with RT of 11.4 min (chromatogram not shown). HPLC
analysis of control incubations of 1′-hydroxymethyleugenol in the absence of NAD+ revealed
no appearance of the peak at RT of 11.4 min (chromatogram not shown).  This argument was
used as a confirmation for the formation of the GSH adduct of 1′-oxomethyleugenol and thus of
1′-oxomethyleugenol in the incubation with NAD+. Previously the nature of this metabolite was
confirmed by LC-MS revealing a deprotonated molecule at m/z 500 (Al-Subeihi et al., 2011).
Incubations with human liver microsomes in the presence of other cofactors, including NADH,
NADP+, or NADPH and GSH also revealed some formation of the glutathione adduct with 1′-
oxomethyleugenol, but at a much smaller extent than the incubations with NAD+. These
reactions were therefore not considered to significantly contribute to the overall reaction rate
(chromatograms not shown).
HPLC analysis of the incubations of 1′-hydroxymethyleugenol with human liver cytosol
using NADP+ as cofactor and GSH as a trapping agent for the reactive 1′-oxomethyleugenol
also revealed formation of the glutathione conjugate of 1′-oxomethyleugenol. Using a different
HPLC method than for the analysis of the incubations with human liver microsomes for the
same reaction the RT of this metabolite was observed to be 18.2 min (chromatogram not
shown). HPLC analysis of control incubations of 1′-hydroxymethyleugenol in the absence of
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NADP+ revealed no peak at this retention time (chromatogram not shown). Incubations with
human liver cytosol in the presence of other cofactors, including NAD+ or NADH and GSH
also revealed formation of the glutathione adduct with 1′-oxomethyleugenol, but to a much
smaller extent than the incubations with NADP+. These reactions were therefore not considered
to significantly contribute to the overall reaction rate. The same incubations with NADPH as
cofactor, revealed no formation of the glutathione adduct with 1′-oxomethyleugenol
(chromatograms not shown).
1′-Sulfooxymethyleugenol
HPLC analysis of an incubation of 1′-hydroxymethyleugenol with human liver S9 using
PAPS as a cofactor and GSH as a scavenger for the reactive carbo-cation derived from the
unstable 1′-sulfooxymethyleugenol metabolite, revealed formation of a metabolite with RT of
12.9 min (chromatogram not shown). HPLC analysis of incubations of 1′-
hydroxymethyleugenol in the absence of GSH and in the presence of PAPS and liver S9 protein
revealed no appearance of the peak at 12.9 min (chromatogram not shown).  This argument was
used as a confirmation for the formation of the GSH adduct of the carbo-cation of 1′-
sulfooxymethyleugenol, and thus an indirect detection of formation of 1′-
sulfooxymethyleugenol in the complete incubation. Furthermore the spectrum of the metabolite,
obtained by LC-MS, reveals a protonated molecule at m/z 484, which corresponds to the
theoretically expected mass and confirms that the metabolite corresponds to the GSH adduct of
the carbo-cation formed from 1′-sulfooxymethyleugenol (Al-Subeihi et al., 2011).
Kinetics of phase II metabolite formation
Figure 5A presents the formation of 1′ -hydroxymethyleugenol glucuronide in incubations
with microsomal preparations from human liver and UDPGA at increasing 1′-
hydroxymethyleugenol concentrations. Figure 5B and Figure 5C present the formation of 1′-
oxomethyleugenol in incubations with microsomal or cytosolic preparations from human liver
and either  NAD+ or NADP+ plus GSH at increasing 1′-hydroxymethyleugenol concentrations.
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C. D.
Figure 5. Formation rate of 1′-hydroxymethyleugenol metabolites including A. 1′-hydroxymethyleugenol glucuronide
(1′HMEG) in incubations with human liver microsomes at increasing concentration of 1′-hydroxymethyleugenol (50 –
2000 µM), B. 1′-oxomethyleugenol (1′OME) in incubations with human liver microsomes at increasing concentration
of 1′-hydroxymethyleugenol (50 – 2000 µM), C. 1′-oxomethyleugenol (1′OME) in incubations with human liver
cytosol at increasing concentration of 1′-hydroxymethyleugenol (50 – 2000 µM), and D. 1′-sulfooxymethyleugenol
(1′HMES) in incubations with human liver S9 at increasing concentration of 1′-hydroxymethyleugenol (50 – 1500 µM).
In addition, Figure 5D presents the formation of the GSH conjugate of the carbo-cation of 1′-
sulfooxymethyleugenol in incubations with a human liver S9 preparation, PAPS, GSH and
increasing 1′-hydroxymethyleugenol concentrations. The kinetic parameters (Vmax and Km),
obtained by fitting the data to the standard Michaelis-Menten equation, are presented in Table3.
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Table 3. Kinetic parameters for the metabolites of 1'-hydroxymethyleugenol in incubations with human
liver preparations.
metabolite km(app)
a,b Vmax(app)
a
in vitro
catalytic efficiency
(Vmax(app)/Km(app)
Scaled Vmax,
in vivoh
in vivo
catalytic efficiency i
(scaled Vmax, in vivo/Km(app))
1'-hydroxymethyleugenol
glucuronide
2393 ± 486 0.66 ± 0.087c 0.28 e 1.27 0.53
1'-oxomethyleugenol
in liver microsomes
1744 ± 2997 2.1 ± 1.83c 1.2 e 4.03 2.31
1'-oxomethyleugenol
in liver cytosol
1580 ± 538 1.58 ± 0.206c 1f 7.65 4.84
1'-sulfooxymethyleugenol 139 ± 82 0.0009 ± 0.0002d 0.0065g 0.0077 0.056
a mean ± SD
bµM
cnmol/min/(mg microsomal protein)
d nmol/min/(mg S9 protein)
e(µL/min/(mg microsomal protein)
f(µL /min/(mg cytosolic protein)
g(µL/min/(mg S9 protein)
hµmol/(hr(g liver)), calculated from the in vitro Vmax(app) based on a microsomal protein yield of  32 mg/(g liver),
cytosolic protein yield of 80.7  mg/(g liver) and a S9 protein yield of 143 mg/(g liver)
iL/(hr (g liver))
Comparing the scaled kinetic constants for glucuronidation to sulfonation and oxidation reveals
that the scaled Vmax(app) for 1′-sulfooxymethyleugenol formation was about 165 times lower than
the scaled Vmax(app) for formation of 1′-hydroxymethyleugenol glucuronide. Overall, the scaled
catalytic efficiency for the formation of the 1′-sulfooxymethyleugenol by human liver proteins,
calculated as the scaled Vmax(app)/Km(app), was about 9.5 times lower than the catalytic efficiency
for the formation of 1′-hydroxymethyleugenol glucuronide by human liver proteins. The scaled
Vmax(app) for 1′-oxomethyleugenol by human liver cytosolic proteins was about 6 times higher
than the scaled Vmax(app) for formation of 1′-hydroxymethyleugenol glucuronide by human liver
proteins, whereas the Km(app) was about 1.5 times lower.   The catalytic efficiency for the
formation of the 1′-oxomethyleugenol by human liver cytosolic proteins (scaled Vmax(app)/Km(app))
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was about 9 times higher than the catalytic efficiency for the formation of 1′-
hydroxymethyleugenol glucuronide (scaled Vmax(app)/Km(app)) by human liver proteins.  Thus,
based on these kinetic data it can be concluded that in human liver oxidation may be the
preferential pathway for conversion of 1′-hydroxymethyleugenol, followed by conjugation to1′-
hydroxymethyleugenol glucuronide and to a much lower extent by sulfonation to 1′-
sulfooxymethyleugenol.
Performance of the PBK model
With the kinetic constants obtained, all parameters of the PBK model were defined (Table 2
and Table 3) and the model as described in the Materials and Methods section was used for
model predictions. In a first step, predictions were made that allow investigating the
performance of the PBK model obtained. To this end, the PBK model-based predictions for
concentrations of reported serum blood levels of methyleugenol reported for nine human
volunteers after consumption of a meal consisting of 12 gingersnaps, containing approximately
0.216 mg methyleugenol (0.0034 mg/(kg bw)), considering an average body weight of 63.8 kg)
.
Figure 6. PBK predicted log10 concentrations of methyleugenol (expressed in ppt (pg/ml))in whole blood of  human
(▬▬) compared with the reported log10 concentrations (ppt) in serum blood of human (■), at an oral dose of 0.0034
mg/(kg bw) (Schecter et al., 2004), assuming A. 100% and B. 15% bioavailability.
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(Schecter et al., 2004). Figure 6 A presents the results obtained and reveals that the PBK model
predicted blood concentrations of methyleugenol are higher than the actually measured ones. In
these original calculations by the PBK model 100% bioavailability of methyleugenol was
assumed. However, in the human intervention study bioavailability may have been significantly
lower, because volunteers were given methyleugenol in the form of gingersnaps containing
methyleugenol together with an orange juice beverage. Additional PBK modeling revealed that
when the bioavailability of methyleugenol from the gingersnaps and orange juice food matrix
would be 13.8%, the experimental value would match the PBK predicted values (Figure 6B).
Model predictions
The PBK model developed was used to predict the liver concentrations of methyleugenol
and 1′-hydroxymethyleugenol and conversion of 1′-hydroxymethyleugenol to 1′-
hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-sulfooxymethyleugenol in the
liver of human.  Figure 7 presents the time dependent predicted concentration (nmol/(g liver))
of methyleugenol and 1′-hydroxymethyleugenol, and the time dependent predicted formation
(nmol/(g liver)) of 1′-hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-
sulfooxymethyleugenol at a dose of 0.0034 mg/(kg bw). This dose of 0.0034 mg/(kg bw)
represents the dose of methyleugenol used in the study of Schecter et al. (2004). Since the
model does not contain further reactions for the phase II metabolites of 1′-
hydroxymethyleugenol, the PBK model estimates the total formed amounts of 1′-
hydroxymethyleugenol metabolites in liver over time but not the actual time dependent
concentrations present in the liver. The model outcomes predict that 24 hr after dosing,
methyleugenol and 1′-hydroxymethyleugenol are completely metabolized and indicate a total
overall formation of 0.0035 nmol/(g liver) of 1′-hydroxymethyleugenol glucuronide, 0.015
nmol/(g liver) of 1′-oxomethyleugenol, and 0.00037 nmol/(g liver) of 1′-
sulfooxymethyleugenol, corresponding to 0.48%, 6.5%, and 0.05% of the dose respectively.
A PBK MODEL FOR METHYLEUGENOL IN HUMAN
110
A. B.
C. D.
E.
Figure 7. PBK model-predicted time dependent concentration (nmol/(g liver)) of (A) methyleugenol, (B) 1′-
hydroxymethyleugenol, and formation of (C) 1′-hydroxymethyleugenol glucuronide, (D) 1′-oxomethyleugenol, and (E)
1′-sulfooxymethyleugenol following an oral dose of 0.0034 mg/(kg bw).
Sensitivity analysis
A sensitivity analysis was performed to determine the model parameters which affect the
formation of 1′-hydroxymethyleugenol and 1′-sulfooxymethyleugenol in the liver as model
outputs. Figure 8 presents the parameters which have an effect on the formation of 1′-
hydroxymethyleugenol and the formation of 1′-sulfooxymethyleugenol at methyleugenol dose
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Figure 8. Sensitivity of the predicted formation of 1′-hydroxymethyleugenol and 1′-sulfooxymethyleugenol to different
model parameters at a dose 0.0034 mg/(kg bw). Black bars correspond to the normalized sensitivity coefficients for
formation of 1′-hydroxymethyleugenol and grey bars correspond to the normalized sensitivity coefficients for formation
of 1′-sulfooxymethyleugenol. MPL = Liver microsomal protein yield, S9PL = Liver S9 protein yield, CytPL = Liver
cytosolic protein yield, Vmax and Km are the maximum rate of formation and the Michaelis-Menten constant for the
formation of the different metabolites (M) in liver: methyleugenol-2′,3′-oxide (MEO), 1′-hydroxymethyleugenol
(1′HME), 3-(3,4-dimethoxyphenyl)-2-propen-1-ol (3DMPOH), 2-hydroxy-4,5-dimethoxyallylbenzene (2HDME),
eugenol (1EU), 3-hydroxy-4-methoxyallylbenzene (3HMA), 1′-hydroxymethyleugenol glucuronide (1′HMEG), 1′-
oxomethyleugenol formed by microsomal enzyme (1′OMEmic), 1′-oxomethyleugenol formed by cytosolic enzyme
(1′OMEcyt) and 1′-sulfooxymethyleugenol (1′HMES) in liver tissue.
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of 0.0034 mg/(kg bw). Formation of 1′-hydroxymethyleugenol primarily depends on the kinetic
constant for its formation (Vmax,L_1′HME, Km,L_1′HME) and the kinetic constants for formation of
methyleugenol-2′,3′-oxide (Vmax,L_MEO, Km,L_MEO). To a small extent, the formation of 1′-
hydroxymethyleugenol depends on the kinetic constants for formation of eugenol (Vmax,L_1EU,
Km,L_1EU). On the other hand, the formation of 1′-sulfooxymethyleugenol primarily depends on
the kinetic constants for formation of 1′-hydroxymethyleugenol (Vmax,L_1′HME, Km,L_1′HME),  the
kinetic constants (Vmax,L_MEO, Km,L_MEO) for the formation of methyleugenol-2′,3′-oxide, and  the
kinetic constants  for  the  formation  of  1′-oxomethyleugenol (Vmax,L_1′OME , Km,L_1′OME) from
the microsomal metabolism and the cytosolic metabolism as well. The formation of 1′-
sulfooxymethyleugenol also depends on the kinetic constants for formation of this metabolite
itself (Vmax,L_1′HMES, Km,L_1′HMES) and on the kinetic constants for the formation of eugenol
(Vmax,L_1EU, Km,L_1EU). Moreover the formation of 1′-sulfooxymethyleugenol also depends on the
liver microsomal protein yield (MPL), the liver cytosolic protein (CytPL), and the liver S9
protein yield (S9PL).
Impact of species differences on the bioactivation and detoxification of methyleugenol
Species differences have been shown to affect the metabolism of estragole into some
metabolites (Punt et al., 2009). Also, the outcomes of the rat PBK model (Al-Subeihi et al.,
2011) and the outcomes of human PBK model, developed in the present study, reveal some
species differences in phase I and phase II metabolism. Figure 9 shows an overview of the
PBK-based predictions for the dose-dependent formation of methyleugenol-2′,3′-oxide, eugenol
(only in the liver of human), 1′-hydroxymethyleugenol, the proximate carcinogenic metabolite,
1′-hydroxymethyleugenol glucuronide, 1′-oxomethyleugenol, and 1′-sulfooxymetheugenol
which readily undergoes desulfonation to a reactive carbo-cation that can form DNA adduct in
the liver of rat and human at dose levels up to 300 mg(kg bw). The results obtained clearly
reflect significant species-dependent differences in the relative importance of O-demethylation,
being an important metabolic pathway only in human (Figure 9B), while the detoxification
of 1′-hydroxymethyleugenol to 1′-hydroxymethyleugenol glucuronide is an important pathway
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Figure 9. PBK model-based predictions for the dose-dependent formation of (A) methyleugenol-2',3'-oxide, (B)
eugenol, (C) 1'-hydroxymethyleugenol, (D) 1'-hydroxymethyleugenol glucuronide, (E) 1'-oxomethyleugenol, and (F)
1'-sulfooxymethyleugenol of rat (solid line) and human (dotted line) at dose levels up to 300 mg/(kg bw).
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in male rat (Figure 9D) and its detoxification to 1′-oxomethyleugenol is an important pathway
in human (Figure 9E). These results also indicate that lower levels of urinary excretion of 1′-
hydroxymethyleugenol glucuronide in human than in male rat do not necessarily reflect lower
levels of formation of the proximate carcinogenic metabolite 1′-hydroxymethyleugenol and 1′-
sulfooxymethyleugenol which readily undergoes desulfonation to a reactive carbo-cation that
can form DNA adduct. The PBK results obtained indicate that in spite of marked species
differences in glucuronidation and oxidation of 1′-hydroxymethyleugenol, the resulting species
differences in formation of 1′-sulfooxymethyleugenol in human and male rat seems to be
negligible at a dose of 0.0034 mg/(kg bw) and 300 mg/(kg bw) respectively. Formation of 1′-
oxomethyleugenol has not been considered to be an important metabolic route of 1′-
hydroxymethyleugenol before because in rat relatively small amounts of this metabolite are
formed (Al-Subeihi et al., 2011). Based on the approach of identifying principal metabolic
pathways of methyleugenol in incubations with tissue fractions of relevant organs, it could be
revealed that in human oxidation of 1′-hydroxymethyleugenol is a substantial metabolic
pathway, and it was predicted by the PBK model to account for 6.6% to 15.9% at the dose of
0.0034 to 300 mg/(kg bw).
Implications of the PBK data for risk assessment
Figure 10 shows the PBK predicted dose dependent formation of 1′-sulfooxymethyleugenol
in the liver of human and male rat as a function of dose, also presenting the value of the BMD10
and the so-called virtual safe dose (VSD). The BMD10 is the dose at which 10% extra tumor
incidence above background level is observed in rodent bioassays. This value was previously
calculated to amount to 27-47 mg/(kg bw)/day when using data for the induction of hepatomas
in male rats (Rietjens et al., 2008) or to 12 to 27 mg/(kg bw)/day when using data for induction
of liver adenomas or carcinomas (combined) for male rats (Smith et al., 2010). The latter study
also reported a model average value of 22 mg/(kg bw)/day. From the lowest BMD10 value for
the induction of the malignant hepatomas the value for the so-called virtual safe dose (VSD),
the dose that would result in an estimated additional cancer risk of one in a million upon life
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time exposure, can be calculated using linear extrapolation. The VSD thus obtained amounts to
0.27 µg/(kg bw)/day. The results thus obtained and depicted in Figure 10 indicate that the PBK
predicted formation of 1′-sulfooxymethyleugenol which readily undergoes desulfonation to a
reactive carbo-cation that can form DNA adduct, in the liver of both male rat and human
appears to be linear from a dose as high as the BMD10 down to a dose as low as the VSD when
plotted on a log-log scale as done in Figure 10 as well as on a linear scale (Figure not shown).
Since the BMD10 appears to be within the linear part of the curve and since the rat and human
curves do not differ substantially as the absolute difference between the rat and human curve is
0.49 to 1.06 fold over the whole dose, the PBK results of the present study support that possible
nonlinear kinetics and species differences in kinetics should not be used as arguments against
using a linear low dose cancer risk extrapolation from high dose animal data to the low dose
human situation.
Figure 10. PBK model predicted dose-dependent formation of 1'-sulfooxymethyleugenol in the liver of rat (solid line)
and human (dotted line).
Model predictions were made assuming 100% bioavailability of methyleugenol.
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Discussion
The objective of the present study was to define a PBK model for methyleugenol in human,
based on in vitro metabolic parameters. With this model, the formation of 1′-
hydroxymethyleugenol (the proximate carcinogenic metabolite) and of 1′-
sulfooxymethyleugenol (which readily undergoes desulfonation to a reactive carbo-cation that
can form DNA adduct) in the liver of human could be predicted at different oral doses of
methyleugenol. The model therefore allows evaluation of possible dose-dependent effects in
bioactivation and detoxification at different oral doses of methyleugenol as well as evaluation
of the overall differences between humans and male rats in bioactivation and detoxification of
methyleugenol. The outcome of the human PBK model shows a linear increase up to a dose of
500 mg/(kg bw) in formation of the proximate carcinogenic metabolite, 1′-
hydroxymethyleugenol, leading to a linear increase in the formation of 1′-
sulfooxymethyleugenol which readily undergoes desulfonation to a reactive carbo-cation that
can form DNA adduct. The result that increased formation of 1′-hydroxymethyleugenol results
in increased possibilities for formation of 1′-sulfooxymethyleugenol and, as a result increased
DNA adduct formation, is in line with the results of Gardner et al. (1996) who reported that rats
treated with different oral doses of methyleugenol show a linear increase in the protein adduct
formation in the liver.
The PBK model defined was evaluated by comparing the PBK model predicted
concentration of methyleugenol in blood to literature data on methyleugenol concentrations in
serum blood of human volunteers at different time points upon intake of methyleugenol
(Schecter et al., 2004). These experimental data reveal the occurrence of methyleugenol already
in serum blood of humans, even after prolonged fasting. This observation has been taken to
suggest that some methyleugenol may be stored in distribution matrices like adipose tissue that
are at equilibrium with the blood (Robison and Barr, 2006). The fasting, from midnight to 07.30
hr as applied in the study by Schecter et al. (2004), might not be enough to get rid of all
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methyleugenol from the body of the volunteers, explaining their relatively high background
levels. At 15, 30, 60, and 120 min, the outcomes of the PBK model were 5.7 to 7.9-fold higher
when compared with the literature results. This deviation of the PBK model predictions from
the experimental data might be due to several reasons. First, the bioavailability of
methyleugenol in blood when given orally in a pure form is likely to be higher than when it is
given as a part of the food matrix. The human experimental data were based on a study in which
volunteers were served a breakfast known to contain methyleugenol, consisting of a brand of
gingersnaps found on initial analysis to contain approximately 3.3 μg methyleugenol per gram,
or 18 μg/cookie. The gingersnaps were purchased locally from a large supermarket. Orange
juice was provided as a beverage. Each subject's meal consisted of 12 gingersnaps, containing
approximately 216 μg methyleugenol. From this it becomes clear that the dose of
methyleugenol was only known approximately and, even more important, that it was not given
as a pure compound but as part of gingersnaps and also consumed together with an orange juice
beverage. This provides an additional uncertainty about the dose level in the in vivo study
because of the unknown bioavailability of methyleugenol form the gingersnaps when consumed
within a complex food matrix. In the original calculations by the PBK model 100%
bioavailability was assumed. However, bioavailability in this available human study may be
significantly lower. Additional PBK modeling revealed that when the bioavailability of
methyleugenol from the gingersnaps and orange juice food matrix would be 13.8%, the
experimental value would accurately match the PBK predicted values (Figure 6B).
Furthermore, an analysis of other model adjustments including parameters that appeared to be
of influence on the model outcome based on a sensitivity analysis (blood flow, cardiac output,
volume of the liver, maximum rate of formation and Michaelis-Menten constants for formation
of phase I and phase II metabolites, and absorbance rate constant) was performed. None of
these model adjustments resulted in improvement of the fit to a level comparable to that
achieved by the adjustment of the bioavailability (data not shown). The occurrence of such a
difference in the bioavailability of a compound when ingested within a food matrix or as a pure
compound has been reported for other compounds as well. Manach et al. (2004) for example
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reported that the level of ferulic acid metabolites recovered in the urine of rats amounts to only
3% of the ingested dose when ferulic acid is provided as wheat bran, whereas the metabolites
represent 50% of the dose when ferulic acid is dosed as a pure compound. Also the
bioavailability of ß-carotene is one order of magnitude higher when provided as a pure
compound added to foods than when it is present naturally in foods (van het Hof et al., 2000).
Another reason contributing to the difference in predicted and observed blood concentrations of
methyleugenol could be the fact that the model predicts whole blood concentrations whereas the
in vivo study covers serum concentrations. This comparison between whole blood and serum
concentrations can only be made based on the assumption that the whole blood and serum
concentrations are equal. Furthermore, protein binding may provide another explanation for the
fact that the PBK predicted blood concentrations of methyleugenol are higher than the observed
serum blood concentrations.  Finally it is important to stress that outcomes of PBK models
should be used preferably in a relative way as done when making the dose- and species-
dependent predictions of the present study.
The present study focused on the species differences between male rat and human at
different dose levels including those relevant dietary human intakes. The PBK-based
predictions for the formation of metabolites at different oral doses show significant species
differences as reflected in a 1.8 to 2.5-fold lower formation of the proximate metabolite 1′-
hydroxymethyleugenol accompanied by a higher formation of eugenol resulting from O-
demethylation in the liver of human (eugenol was not formed in the liver of rat) compared with
male rat at dose levels up to 300 mg/(kg bw). In spite of the lower formation of the proximate
carcinogenic metabolite 1′-hydroxymethyleugenol in humans, this does not necessarily reflect
lower levels of formation of the 1′ -sulfooxymethyleugenol metabolite which readily undergoes
desulfonation to a reactive carbo-cation that can form DNA adduct. The PBK-model results
obtained indicate that there are no substantial species differences in formation of 1′-
sulfooxymethyleugenol up to dose levels of 300 mg/(kg bw). The PBK model predicted
formation of 1′-sulfooxymethyleugenol was 1.14 to 1.57-fold higher in human than in male rat
over the whole dose. This indicates that the species-dependent differences in bioactivation of
CHAPTER 3
119
methyleugenol to 1′-sulfooxymethyleugenol are smaller than the default factor of 4 generally
assumed to reflect interspecies variation in kinetics (assuming that the default factor of 10 can
be divided into a factor of 4 for kinetics and 2.5 for dynamics) (WHO, 1999).  This can be taken
into account when extrapolating the carcinogenicity data obtained in animals at high doses to
the human situation.
It is also of interest to note that Zhou et al. (2007) reported the formation of DNA adducts in
human HepG2 cells following treatment with methyleugenol at concentrations in the range of
about 50-450 µM. The PBK model now developed predicts that such concentrations of
methyleugenol in human liver are reached at dose levels of 4.6 to 26.7 mg/(kg bw). These are
dose levels at which in animal bioassays tumor formation is observed (NTP, 2000).
Worldwide different approaches exist to assess the risk of compounds that are both
genotoxic and carcinogenic. Numerical estimates of the risk associated with human exposure
might be derived by extrapolation of carcinogenicity data obtained in animals at high dose
levels to low dose levels relevant for the human situation. Many mathematical models have
been proposed by which such an extrapolation below the available experimental data can be
performed, of which linear extrapolation is the simplest and most conservative form (COC,
2004). Extrapolating from animal tumor data at high doses using mathematical modeling in
order to obtain estimates of the risk to humans at low dose exposure levels has been much
debated, since it is not known whether or not the model chosen actually reflects the underlying
biological processes. In addition, it is argued that species differences are not taken into account.
Furthermore obtaining numerical estimates may be misused or misinterpreted in further risk
management and risk communication, where the uncertainties and inaccuracy connected to the
model may not be communicated (EFSA, 2005).
The results of the PBK models for male rat (Al-Subeihi et al., 2011) and human, the latter
obtained in the present study, indicate that kinetic data do not provide a reason to argue against
a linear extrapolation from the rat tumor data to the human situation. This is illustrated in Figure
10, in which the PBK-model predicted dose-dependent formation of 1′-sulfooxymethyleugenol
in the liver of rat and human is displayed. Both curves are observed to be linear from doses as
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high as the BMD10 down to dose levels as low as the VSD, when plotted on a log-log scale as
done in Figure 10 and almost linear when plotted on a linear scale (Figure not shown).
Deviations from linearity in formation of 1′-sulfooxymethyleugenol are only observed for both
rats and human at dose levels above 60 mg/(kg bw)/day, which is higher than the BMD10. Since
the BMD10 appears to be located within the linear part of the curves and since the rat and
human curves do not differ substantially, the PBK results of the present study support that
possible non-linear kinetics and species differences in kinetics should not be used as an
argument against using a linear low dose cancer risk extrapolation from animal data to the low
dose human situation. This illustrates that PBK models provide a useful tool in risk assessment
of food-borne chemicals when evaluating human risks.
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Abstract
Methyleugenol occurs naturally in a variety of spices, herbs, including basil, and their
essential oils. Methyleugenol induces hepatomas in rodent bioassays following its conversion to
a DNA reactive metabolite. In the present study, the basil constituent nevadensin was shown to
be able to inhibit DNA adduct formation in HepG2 cells exposed to the proximate carcinogen
1′-hydroxymethyleugenol in the presence of this flavonoid. This inhibition occurs at the level of
sulfotransferase (SULT)-mediated bioactivation of 1′-hydroxymethyleugenol. In order to
investigate possible in vivo implications the SULT inhibition by nevadensin was integrated into
the male rat and human PBK models for bioactivation and detoxification of methyleugenol. The
results thus obtained reveal that co-administration of methyleugenol with nevadensin may
reduce the levels of bioactivation of 1′-hydroxymethyleugenol to the DNA reactive metabolite,
without reducing its detoxification via glucuronidation or oxidation. This effect may be
significant even at realistic low dose human exposure levels. The results obtained point at a
potential reduction of the cancer risk when methyleugenol exposure occurs by oral intake
within a relevant food matrix containing SULT inhibitors compared to what is observed in
rodent bioassays upon exposure to pure methyleugenol dosed by gavage.
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Introduction
Methyleugenol is a compound naturally occurring in a variety of spices and herbs, including
clove, allspice, cinnamon leaves, walnuts, basil, nutmeg, anise, pimento, citronella, laurel fruits
leaves and others, as well as in their essential oils (Smith et al., 2010). The general population is
primarily exposed to methyleugenol via ingestion of food stuffs flavored with methyleugenol
containing essential oils (Smith et al., 2010), including for instance, candy, cookies such as
gingersnaps, ice cream, tomato ketchup and relish (Burdock, 1995; Leung, 1980). The average
daily intake of methyleugenol was estimated by the Scientific Committee on Food (SCF) to be
13 mg/day, corresponding to 0.217 mg/(kg bw)/day for a 60 kg person (SCF, 2001), while the
Flavor and Extract Manufacturers Association (FEMA), using a different methodology,
estimated the average daily intake of methyleugenol resulting from flavor use to be less than
0.01 mg/(kg bw)/day (Smith et al., 2002). The estimation of the SCF was based on theoretical
maximum use levels of methyleugenol in various food categories and consumption data for
these food categories, whereas the intake estimation of the FEMA was based on production
volume data for flavor use (SCF, 2001; Smith et al., 2002). In the European Union, but not in
the US, the usage of pure methyleugenol in food has been banned (European Commission,
2008). It was reported that methyleugenol displays cytotoxic and genotoxic activity in rat
hepatocytes (Burkey et al., 2000).
Methyleugenol was shown to induce tumours in various tissues of rats and mice at high dose
levels (Miller et al., 1983; NTP, 2000). In particular, the compound was shown to be a
hepatocarcinogen in both species. Methyleugenol was nominated for toxicological
characterization and testing by the National Toxicology Program (NTP) because it is widely
used in a variety of foods, beverages, and cosmetics, as well as because of its structural
resemblance to the known carcinogens safrole and estragole (Miller et al., 1983; NTP, 1998).
In 2000, the carcinogenicity of methyleugenol was investigated in mice and rats (NTP,
2000). The NTP reported that methyleugenol is carcinogenic in both rats and mice when dosed
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at high dose levels as pure compound suspended in methylcellulose 0.5 % (NTP, 2000).
Methyleugenol was shown to form DNA adducts in liver and other tissues of rodent models,
suggesting that the compound is a DNA reactive carcinogen (Boberg et al., 1983; Phillips et al.,
1981). However, methyleugenol tested negative in the Ames test and other standard in vitro
genotoxicity assays (Ding et al., 2011; NTP, 2000).
Methyleugenol is unreactive by itself but undergoes metabolic activation to produce an
electrophilic metabolite that acts as the DNA reactive intermediate (Gardner et al., 1997; Miele
et al., 2001). Figure 1 displays the bioactivation pathway of methyleugenol which starts with
hydroxylation of the 1'-position of methyleugenol to produce the proximate carcinogenic
metabolite 1′-hydroxymethyleugenol (Drinkwater et al., 1976; Miller et al., 1983). In a next
step 1′-hydroxymethyleugenol can be sulfonated by SULT to form 1′-sulfoxymethyleugenol
which readily undergoes desulfonation to a carbo-cation that can form DNA adducts (Miller et
al., 1983). Recently, studies using Salmonella typhimurium TA100 strains with expression of
human SULT revealed that SULT1A1 and SULT1E1 are the main liver sulfotransferease
enzymes involved in activation of 1′-hydroxymethyleugenol to DNA reactive metabolites
(Herrmann et al., 2012).
Figure 1. Structural representation of the pathway for bioactivation of methyleugenol.
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However, it is important to note that the carcinogenicity observed in studies in which
animals are exposed to high dose levels of the pure compound by gavage may not be
representative for the situation where humans are exposed to methyleugenol at low levels via
dietary intake with a food matrix being present. For the related alkenylbenzene estragole  it was
actually demonstrated that other ingredients present in an alkenylbenzene containing herb or
food item may inhibit the SULT mediated bioactivation of estragole to its ultimate DNA
reactive 1′-sulfooxy metabolite (Alhusainy et al., 2010; Jeurissen et al., 2008). For instance a
methanolic basil extract was shown to cause a dose dependent inhibition of DNA adduct
formation in 1′-hydroxyestragole exposed human HepG2 cells (Jeurissen et al., 2008). In a
subsequent study, the flavonoid nevadensin (Figure 2) was identified as the potent SULT
inhibitor present in these methanolic basil extracts (Alhusainy et al., 2010). So far, the existence
of such matrix dependent interactions with the bioactivation of alkenylbenzenes was only
demonstrated for estragole (Alhusainy et al., 2010). Therefore the objective of the present study
was to study the potential of nevadensin to inhibit the SULT mediated bioactivation and
subsequent DNA adduct formation of methyleugenol. By incorporating the nevadensin
mediated SULT inhibition in the recently developed physiologically based models for
bioactivation and detoxification of methyleugenol in rat (Al-Subeihi et al., 2011) and human
(Al-Subeihi et al., 2012), the possible effects of SULT inhibition by nevadensin expected to
occur in the in vivo situation at realistic low dose exposure scenario′s was also investigated.
Figure 2. Structural formula of nevadensin
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Materials and Method
Materials
2′-Deoxyguanosine was purchased from Sigma (Basel, Switzerland), and 1,2,3,7,9-15N5-2′-
deoxyguanosine was obtained from Cambridge Isotope Laboratories (Cambridge, MA). Fetal
bovine serum (FBS), DMEM/F12 (L-glutamine, 15 mM HEPES) medium and phosphate
buffered saline (PBS) (pH 7.4) were purchased from Gibco (UK). Dimethyl sulfoxide (DMSO),
methanol, zinc sulphate (heptahydrate), phosphodiesterase I from Crotalus adamanteus (venom
phosphodiesterase), phosphodiesterase II from bovine spleen (spleen phosphodiesterase),
nuclease P1 and alkaline phosphatase were purchased from Sigma (Schnelldorf, Germany).
Acetonitrile was purchased from Biosolve BV (Valkenswaard, The Netherlands). Formic acid
and ethanol were obtained from VWR Merck (Darmstadt, Germany). Nevadensin was
purchased from Apin Chemicals (Milton, UK). Pentachlorophenol (PCP, 98%) was obtained
from Sigma-Riedel de Haen (Seelze, Germany). 1′-hydroxymethyleugenol and 1′-
acetoxymethyleugenol were synthesized as described previously (Al-Subeihi et al., 2011).
Human HepG2 cells were purchased from the American type culture collection (Manassas,
Virginia).
Synthesis of N2-(trans-isomethyleugenol-3′-yl)-2′-deoxyguanosine (ME-3'-N2-dG) and 15N5-
labelled N2-(trans-isomethyleugenol-3′-yl)-2′-deoxyguanosine ((15N5) ME-3'-N2-dG)
ME-3'-N2-dG was synthesized via a reaction between 1′-acetoxymethyleugenol and 2′-
deoxyguanosine based on the protocol of Punt et al., (2007). In brief, 250 μL of a 0.01 g/mL
solution of 1′-acetoxymethyleugenol in DMSO was added to 2250 μL of 2.5 mM 2′-
deoxyguanosine in 2.5 mM ammonium carbonate (pH 7.4). The same reaction was performed
for the synthesis of (15N5) ME-3'-N
2-dG in which 1′-acetoxymethyleugenol was allowed to react
with 15N5- labeled 2′-deoxyguanosine. The incubations were stirred for 48 hr at 37 °C. Both
ME-3'-N2-dG and (15N5) ME-3'-N
2-dG were purified by HPLC-UV on a M600 liquid
CHAPTER 4
133
chromatography system (Waters, Milford, MA) equipped with an Alltima C18 5 µm column,
150 x 4.6 mm (Alltech, Breda, The Netherlands). The gradient was made with ultrapure water
and acetonitrile. The flow rate was 1 mL/min. A linear gradient was applied from 10% to 15%
acetonitrile over 30 min after which the percentage of acetonitrile was increased to 100% over 2
min, kept at 100% for 1 min, lowered to 10% in 2 min, and kept at these initial conditions for
10 min for equilibration of the system. Detection was carried out using a Waters 966
photodiode array detector (Waters, Milford, MA) at 260 nm. Both ME-3'-N2-dG and (15N5) ME-
3'-N2-dG were collected at a retention time of 11.4 min. The purity of both ME-3'-N2-dG and
(15N5) ME-3'-N
2-dG was more than 98%, according to LC-MS/MS and HPLC analyses.
Cytotoxicity test
The cytotoxicity of nevadensin, 1′-hydroxymethyleugenol, PCP, and DMSO was evaluated
using the MTT test (Hussain et al., 1993; Mosmann, 1983). HepG2 cells were plated in a 96-
well plate at a density of 2 x104 cells per well 24 hr prior to exposure. Just before exposure the
medium was removed and cells were washed with 100 µL HBSS. Cells were exposed to 0.5%
DMSO (control) or the test compounds in exposure medium (DMEM/F12 + glutamax + 50
µg/mL gentamicin) at concentrations of nevadensin, 1′-hydroxymethyleugenol, and/or PCP as
indicated and added from respectively 5000, 1000, and 400 times concentrated stock solutions
in DMSO for 4 hr in a humidified atmosphere at 37 °C. Then, 5 µL of a 5 mg/mL MTT solution
in PBS were added and the cells were incubated for another 1 hr. Thereafter, the medium was
removed and 100 µL of DMSO were added to all wells to dissolve the formazan crystals. The
absorbance was measured at 562 nm and cell viability was defined as the ratio between the
absorbance measured for nevadensin, 1′-hydroxymethyleugenol, PCP or DMSO treated cell
samples and the absorption measured for untreated cell samples.
Incubation of HepG2 cells with 1′-hydroxymethyleugenol
Human HepG2 cells were cultured in a 75cm2 flask (Corning, NY, USA) with DMEM/F12
medium containing glutamax, 10% FBS and incubated in a humidified incubator under 5% CO2
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and 95% air at 37 °C. Once reaching 80-90% confluence the cells were incubated overnight
(~14 hr) in the presence of 1′-hydroxymethyleugenol at a final concentration of 100 µM (added
from a 1000 times concentrated stock solution in DMSO) and nevadensin at a final
concentration of 0, 0.002, 0.02, 0.2, or 2 µM (added from 5000 times concentrated stock
solutions in DMSO) or PCP at a final concentration of 12.5 µM (added from a 400 times
concentrated stock solution in DMSO). The final DMSO concentration was 0.35%. After
overnight incubation, cells were washed twice with phosphate–buffered saline (PBS), scraped,
collected into an eppendorf tube, and pelleted at 211 g (1500 rpm, Eppendorf Centrifuge 5424)
for 5 min. DNA was extracted and digested as reported in the next section.
DNA extraction and digestion
DNA was extracted from human HepG2 cells as previously described (Alhusainy et al.,
2010; Jeurissen et al. 2008; Paini et al., 2010). Briefly, DNA was extracted using the Get pure
DNA Kit-Cell protocol (Dojindo Molecular Technology Inc., Kumamoto, Japan) and 3 to 10
*106 cells per sample (following the manufacturer's instructions). The yield and purity of the
extracted DNA was determined using the NanoDrop technique measuring the absorbance ratio
A260 nm/A280 nm. DNA samples with an absorbance ratio of 1.8-2 were considered
sufficiently pure. The quantity of DNA per sample was calculated from the NanoDrop output in
ng/mL using a molar extinction coefficient for double stranded DNA of 50 L/(mol*cm) at a
wavelength of 260 nm.  Digestion of isolated DNA was done as reported previously (Paini et
al., 2010). In short, to 50 µg DNA in 80 µL water, 20 µL buffer P1 (300 mM sodium acetate, 1
mM ZnSO4, pH 5.3), 11 µL SPDE (spleen phosphodiesterase) solution (0.0004 U/µL in water),
and 10 µL nuclease P1 (0.5 µg/µL in water) were added and the resulting solution was
incubated for 4 hr at 37 °C. Following incubation, 20 µL buffer (500 mM Tris-HCl, 1 mM
EDTA, pH 8.0), 12 µL VPDE (venom phosphodiesterase) solution (0.00026 U/µL in water),
and 6 µL alkaline phosphatase (0.764 U/µL in water) were added and the mixture was
incubated for 3 hr at 37 °C (Paini et al., 2010). Following these incubations samples were
filtered using eppendorf tubes with a cut off membrane of 5,000 nominal molecular weight limit
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(NMWL) (Millipore). The hydrolyzed filtered sample was evaporated to dryness and
reconstituted in 50 µL water and stored at -20 °C until LC-MS/MS analysis.
LC-MS/MS method for detection and quantification of ME-3'-N2-dG
LC-MS/MS analysis was performed on a Perkin Elmer 200 Series HPLC System (Perkin
Elmer, Waltham, Massachusetts) coupled to an API 3000 system (Applied Biosystem, Foster
City, California). Samples were injected on an Agilent Zorbax Extend-C18 column, 2.1*50
mm, 3.5 Micron 80 Å (Basel, Switzerland), with a Zorbax guard column. The gradient was
made with ultrapure water containing 0.1% (v/v) formic acid and 100% acetonitrile. The flow
rate was set at 0.3 mL/min. A linear gradient was applied from 10% to 50% acetonitrile over 3
min, after which the percentage of acetonitrile was brought to 100% in 1 min, and kept at 100%
acetonitrile over 2 min. The amount of acetonitrile was lowered to 10% over 1 min, and the
column was equilibrated at these initial conditions for 8 min. ME-3'-N2-dG eluted at 2.58
minutes. The mass spectrometric analysis was performed with the following settings: nebulizer
gas (air) was set at 15 psi, curtain gas (nitrogen, which is used to keep the analyser region
clean) was set at 10 psi, the ion spray voltage at 4700 V, the collision gas (CAD) was 5 eV, the
ion source temperature was set at 300 °C, the declustering potential was set at 37 V, the
focusing potential was set at 200 V, the entrance potential at 9 V, and the collision cell exit was
set at 15 V. Nitrogen was used as sheath gas turbo, ion spray, with a pressure of 7000 L/h. The
dwell time per transition was 0.05 sec. A divert valve was used in order to discard the gradient
after elution of the peak. Quantification of the DNA adduct was carried out using selected-ion
detection in the multiple reaction-monitoring mode (MRM), the characteristic transitions for the
ME-3′-N2-dG and for the (15N5) ME-3'-N
2-dG are displayed in Table 1.
Inhibition constant (Ki)
In the present study a Ki of 4 nM for nevadensin was used. This value was obtained from a
previous study (Alhusainy et al., 2010) and represents the Ki for inhibition of SULT mediated
conversion of 7-hydroxycoumarin to 7-hydroxycoumarin sulphate by the identified inhibitor
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Table 1. Transition reaction (m/z) and the collision energy used to obtain the daughter fragments by LC-
MS/MS.
Transition(m/z)
(used for
quantification)
Collision
energy (eV)
Transition (m/z)
(used for confirmation)
Collision energy
(eV)
ME-3′-N2-dG 444328 18 444177
444164
37
40
(15N5) ME-3′-N2-dG 449333 18 449169 40
nevadensin. This Ki was used in the model of methyleugenol assuming equal Ki values for the
two substrates (1′-hydroxymethyleugenol and 7-hydroxycoumarin) and this was based on the
fact that the type of inhibition was found to be non-competitive and, thus, not occurring at the
substrate binding site of SULT.
Methyleugenol PBK model
The rat and human PBK models developed in our previous work to describe the dose-
dependent bioactivation and detoxification of methyleugenol in male rat liver (Al-Subeihi et al.,
2011) and human liver (Al-Subeihi et al., 2012) were used in the present study to model the
possible consequences of SULT inhibition for bioactivation and detoxification of
methyleugenol. Figure 3 (A-B) and Table 2 present the schematic overview of the model as
well as an overview of the parameters used. Differential equations used to describe metabolite
formation and conversion in the various organs can be found in our previous work (Al-Subeihi
et al., 2011, 2012).  The models include separate compartments for liver, lung and kidney,
which were found to be involved in the metabolism of methyleugenol. Furthermore, a separate
compartment for fat tissue was included in order to take into account the relatively higher
partition coefficient of methyleugenol in fat tissue. All other tissues were lumped into a rapidly
perfused tissue group or a slowly perfused tissue group. The kinetic constants for phase I
metabolism of methyleugenol as well as for metabolism of 1′-hydroxymethyleugenol are
summarized in Table 3 and were according to our previous studies (Al-Subeihi et al., 2011,
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A.
Figure 3. Representation of the conceptual model for the physiologically based kinetic model for methyleugenol in (A)
male rat and (B) human.
 B.
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Table 2. Parameters used in the physiologically based kinetic model for methyleugenol in both male rat
and human.
Physiological parametersa Rat Human
Tissue: blood partition
coefficientsb
Rat Human
body weight (kg) 0.3 63.8 methyleugenol
percentage of body weight
liver 3.4 2.6 liver 2.3 6.2
lungs 0.5 lungs 2.3
kidney 0.7 kidney 2.3
fat 7 21.4 fat 70 103
rapidly perfused 4.4 5 rapidly perfused 2.3 6.2
slowly perfused 68 51.7 slowly perfused 0.8 3.9
blood 7.9
arterial blood 1.9
venous blood 5.6
cardiac output  (L/hr) 5.4 323 1'-hydroxymethyleugenol
liver 1.1 1.4
percentage of cardiac output
liver 25 22.7
kidney 14
fat 7 5.2
rapidly perfused 37 47.3
slowly perfused 17 24.8
a Brown et al. (1997)
b Calculated based on DeJongh et al.(1997)
2012). In the present study the inhibition of SULT-mediated conversion by the identified
inhibitor nevadensin (Alhusainy et al., 2010) was integrated in the model. Since the inhibitor
nevadensin was shown to inhibit the SULT catalyzed conversion of 7-hydroxycoumarin to 7-
hydroxycoumarin sulphate in a non-competitive way, reducing Vmax and not affecting Km, a
modulation factor (1+([I]/Ki) for the apparent Vmax value was included in the Michaelis–Menten
equation representing the sulfonation pathway as follows:
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AM1′HMES=Vmax,L_1′HMES/(1+([I]/Ki))*CL1′HME/PL1′HME/(Km,L_1′HMES+CL1′HME/PL1′HME)
where AM1′HMES is the amount of 1′-sulfooxymethyleugenol (μmol), Vmax,L_1′HMES is the
maximum rate of formation of 1′-sulfooxymethyleugenol, [I] is the concentration of the
identified SULT inhibitor nevadensin in the liver (μmol/L), Ki is the inhibition constant for
inhibition of the sulfonation by the identified SULT inhibitor (μmol/L), CL1′HME is the
concentration of 1′-hydroxymethyleugenol in the liver (μmol/L), PL1′HME is the liver/blood
Table 3. Kinetic parameters for phase I metabolism of methyleugenol in incubations with human liver
microsomes.
organ phase I metabolite Km(app)a,b Vmax(app)a,c
rat human rat human
methyleugenol-2′,3′-oxide 81 ± 15.5 23.7 ± 5 1.84  ± 0.08 0.66  ± 0.11
1′-hydroxymethyleugenol 253  ± 90 404  ± 195 3.26  ± 0.45 1.38  ± 0.38
3-(3,4-dimethoxyphenyl)-2-propen-1-ol 28  ± 2.3 161 ± 90 0.68  ± 0.025 0.39  ± 0.08
liver 2-hydroxy-4,5-dimethoxyallylbenzene 32 ± 1.1 415 ± 84 0.27 ± 0.006 0.10 ± 0.02
eugenol - 13.6 ± 12.3 - 0.15 ± 0.02
3-hydroxy-4-methoxyallylbenzene 150 ± 55.5 1097 ± 142 0.13 ± 0.018 0.21 ± 0.02
M6 (unidentified metabolite) 259 ± 16.4 - 0.44 ± 0.004 -
lung eugenol 19 ± 3 - 0.21± 0.03 -
3-hydroxy-4-methoxyallylbenzene 33 ± 18.7 - 0.67  ± .077 -
kidney methyleugenol-2′,3′-oxide 968 ± 230 - 0.31± 0.05 -
1′-hydroxymethyleugenol (1'HME) metabolite
1'-hydroxymethyleugenol glucuronide 799 ± 192 2393 ± 486 28.1 ± 6.1 0.66 ± 0.087c
liver 1'-oxomethyleugenol in liver microsomes 3534 ± 3038 1744 ± 2997 2.83 ± 0.92 2.1 ± 1.83
c
1'-oxomethyleugenol in liver cytosol - 1580 ± 538 - 1.58 ± 0.206d
1'-sulfooxymethyleugenol 102 ± 29.5 139 ± 82 0.0022 ± 0.0054 0.0009 ± 0.0002e
amean±SD
bµM
cnmol/ min/mg microsomal protein
dnmol/ min/ mg cytosolic protein
enmol/min/mg S9 protein
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partition coefficient of 1′-hydroxymethyleugenol, and Km,L is the Michaelis–Menten constant
for the formation of 1′-sulfooxymethyleugenol (μmol/L) in the liver. Using our PBK models for
methyleugenol bioactivation and detoxification (Al-Subeihi et al., 2011, 2012), the time
dependent concentration of methyleugenol (CLME) in the liver of male rat and human following
an exposure to different doses of methyleugenol in the presence of varying amounts of
nevadensin can be predicted. As a first approximation, the molar ratio (f) between
methyleugenol and nevadensin was kept at a constant value during the modeling time. To this
end, nevadensin was assumed to follow a similar time dependent concentration curve in the
liver as methyleugenol and this was represented in the model by using the following equation:
[I] =CLME*f where CLME is the concentration of methyleugenol in the liver (μmol/L) and f
represents the molar ratio between the nevadensin and methyleugenol concentrations. To obtain
some insight into the effects resulting from possible differences in kinetics and bioavailability
of the two compounds, the modeling was performed at different molar ratios (f). Thus the molar
ratio (f) was varied from 0 (no nevadensin) to 2 (representing a nevadensin concentration that is
twice as high as methyleugenol). Accordingly, the effect of varying doses of nevadensin on the
formation of 1′-sulfooxymethyleugenol, 1′-hydroxymethyleugenol glucuronide, and 1′-
oxomethyleugenol after 24 hr could be predicted at different methyleugenol doses. The doses of
methyleugenol chosen for the modeling were 0.217 mg/(kg bw), the dose level considered
relevant for human dietary exposure from all food sources (SCF, 2001) and 50 mg/(kg bw)
representing a dose level higher than the dose at which methyleugenol was demonstrated to
produce a single 44 kDa microsomal protein adduct in rats (Smith et al., 2002) and in the range
of dose levels that induce liver tumor formation (NTP, 2000).
Statistical analysis
To test whether the effects were significant, a two sample t-test (one-sided, equal variances)
was performed, after an F test for equal variances was done, using Excel (Microsoft Office
2000).
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Results
Synthesis and characterization of ME-3'-N2-dG and (15N5) ME-3'-N
2-dG
Incubation of 1′-acetoxymethyleugenol with 2′-deoxyguanosine resulted in the formation of
several adducts with 2′-deoxyguanosine as detected by HPLC-UV (Figure 4). Our
chromatographic profile was comparable to that reported in the literature for the same reaction
between the structurally related 1′-acetoxyestragole and 2′-deoxyguanosine (Punt et al., 2007).
Based on analogy to outcomes of the synthesis of E-3'-N2-dG from 1′ -acetoxyestragole by the
same procedure it was expected that the most abundant peak at 11.4 min (Figure 4) corresponds
to the adduct of interest ME-3'-N2-dG. Figure 5 presents the structures of the various adducts
detected based on this analogy to previous adducts identified for N2-(trans-isoestragole-3′-yl)-
2′-deoxyguanosine (ES-3'-N2-dG).  This  nature of the major adduct is also in line with results
reported by Phillips et al. (1981), Punt et al., (2007), and Wiseman et al. (1985) for the nature
of the major DNA adduct of estragole; E-3′-N2-dG. ME-3'-N2-dG thus obtained was collected at
11.4 min and subsequently used as a standard to confirm the formation of the adduct of interest
and to develop the quantitative LC-MS/MS method for detecting and quantifying DNA
nucleotide adducts of methyleugenol. A similar chromatographic profile was obtained when the
Figure 4. HPLC-UV chromatogram of methyleugenol adducts with 2′-deoxyguanosine formed in a reaction between 1′-
acetoxymethyleugenol and 2′-deoxyguanosine. On the basis of previous identification by Phillips et al. (1981), Punt et
al. (2007), and Wiseman et al. (1985) for the 2′-deoxyguanosine adduct of estragole, peaks were characterized as two
diastereomers of ME-1′-N2-dG and ME-3′-N2-dG.
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Figure 5. Expected structure of adducts of methyleugenol reactive metabolite with 2′-deoxyguanosine based on the
analogy of reaction of estragole with 2′-deoxyguanosine as identified by Phillips et al. (1981) and Wiseman et al.
(1985). ME-3'-N2-dG = N2-(trans-isomethyleugenol-3'-yl)-2'-deoxyguanosine, ME-3'-8-dG = 8-(trans-isomethyl-
eugenol-3'yl)-2'-deoxyguanosine, ME-1'-N2-dG = N2-(methyleugenol-1'-yl)-2'-deoxyguanosine, and ME-3'-7-dG = 7-
(trans-methyleugenol-3'-yl)-2'-guanine.
reaction was performed using (15N5) ME-3'-N
2-dG, and the isolation of the labeled adduct was
undertaken in the same way as described for the non-labeled analogue.
The characterizations of ME-3'-N2-dG and (15N5) ME-3'-N
2-dG were carried out on the basis
of the LC-MS/MS results depicted in Figure 6. In Figure 6A, the transitions used for the
MS/MS spectrum of ME-3'-N2-dG provided a molecular ion at m/z 444 corresponding to the
protonated molecule [M + H]+. The 5 Da upmass shift observed in the MS/MS spectrum of
(15N5) ME-3'-N
2-dG (m/z 449) (Figure 6B) was consistent with the penta-15N labeling of the
guanine moiety. When fragmented by collision, the ion of ME-3'-N2-dG at m/z 444 gave rise to
three major fragment ions at m/z 328, 177, and 164 (insert Figure 6A). The fragment ions at m/z
328, m/z 177, and m/z 164 were rationalized in terms of a loss of the deoxyribose group, loss of
the 2′-deoxyguanosine group, and loss of deoxyribose and phenylethyl groups, respectively.
The same MS/MS spectrum of ME-3'-N2-dG was obtained in the study of Herrmann et al.
(2012). Identification of  ME-3'-N2-dG was further supported by the observation of the mass
ME-3'-N -dG ME-1'-N -dG ME-3'-8-dG  ME-3'-7-dG
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Figure 6. API 3000 Q1 spectrum of the parent ion representing: (A) the non-labelled synthesised ME-3′-N2-dG (444
m/z, Da). The insert represents the daughter ions (328, 177, 164 m/z, Da) formed from the parent ion (444 m/z, Da) and
(B) the labelled synthesised (15N5) ME-3'-N2-dG (449 m/z, Da). The insert represents the daughter ions (338, 169 m/z,
Da) formed from the parent ion (449 m/z, Da).
loss of the deoxyribose group and the phenylethyl group in the transition m/z 449 → 333 and
m/z 449 → 169, respectively obtained in the case of (15N5) ME-3'-N
2-dG (insert Figure 6B).
Inhibition of ME-3'-N2-dG formation in the human hepatoma cell line HepG2
Figure 7A shows the LC-MS/MS chromatogram for the 444 → 328 transition of hydrolysed
DNA isolated from human HepG2 incubated with 100 µM 1′-hydroxymethyleugenol. The peak
of ME-3'-N2-dG appears at 2.7 min in the chromatogram. Figure 7B presents the ME-3'-N2-dG
formation detected in HepG2 cells exposed to 100 µM 1′-hydroxymethyleugenol (1′HME)
for ~14 hr in the absence and presence of increasing concentrations of nevadensin or 12.5 µM
PCP added as a positive control for SULT inhibition. At the concentrations tested the
compounds were not toxic to the HepG2 cells according to the results of the MTT test (data not
shown). The results of Figure 7B reveal that ME-3'-N2-dG formation in HepG2 cells exposed to
1′-hydroxymethyleugenol was almost completely blocked by co-exposure to the model SULT
inhibitor PCP. For nevadensin, a dose dependent inhibition was observed with 0.2 and 2 µM
inhibiting ME-3'-N2-dG formation in HepG2 cells exposed to 1′-hydroxymethyleugenol by 80
and 88 % respectively.
A.        B.
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Figure 7. LC-MS/MS chromatogram of the adduct (444→328) formed in human HepG2 cells exposed to 100 µM 1′-
hydroxymethyleugenol (A) and DNA adduct levels detected in human HepG2 cells treated with 100 µM 1′-
hydroxymethyleugenol (1′HME) and increasing concentration of nevadensin (NEV) or 12.5 µM pentachlorophenol
(PCP) as positive control (B). Data points represent mean (± SD) of triplicate measurements obtained in independent
experiments. An asterisk (*) indicates a significant inhibition compared to the incubation without inhibitor, * p< 0.05;
** p≤ 0.01.
PBK-based predictions for methyleugenol phase II metabolism in the presence of
nevadensin
Figure 8 illustrates the PBK predicted effect of an increasing dose of nevadensin (expressed
as molar ratio to the dose of methyleugenol, which was kept at a constant value of 0.217 mg/(kg
CHAPTER 4
145
bw) or 50 mg/(kg bw) respectively in Figure 8A and 8B) on the formation of 1′-
sulfooxymethyleugenol in male rat and human liver. The data calculated for varying molar
ratios of nevadensin to methyleugenol also reflect what would happen if the bioavailability of
nevadensin would be lower than 100%, which is not unlikely given the value of 20% reported
in literature (Han et al., 1981). As predicted by the PBK model, the co-administration of a dose
of methyleugenol of 0.217 mg/(kg bw) (SCF, 2001) together with an increasing dose of
nevadensin will lead to a dose dependent decrease in the formation of the ultimate DNA
reactive metabolite 1′-sulfooxymethyleugenol (Figure 8A), whereas the levels of 1′-
hydroxymethyleugenol glucuronide and 1′-oxomethyleugenol formation were predicted to
remain unaffected (data not shown). Assuming 100% uptake of nevadensin and hepatic
clearance similar to that of methyleugenol, the PBK model predicts that at a molar ratio
between methyleugenol and nevadensin of 1, a 92.2% and 97.7% inhibition of the formation of
1′-sulfooxymethyleugenol in the liver of male rat and human can be expected (Figure 8A).
Assuming 1% instead of 100% uptake of nevadensin (equivalent to a nevadensin to
methyleugenol molar ratio of 0.01), the model still predict about 27.5 % and 60.4 % inhibition
of 1′ -sulfooxymethyleugenol formation as compared to control in male rat and human
respectively (Figure 8A).
Figure 8B presents the results obtained when the same PBK modeling was performed at a
dose of methyleugenol of 50 mg/(kg bw) (Smith et al., 2002). At a molar ratio of nevadensin to
methyleugenol of 0.06 (assuming the same ratio at which the nevadensin and the related
alkenylbenzene estragole are expected to be present in dried basil (Alhusainy et al., 2010)) the
model predicts an almost complete inhibition of 1′-sulfooxymethyleugenol formation in the
liver of male rat and human when assuming 100% uptake of nevadensin (Figure 8B). At the
same molar ratio of 0.06 but assuming 1% uptake of nevadensin (theoretically equivalent to a
nevadensin to methyleugenol molar ratio of 6×10−4), the PBK model still predicts 85% and 93%
inhibition of 1′-sulfooxymethyleugenol formation in the two species respectively (Figure 8B).
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Figure 8. PBK-based predictions for the dose-dependent effect of nevadensin on 1′-sulfooxymethyleugenol formation in
the liver of male rat (grey bar) and human (black bar) at (A) 0.217 mg/(kg bw) and (B) 50 mg/(kg bw) of
methyleugenol.
Discussion
Methyleugenol is an alkenylbenzene that occurs in many herbs and spices. The compound is
carcinogenic in various livers of mice and rats when administered at high dose levels but
negative in standard in vitro genotoxicity tests (Ding et al., 2011). It has been indicated that
hydroxylation followed by sulfonation is an important bioactivation pathway leading to DNA
adduct formation and eventually tumor formation by methyleugenol in animal models (Smith et
al., 2002).
In a previous study, it was demonstrated that the flavonoid nevadensin, which is an
important constituent of herbs like basil (Grayer et al., 1996), is able to inhibit the bioactivation
of the related alkenylbenzene estragole to its DNA reactive metabolite at the level of the SULT
mediated conversion of 1′-hydroxyestragole to 1′-sulfoxyestragole (Alhusainy et al., 2010;
Jeurissen et al., 2008). The objective of the present study was to examine whether the herb
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based constituent nevadensin would also be able to inhibit the SULT mediated bioactivation of
methyleugenol and its subsequent formation of DNA adducts, and to investigate the possible in
vivo consequences of such an inhibition using PBK modeling. The effect of nevadensin on the
SULT mediated DNA adduct formation by 1′-hydroxymethyleugenol was investigated in the
human hepatoma cell line HepG2. HepG2 cells contain different enzymes involved in the
metabolism of 1′-hydroxymethyleugenol such as SULT and UDP-glucuronosyltransferases
(Brandon et al., 2003, 2006; Knasmuller et al., 1998). A method for the quantification of ME-
3′-N2-dG was developed based on a recently developed LC-MS/MS method also suitable to
quantify the corresponding adducts from estragole (Punt et al., 2007). Incubations with human
HepG2 cells exposed to 1′-hydroxymethyleugenol in the presence of increasing concentrations
of nevadensin revealed a dose-dependent inhibition of ME-3′-N2-dG formation by nevadensin at
concentrations ranging from 0.002 to 2 µM. At 2 µM ME-3′-N2-dG formation was inhibited by
88%.
In subsequent investigations of the present study the inhibition of SULT by nevadensin was
incorporated into our PBK models for methyleugenol bioactivation and detoxification in male
rat and human (Al-Subeihi et al., 2011, 2012). These modified PBK models allow evaluation of
the bioactivation and detoxification of methyleugenol in the liver of male rat and human when
exposure to methyleugenol is combined with exposure to nevadensin. This approach illustrates
the conclusions reported before that PBK modeling facilitates the extrapolation of the
occurrence and magnitude of interactions of binary mixtures from the in vitro to the in vivo
situation (Krishnan et al., 2002). The modified PBK models described in the present study
allowed prediction of the dose-dependent inhibition of the formation of the ultimate DNA
reactive metabolite 1′-sulfooxymethyleugenol in the liver of male rat and human administered
methyleugenol in the presence of nevadensin. The models also predict the nevadensin-mediated
changes in the overall formation of the metabolites that reflect detoxification by
glucuronidation and oxidation of 1′-sulfooxymethyleugenol. The present PBK models do not
contain a sub-model for nevadensin since that would be a study in itself. We defined the Ki for
inhibition of SULT activity by nevadensin and included this inhibition kinetics in the model. As
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a first approximation for the ADME (absorption, distribution, metabolism and excretion)
characteristics of nevadensin we assumed these characteristics to be similar to those of
methyleugenol, resulting in a fixed ratio between the concentration of methyleugenol and that
of nevadensin at any point in time. Possible differences in the uptake and kinetics of nevadensin
compared to that of methyleugenol were investigated by modeling several ratio′s between
nevadensin and methyleugenol with a ratio of 1 assuming similar uptake, but a ratio of 0.01
assuming only 1 % uptake of nevadensin as compared to 100% methyleugenol uptake. In this
way the effect of nevadensin ADME characteristics on the inhibition of methyleugenol
bioactivation could be evaluated without the need for parameterization and individual
nevadensin sub-model. Different molar ratios of the two compounds were modeled to provide
some insight in the effects of possible differences in kinetics and bioavailability of the two
compounds. The PBK models developed predict that at a methyleugenol dose level of 50
mg/(kg bw) and a nevadensin to methyleugenol ratio of 0.06, the estimated ratio between the
nevadensin and the related alkenylbenzene estragole in basil, nevadensin would inhibit 1′-
sulfooxymethyleugenol formation in male rat and human liver by respectively 98% and 99% or
85% and 93% assuming 100 or 1% nevadensin uptake respectively. Thus formation of 1′-
sulfooxymethyleugenol is expected to be significantly, though not completely, blocked. Other
flavonoids that are part of the human diet, including quercetin, possess a potent SULT
inhibitory activity as well (De Santi et al., 2002; Gibb et al., 1987; Marchetti et al., 2001;
Morimitsu et al., 2004) implying that the formation of 1′-sulfooxymethyleugenol could be even
lower due to the combination of methyleugenol exposure with other food borne SULT
inhibitors together with nevadensin from basil (Alhusainy et al., 2012). Moreover, not only can
the bioactivation of allylalkoxybenzenes be affected by the food matrix but also their
bioavailability might be reduced (Schilter et al., 2003) due to reduced absorption from the
gastrointestinal tract which can be attributed to slow or inadequate release of
allylalkoxybenzenes from the complex food matrix. Support for this possible limited release of
methyleugenol from a food matrix can be found in our previous work where PBK model based
predictions for methyleugenol blood levels were compared to data from a study in which nine
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volunteers consumed a meal consisting of gingersnaps containing approximately 0.216 mg
methyleugenol (0.0034 mg/(kg bw), considering an average body weight of 63.8 kg) (Schecter
et al., 2004). The serum blood levels of the volunteers were measured at different time points
and compared to the venous blood levels of PBK model-based predictions for blood levels of
methyleugenol (Al-Subeihi et al., 2012). The results obtained revealed that the PBK model
predicted blood concentrations of methyleugenol were higher than the actually measured ones
(Al-Subeihi et al., 2012); a discrepancy that may be due to limited bioavailability of
methyleugenol from the ginger snap food matrix as compared to the 100% bioavailability of
methyleugenol assumed in the PBK modeling. At 13.8 % bioavailability of methyleugenol from
the ginger snaps predicted and observed venous blood levels of methyleugenol were similar.
Another point of interest is that the modeling also reveals that the effect of a given ratio of
nevadensin to methyleugenol on 1′-sulfooxymethyleugenol formation varies with the dose of
methyleugenol. Thus at a molar ratio of nevadensin to methyleugenol of 0.06, the percentage of
inhibition decreases going from 98% and 99 % at a methyleugenol dose of 50 mg/(kg bw) to
62.2% and 84.7% at a methyleugenol dose of 0.217 mg/(kg bw) in male rat and human liver,
respectively. This can be explained by the fact that the concentration of the inhibitor nevadensin
is higher in the former situation (at 50 mg/(kg bw)) than in the latter situation (at 0.217 mg/(kg
bw)) resulting in more efficient inhibition given the Ki of 4 nM. This is a well-known
characteristic of non-competitive inhibition (Simmons, 1996). Altogether, the PBK modeling
reveals that the inhibition of SULT mediated bioactivation to 1′-sulfooxymethyleugenol upon
combined exposure to methyleugenol and nevadensin may be significant even at realistic low
dose human exposure levels and even when the uptake of nevadensin would be significantly
lower than 100%. The efficiency of nevadensin in inhibiting the sulfonation of 1′-
hydroxymethyleugenol and thus its potential protective effect against bioactivation of
methyleugenol to the proximate DNA reactive metabolite still needs to be established in in vivo
experiments where factors such as its bioavailability and metabolic stability will play a crucial
role. Recent studies in which estragole was dosed to rats in either the absence or presence of
nevadensin revealed significant reduction in the amount of estragole DNA adducts formed in
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the liver upon co-administration of estragole with the flavonoid SULT inhibitor nevadensin
(Alhusainy et al., 2012), suggesting that the effects observed in the present study for
methyleugenol may in future also appear relevant for the in vivo situation. Of interest in this
respect is as well that methylated flavones such as nevadensin have been demonstrated to be
much more metabolically stable than their non-methylated analogues which is reflected by their
resistance to hepatic metabolism and stability in the intestinal epithelial cell layer (Walle, 2007;
Wen and Walle, 2006). Furthermore, they also have higher intestinal absorption through Caco-2
cell monolayers (Walle, 2007; Wen and Walle, 2006). Both factors should increase their oral
bioavailability as compared to the bioavailability of non-methylated flavones.
In conclusion, the present study points at an important matrix effect of combined exposure
to methyleugenol and nevadensin. SULT inhibition was shown to lead to the inhibition of the
formation of the ultimate DNA reactive metabolite. If, like for estragole, the PBK predicted
data can be validated in vivo, which is an important issue for future research, this would imply
that the consumption of methyleugenol within a matrix of sweet basil or other food items
containing SULT inhibitors would pose a risk that is lower than what would be estimated based
on results from rodent bioassays in which methyleugenol is dosed as a pure compound by
gavage without the relevant food matrix being present.
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Abstract
The present study aims at predicting the level of formation of the ultimate carcinogenic
metabolite of methyleugenol 1′-sulfooxymethyleugenol in the human population by taking the
variability in key bioactivation and detoxification reactions into account using Monte Carlo
simulations. Insight in the variation in relevant metabolic routes was obtained by determining
kinetic constants for the metabolic reactions by specific isoenzymes or by measuring the kinetic
constants in incubations with a range of individual human liver fractions. The results of the
study indicate that formation of 1′-sulfooxymethyleugenol is predominantly affected by i) P450
1A2 catalyzed bioactivation of methyleugenol to 1′-hydroxymethyleugenol ii) P450 2B6
catalyzed epoxidation of methyleugenol and iii) the apparent kinetic constants for detoxification
of 1′-hydroxymethyleugenol via oxidation and iv) the apparent kinetic constants for
bioactivation of 1′-hydroxymethyleugenol to 1′-sulfooxymethyleugenol. Based on the Monte
Carlo simulation a chemical-specific adjustment factor (CSAF) for intraspecies variation could
be derived which is defined as the 95th or 99th percentile divided by the 50th percentile of the
predicted distribution of the formation of 1′-sulfooxymethyleugenol in the liver.  The obtained
CSAF value at the 95th percentile was 3.7 indicating that the default uncertainty factor of 3.16
for human variability in kinetics may adequately protect 95% of the population. Protecting 99%
of the population requires a larger uncertainty factor of 5.8.
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Introduction
Methyleugenol (3,4-dimethoxyallylbenzene) is a member of a family of chemicals known as
alkoxy allylbenzenes which includes also compounds such as safrole and estragole (Robison
and Barr, 2006). Methyleugenol enters the diet via different food sources like herbs and spices
(e.g. basil, sweet bay, cloves and lemon grass) which are consumed at low levels in the human
diet (Gardner et al., 1997). Methyleugenol was selected to be studied by the National
Toxicology Program (NTP) because of its broad use and its structural resemblance to the other
carcinogenic alkoxy allylbenzenes including safrole and estragole. Based on the results of the
National Toxicology Program (NTP) study, methyleugenol revealed a carcinogenic effect in
both F344 rat and B6C3F1 mice (NTP, 2000). The Expert Panel of the Flavor and Extracts
Manufacturers Association (FEMA) classified methyleugenol as GRAS (generally recognized
as safe) at the proposed levels of flavor use in 1965 (Hall and Oser, 1965). In 2001, the FEMA
Panel reassessed the available data for methyleugenol and confirmed that there is no
considerable cancer risk resulting from consumption of methyleugenol as flavouring substance
and affirmed the GRAS status of methyleugenol as a flavoring substance given the low levels of
exposure (Smith et al., 2002). In 2001, the Scientific Committee on Food (SCF) of the
European Union published a scientific opinion on methyleugenol in which it was concluded that
methyleugenol is genotoxic and carcinogenic and that reductions in exposure and restrictions in
use levels are indicated (SCF, 2001). The average daily intake of methyleugenol was estimated
by the SCF to be 13 mg/day, corresponding to 0.217 mg/(kg bw)/day for a 60 kg person (SCF,
2001). The FEMA, using a different methodology, estimated the average daily intake of
methyleugenol to be less than 0.01 mg/(kg bw)/day (Smith et al., 2002). The estimation of the
SCF was based on theoretical maximum use levels of methyleugenol in various food categories
and consumption data for these food categories, whereas the intake estimation of the FEMA
was based on production volume data for flavor use (SCF, 2001; Smith et al., 2002).
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Methyleugenol is unreactive by itself and requires metabolic activation to produce
electrophilic metabolites that act as the DNA reactive intermediates (Gardner et al., 1997; Miele
et al., 2001). Figure 1 displays the metabolic pathways of methyleugenol. Important metabolic
pathways include O-demethylation of the methoxy moieties on the benzene ring, and 2′,3′-
epoxidation and 1′-hydroxylation of the allylic side chain (NTP, 2000; Solheim and Scheline,
1976). O-demethylation of the methoxy substituents of methyleugenol yields the corresponding
phenolic derivatives, which may be excreted as sulfate or glucuronic acid conjugate (Smith et
al., 2002). Epoxidation of the side chain yields a 2′,3′-epoxide. This epoxide is detoxified by
epoxide hydrolase to form the dihydrodiol or via glutathione conjugation (Luo and Guenther,
1995). Hydroxylation at the 1'-position of methyleugenol is considered to represent the
bioactivation pathway producing the proximate carcinogenic metabolite 1′-
hydroxymethyleugenol (Drinkwater et al., 1976; Miller et al., 1983). In a next step 1′-
hydroxymethyleugenol can be sulfonated by sulfotransferases to form 1'-
sulfooxymethyleugenol which readily undergoes desulfonation to a reactive carbo-cation that
can form DNA or protein adducts (Miller et al., 1983).
Genotype- and lifestyle-based factors can influence the activity of the enzymes involved in
the bioactivation and detoxification of methyleugenol which could in theory lead to large
variability in the level of formation of the ultimate carcinogenic metabolite 1′-
sulfooxymethyleugenol. Results from previously published physiologically based kinetic (PBK)
models for methyleugenol in rat and human (Al-Subeihi et al., 2011, 2012), and sensitivity
analyses for these models, revealed that formation of 1′-sulfooxymethyleugenol is mainly
affected by the kinetic constants for 1′-hydroxylation, O-demethylation, and epoxidation of
methyleugenol as well as kinetic constants for oxidation and sulfonation of 1′-
hydroxymethyleugenol. For male rat the formation of 1′-sulfooxymethyleugenol was
furthermore significantly affected by the extent of glucuronidation of 1′-hydroxymethyleugenol
(Al-Subeihi et al., 2011). The present study aims at predicting the level of formation of 1′-
sulfooxymethyleugenol in the human population by taking the variability in these metabolic
reactionsintoaccount using MonteCarlo simulations. Insight in the variation in the key metabolic
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Figure 1. Suggested metabolic pathways of methyleugenol.
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routes was obtained by determining kinetic constants for the metabolic reactions by specific
isoenzymes and taking the literature reported level of variation in activity of these enzymes in
the population into account or, when specific isoenzymes were not commercially available, by
measuring the kinetic constants in incubations with a range of individual human liver fractions.
Altogether the results of the present study allow evaluation of human interindividual variation
in the formation of the ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol within the
population as a whole.
Materials and Methods
Chemicals and reagents
Supersomes expressing the human P450 enzymes 1A2, 2A6, 2B6, 2C8, 2C9*1, 2C19,
2D6*1, 2E1, or 3A4, supersomes expressing the human UGT enzymes UGT1A1, 1A3, 1A4,
1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, or 2B17 and pooled human liver microsomes were
obtained from BD Gentest (Woburn, MA, USA). Twenty individual human liver S9
homogenates were purchased from Xenotech (Lenexa, Kansas, USA). Two individual human
liver S9 homogenates were purchased from Celsis (Brussels, Belgium). Hydrochloric acid
(37%), potassium dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, and acetic
acid were purchased from VWR International (Darmstadt, Germany). NADPH, NADP+,
NADH and NAD+ were obtained from Roche Diagnostics (Mannheim, Germany).
Methyleugenol, eugenol, methanol, ascorbic acid, dimethylsulfoxide (DMSO), alamethicin and
uridine 5′-diphosphoglucuronic acid (UDPGA) were purchased from Sigma-Aldrich
(Steinheim, Germany). Acetonitrile (UPLC/MS grade) was obtained from Biosolve
(Valkenswaard, Netherlands). Glutathione (GSH) and 3′-phosphoadenosine-5′-phosphosulfate
(PAPS) were obtained from Sigma Aldrich (Schnelldorf, Germany). 1′-Hydroxymethyleugenol,
methyleugenol-2′,3′-oxide, 3-(3,4-dimethoxyphenyl)propane-1,2-diol, and 1′-oxomethyleugenol
were synthesized and characterized as described previously (Al-Subeihi et al., 2011).
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Caution: 1′-hydroxymethyleugenol, methyleugenol-2′,3′-oxide, and 1′-oxomethyleugenol
are carcinogenic and should be handled carefully.
Methods
1′-Hydroxylation, epoxidation, and O-demethylation of methyleugenol by cDNA
recombinant P450 enzymes
Methyleugenol was incubated with supersomes expressing P450 1A2, 2A6, 2B6, 2C8,
2C9*1, 2C19, 2D6*1, 2E1, or 3A4 to determine the human cytochrome P450 enzymes
involved in the 1′-hydroxylation, epoxidation, and O-demethylation of methyleugenol and the
kinetic constants for these reactions. The incubations were performed in 160 µL incubation
mixtures that contained (final concentrations) 3mM NADPH and 0.05 nmol P450/mL
supersomes in 0.2 M Tris-HCl (pH 7.4). The reactions were started after 1 min preincubation
at 37 °C by adding the substrate methyleugenol (ranging from 5 to 1000 µM final
concentrations varying depending on the P450 enzyme studied and added from a 100 times
concentrated stock solution in DMSO). The reactions were terminated after 10 min by adding
40 µL of ice-cold acetonitrile. All incubations were performed in triplicate, and control
incubations were performed without NADPH. Samples were centrifuged for 5 min at 16,000 g
and stored at -20 ᵒC until HPLC analysis. Formation of phase I metabolites was quantified
using the same HPLC conditions for analysis of phase I metabolites as previously described
(Al-Subeihi et al., 2012).
Glucuronidation of 1′-hydroxymethyleugenol by recombinant UGT enzymes
1′-Hydroxymethyleugenol was incubated with supersomes expressing UGT1A1, 1A3, 1A4,
1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, or 2B17 to determine the human UGT enzymes
involved in glucuronidation of 1′-hydroxymethyleugenol. The incubation mixtures had a final
volume of 200 μL, containing (final concentrations) 10 mM UDPGA, and 1 mg/mL protein in
0.2 M Tris-HCl (pH 7.4) containing 10 mM MgCl2. To overcome enzyme latency, the
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incubation mixtures were pre-treated on ice for 15 min with 0.025 mg/mL of the poreforming
peptide alamethicin added from a 200 times concentrated stock in methanol (Fisher et al., 2000;
Lin and Wong, 2002). The reactions were started by the addition of 2000 μM of the substrate
1′-hydroxymethyleugenol from a 200 times concentrated stock solution in DMSO after pre-
incubation of the incubation mixture at 37 °C for 1 min. The reactions were carried out for 6 hr
and terminated by addition of 50 μL cold acetonitrile. Blank incubations were performed
without the cofactor UDPGA. Samples were centrifuged for 5 min at 16,000 g and stored at -20
°C until HPLC analysis. The kinetic constants for glucuronidation of 1′-hydroxymethyleugenol
by UGT1A9 and 2B7, which were observed to catalyse this reaction (see Results section), were
determined using similar incubation conditions as described above but at different protein and
substrate concentrations. In case of UGT1A9 incubations were performed at a protein
concentration of 0.5 mg/mL and a substrate concentration ranging from 100 to 4000 µM and in
case of UGT2B7 at a protein concentration of 1 mg/mL and a substrate concentration ranging
from 250 to 4000 µM. Formation of 1′-hydroxymethyleugenol glucuronide by UGTs was
quantified using the same HPLC conditions as previously described for detection of 1′-
hydroxymethyleugenol glucuronide formed in incubations with pooled mixed human
microsomes (Al-Subeihi et al., 2012).
Oxidation of 1′-hydroxymethyleugenol by individual human liver S9 samples
The kinetics for oxidation of 1′-hydroxymethyleugenol by twenty two individual human
liver S9 samples were determined as previously described by Al-Subeihi et al. (2012) for
determining oxidation by pooled human liver fractions. Incubations were performed using
NAD+ and NADP+ as cofactor and GSH to trap the reactive 1′-oxomethyleugenol at substrate
concentrations that ranged from 100 to 3000 µM 1′-hydroxymethyleugenol. The incubation
mixtures had a final volume of 200 µl, containing (final concentrations) 3 mM NAD+, 3 mM
NADP+, 2 mM GSH, and 1 mg/mL S9 protein in 0.2 M Tris-HCl (pH 7.4). The reactions were
terminated after 10 min by addition of 50 µL cold acetonitrile and the incubation mixtures were
centrifuged for 5 min at 16,000 g and the supernatant was collected and stored at -20 °C until
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UPLC analysis. To this end 3.5 µL of the samples were injected into an Acquity column BEH
C18 1.7 µm 2.1*50 mm, with a guard column filter (Acquity, Waters). The runs were
performed on an Acquity (Waters) UPLC system coupled to a PDA detector. The flow was 0.6
mL/min and the gradient started with 100% of 0.1% acetic acid in nanopure water and 0% of
acetonitrile. After 0.57 min the amount of acetonitrile was increased to 25% and kept at 25%
for 0.2 min, after which the acetonitrile amount was increased to 100% and kept at 100% for 30
s, after which starting conditions were reset. At these conditions the glutathione conjugate of 1'-
oxomethyleugenol (GS-1′-oxomethyleugenol) eluted at 0.97 min. Blank incubations without the
addition of NAD+ and NADP+ were performed for each individual human liver S9 fraction. The
amount of 1'-oxomethyleugenol formed in the different samples was corrected for the amount
formed in blank incubations. Quantification of GS-1′-oxomethyleugenol formed in these
incubations with S9 was performed as described by Al-Subeihi et al. (2012).
Sulfonation of 1′-hydroxymethyleugenol by individual human liver S9 samples
To characterize the kinetics for sulfonation of 1'-hydroxymethyleugenol incubations with 5
individual human liver S9 homogenates (2 mg protein/mL final concentration) were performed
as previously described by Al-Subeihi et al. (2012) in 0.1 M potassium phosphate (pH 8.2).
Incubations contained different concentrations of the substrate 1'-hydroxymethyleugenol, at
final concentrations ranging from 25 to 1000 µM (added from 100 times concentrated stock
solutions in DMSO), PAPS (0.2 mM final concentration) as cofactor, and GSH (5 mM final
concentration) as trapping agent of the transient 1'-sulfooxymethyleugenol. The final volume of
the incubation was 100 µL. The reactions were started after 1 min preincubation at 37 °C by
adding PAPS, and all incubations were carried out for 3 hr at 37 °C. The reactions were
terminated by adding 25 µL acetonitrile, after which incubations were centrifuged for 5 min at
16,000 g and the supernatant was collected and stored at -80 °C until LC-MS/MS analysis.
Blanks were made without the addition of PAPS and the amount of 1′-sulfooxymethyleugenol
formed in the samples was corrected for the amount formed in these blank incubations.
Formation of the glutathione conjugate with 1′-sulfooxymethyleugenol was quantified by LC-
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MS/MS as described by Paini et al. (2012) for quantification of the guanosine conjugate of 1′-
sulfooxyestragole.
PBK modeling and Monte Carlo simulation
The PBK model previously developed for methyleugenol in human (Al-Subeihi et al., 2012)
was used in the present study to integrate the kinetic data obtained. The model was adjusted by
replacing the kinetic constants for 1′-hydroxylation, epoxidation, and O-demethylation of
methyleugenol and the kinetic constants for glucuronidation, oxidation, and sulfonation of 1′-
hydroxymethyleugenol, that were previously defined based on incubations with pooled human
liver samples, with the kinetic constants obtained in the present study from incubations with
recombinant enzymes or individual human liver S9 factions. All other model parameters as well
as the differential equations were kept as they were previously defined (Al-Subeihi et al., 2012).
As a first step, the kinetic data obtained were used to simulate 1′-sulfooxymethyleugenol
formation in an average individual human subject by taking average relative activity factors for
recombinant enzymes into account and the average Km and Vmax values for sulfonation and
oxidation of 1′-hydroxymethyleugenol as obtained in the present study with incubations of
individual human liver S9 fractions. In case of 1′-hydroxyalation, epoxidation, and O-
demethylation of methyleugenol by recombinant cytochrome P450 enzymes and
glucuronidation of 1′-hydroxymethyleugenol by recombinant UGT enzymes the Vmax values,
expressed as nmol/min/(mg recombinant enzyme), were scaled to the liver according to the
following equation:
VmaxP450/UGT* RAFP450/UGT * MMPL * Liver weight. (μmol/hr),
in which the relative activity factor (RAF) represents relative activity of the different P450
enzymes or UGT enzymes in supersomes compared to pooled human liver microsomes as
reported by Patten et al. (2009) and Stresser et al. (2009) for different P450 enzymes and as
determined in the present study for the different UGT enzymes. MMPL represents the
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microsomal protein yield of 32 mg/(g liver) (Barter et al., 2007) and the liver weight represents
an average weight of the liver corresponding to 1659 g in the present model. The RAFs for
UGT1A9 and UGT2B7 were obtained by incubating both pooled human liver microsomes (1
mg/mL) and the supersomes expressing the UGT enzymes (1 mg/mL) with propofol (600 µM
final concentration) as selective probe substrate for UGT1A9 and 3'-azido-3'-deoxythymidine
(AZT) (5 mM final concentration) as selective probe substrate for UGT2B7. Incubations with
these probe substrates were carried out using the same incubation conditions of glucuronidation
of 1′-hydroxymethyleugenol with pooled human liver microsomes but the reaction was
terminated after 1 hr for propofol and 30 min for AZT.
In case of oxidation and sulfonation, the average Vmax values, expressed as nmol/min/(mg S9
protein) obtained from the incubations with different individual human tissue fractions were
scaled to the liver according to the following equation:
VmaxS9* S9PL * Liver weight. (μmol/hr),
in which S9PL represents the S9 protein yield of 143 mg/(g liver) (Punt et al., 2009) and the
liver weight represents an average weight of the liver corresponding to 1659 g .
With this model, representing an average individual human subject, a sensitivity analysis
was performed to analyze the relative effect of changes in activity levels of the recombinant
P450 enzymes involved in 1′-hydroxylation, epoxidation, and O-demethylation of
methyleugenol and the recombinant UGTs enzymes involved in glucuronidation of 1′-
hydroxymethyleugenol as well as the relative effect of changes in activity levels of oxidation of
1′-hydroxymethyleugenol and other metabolic parameters on the formation of 1′-
sulfooxymethyleugenol in human liver. Normalized sensitivity coefficients (SC) were
determined according to the following equation: SC = (C' − C)/(P' − P) *(P/C), where C is the
initial value of model output, C' is the modified value of the model output resulting from an
increase in parameter value, P is the initial parameter value, and P' is the modified parameter
value (Rietjens et al., 2011). Based on the literature a 5% increase in parameter values was
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chosen, to analyze the effect of a change in parameter on the formation of 1′-
sulfooxymethyleugenol expressed nmol/(g liver) over a 24 hr period of time (Evans and
Andersen, 2000). Each parameter was analyzed individually, keeping the other parameters to
their initial values.
In a second step, Monte Carlo simulations were performed to simulate the level of variation
in the formation of 1′-sulfooxymethyleugenol that could occur in the population as a whole. For
this analysis, a total of 10,000 simulations were performed, where in each simulation, the Vmax
values for 1′-hydroxylation, epoxidation and O-demethylation of methyleugenol by different
P450 enzymes, the Vmax values for glucuronidation of 1′-hydroxymethyleugenol by different
UGT enzymes and the apparent Vmax and Km values for oxidation and sulfoantion of 1′-
hydroxymethyleugenol were randomly taken from a log-normal distribution. The kinetic
constants for the different metabolic reactions were assumed to vary independently. For this
simulation, the mean μW and standard deviation σW describing the log-normal distribution of
each Vmax or Km value were derived using the following equation (Zhang et al., 2007):
μW = ln (μX/√(1+CV
2
X)) and σW
2= ln (1+ CV2X),
where μX is the average Vmax or Km and CVX is the coefficient of variation for each of the
reactions representing the extent of variability in the reaction. For P450 enzymes and UGT
enzymes the coefficients of variation were obtained from the literature (Girard et al., 2004;
Holthe et al., 2003; Rostami-Hodjegan and Tucker, 2007). The coefficients of variation in the
Vmax and Km values for sulfonation and oxidation were obtained in the present study based on
the incubations with individual human liver S9. The outputs were then analyzed statistically to
calculate the different percentiles of the distribution of the predicted formation of 1′-
sulfooxymethyleugenol using SPSS (IBM SPSS Version 19, IBM, NY, USA).
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Results
Formation of 1′-hydroxymethyleugenol, methyleugenol-2′,3′-oxide and eugenol by cDNA
recombinant expressed enzymes
Incubations with cDNA recombinant expressed P450 enzymes were performed to define the
human P450 enzymes involved in the formation of 1′-hydroxymethyleugenol, methyleugenol-
2′,3′-oxide, and eugenol. Among the different P450 enzymes P450 1A2, 2C9*1, 2C19, 2D6*1
and 3A4 were observed to be able to catalyse 1′-hydroxylation of methyleugenol. Epoxidation
of methyleugenol to methyleugenol-2′,3′-oxide was observed to be catalysed by P450 2B6 and
2E1, whereas O-demethylation to eugenol was only catalysed by P450 1A2. The kinetic
constants for each of these reactions were determined. Figure 2, Figure 3 and Figure 4, show the
rate of formation of respectively 1′-hydroxymethyleugenol, methyleugenol-2′,3′-oxide and
eugenol by the different cytochrome P450 enzymes, and Table 1 presents the kinetic constants
derived from these data. In addition, Table 1 presents the Vmax values that are scaled to the in
vivo situation, as well as the in vivo catalytic efficiency of each enzyme. The results obtained
show that although various enzymes are intrinsically capable of catalysing 1′-hydroxylation and
epoxidation of methyleugenol, correcting for the in vivo relative activity of each of these
enzymes shows that in vivo P450 1A2 is the main enzyme involved in 1′-hydroxylation of
methyleugenol and P450 2B6 appears to be predominantly responsible for epoxidation of 1′-
hydroxymethyleugenol. The highest overall in vivo catalytic efficiency was predicted for
epoxidation (amounting to 159 L/hr), which was 1.6-fold higher than the sum of the catalytic
efficiencies for 1′-hydroxylation by the different P450 enzymes (amounting to 98.7 L/hr), and
16.7-fold higher than the catalytic efficiency for O-demethylation to eugenol (amounting to 9.5
L/hr).
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E.
Figure 2. Formation rate of 1′-hydroxymethyleugenol in incubations of methyleugenol at varying concentrations (50 –
1000 µM) with different cDNA recombinant P450 enzymes: A. P450 1A2, B. P450 2C9*1, C. P450 2C19, D. P450
2D6*1, and E. P450 3A4.
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Figure 3. Formation rate of methyleugenol-2′,3′-oxid in incubations of methyleugenol at varying concentrations (50 –
1000 µM) with cDNA recombinant P450 enzymes: A. P450 2B6,  and B. P450 2E1.
Figure 4. Formation rate of eugenol in incubations of methyleugenol at varying concentrations (5 – 100 µM) with
cDNA recombinant P450 1A2.
Formation of 1′-hydroxymethyleugenol glucuronide by cDNA recombinant expressed
enzymes
Incubations with cDNA recombinant expressed UGT enzymes were performed to define the
human UGT enzymes involved in the formation of 1′-hydroxymethyleugenol glucuronide.
Among the different UGT enzymes tested, only UGT1A9 and UGT2B7 were observed to be
able to catalyse glucuronidation of 1′-hydroxymethyleugenol. Figure 5 shows the rate of
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Table 1. Kinetic parameters for methyleugenol 1′-hydroxylation, epoxidation, and demethylation by
cDNA expressed cytochrome P450 enzymes.
Metabolic pathway Enzyme Vmax
a Km
a
In vitro
catalytic
efficiency
RAFb
cScaled
Vmax, in vivo
In vivo
catalytic
efficiency
(Vmax/Km) (Vmax, in vivo/Km)
(nmol/min/mg
protein)
(µM)
(µL/min/mg
protein)
(µmol/hr) (L/hr)
P450 1A2 3.2 ± 0.2 16 ±2 200 0.14 1366 85
P450 2C9*1 1.5 ± 0.3 174 ± 33 10 0.42 2007 12
1'-hydroxylation P450 2C19 10.9 ± 1.2 194 ±19 56 0.01 42 0.2
P450 2D6*1 2.9 ± 0.3 457 ±60 6 0.01 128 0.3
P450 3A4 6.8 ± 2.3 2003 ± 650 3 0.16 2407 1.2
Epoxidation P450 2B6 0.7 ± 0.03 7 ±1 100 0.50 1115 159
P450 2E1 1.3 ± 0.5 1050 ± 201 1 0.13 538 0.5
Demethylation P450 1A2 0.6 ± 0.05 26 ± 6 23 0.14 256 9.5
amean ± SD
bRelative Activity Factor (RAF), representing the relative activity of the enzyme in pooled (n=150) human liver
microsomes compared with  BD SupersomesTM as reported by BD Biosciences (Patten et al., 2009; Stresser et al.,
2009) based on the measured activity of selective probe substrates.
cVmax,P450/(1000 nmol/µmol)*(60 min/hr)*RAFP450*(32 mg microsomal protein/g liver)*(1659 g liver)
glucuronidation of 1′-hydroxymethyleugenol by these UGT enzymes, and Table 2 presents the
kinetic constants derived from these data. Table 2 also presents the Vmax values that are scaled
to the in vivo situation based on which the in vivo catalytic efficiencies(Vmax, in vivo/Km) of
these enzymes were calculated. Taking the in vivo catalytic efficiencies of UGT1A9 and 2B7
into account, both enzymes are predicted to contribute significantly to the glucuronidation
reaction of 1′-hydroxymethyleugenol in vivo. The overall in vivo catalytic efficiency was
predicted to amount to 0.95 L/hr corresponding to the sum of the individual catalytic
efficiencies.
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Figure 5. Formation rate of 1′-hydroxymethyleugenol glucuronide in incubations of 1′-hydroxymethyleugenol at
varying concentrations (100 – 4000 µM) with recombinant UGT enzymes: A. UGT1A9 and B. UGT2B7.
Table 2. Kinetic parameters for glucuronidation of 1′-hydroxymethyleugenol by cDNA expressed UGT
enzymes.
enzyme aVmax aKm
in vitro
catalytic
effeciency
bRAF
cScaled Vmax,
in vivo
in vivo
catalytic
efficiency
(Vmax/Km)
(Vmax,
in vivo/Km)
(nmol/min/mg
protein)
(µM)
(µL/min/mg
protein)
(µmol/hr) (L/h)
UGT 1A9 0.084± 0.006 601 ± 113 0.14 0.64 171 0.28
UGT 2B7 0.08± 0.02 715 ± 270 0.11 1.88 479 0.67
amean ± SD
bRelative Activity Factor (RAF), representing the relative activity of the enzyme in pooled (n=20) human liver
microsomes compared with BD SupersomesTM as determined in the present study by measuring the activity of selective
probe substrates.
cVmax,UGT/(1000 nmol/µmol)*(60 min/hr)*RAFUGT*(32 mg microsomal protein/g liver)*(1659 g liver)
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Oxidation and sulfonation of 1′-hydroxymethyleugenol by human individual liver S9
fractions
Table 3 shows the kinetic constants, Vmax and Km, for oxidation of 1′-hydroxymethyleugenol
for 22 human individuals while Table 4 shows the kinetic constants, Vmax and Km, for
sulfonation of 1′-hydroxymethyleugenol for 5 human individuals. These kinetic constants were
derived experimentally by incubating liver S9 homogenates with the relevant cofactors and
increasing concentrations of 1′-hydroxymethyleugenol. The Vmax values that are scaled to the in
vivo situation are also presented in Table 3 and Table 4 based on which the in vivo catalytic
efficiencies (Vmax, in vivo/Km) were calculated. The range between the highest and lowest
catalytic efficiency for oxidation of 1′-hydroxymethyleugenol was observed to be 8.3-fold. The
average in vivo catalytic efficiency for oxidation was 58 L/hr. In case of sulfonation, the range
between the highest and lowest catalytic efficiency was observed to be 4-fold and the average
catalytic efficiency was observed to be 3 L/hr.
PBK modeling and sensitivity analysis
The kinetic data obtained for 1′-hydroxylation, epoxidation, and O-demethylation of
methyleugenol by specific cytochrome P450 enzymes, the kinetic data for glucuronidation of
1′-hydroxymethyleugenol by specific UGT enzymes and the kinetic data for oxidation and
sulfonation by individual human liver S9 were integrated in the previously developed PBK
model for methyleugenol in human. With the developed model, a sensitivity analysis was
performed to identify the metabolic parameters that have the most influence on the predicted
formation of 1′-sulfooxymethyleugenol. Normalized SCs were calculated for different
metabolic parameters at a dose of 0.217 mg/(kg bw) methyleugenol by increasing parameter
values with 5%. Only metabolic parameters that had a normalized SC higher than 0.1 (in
absolute value) are displayed in Figure 6. The predicted formation of 1′-sulfooxymethyleugenol
in the liver was observed to be most sensitive to changes in the kinetic constants for 1′-
hydroxylation of methyleugenol by P450 1A2, epoxidation of methyleugenol by P450 2B6, and
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Table 3. Kinetics parameters for oxidation of 1′-hydroxymethyleugenol by human individual liver S9.
Code Vmax Km
in vitro catalytic
effeciency
scaled Vmax, in
vivoa
in vivo catalytic
efficiency
(Vmax/Km)
(Vmax, in
vivo/Km)
(nmol/min/mg S9
protein)
(µM)
(µL/min/mg S9
protein)
(µmol/hr) (L/h)
HLS9_420 3.01 1230 2.45 42845 34.8
HLS9_438 3.71 1520 2.44 52809 34.7
HLS9_422 3.72 1180 3.15 52951 44.9
HLS9_280 3.8 954 3.98 54090 56.7
HLS9_441 3.85 2350 1.64 54802 23.3
HLS9_133 3.96 864 4.58 56368 65.2
HLS9_120 4.49 1380 3.25 63912 46.3
HLS9_M962 4.51 1720 2.62 64196 37.3
HLS9_428 4.59 1140 4.03 65335 57.3
HLS9_251 4.66 2670 1.75 66331 24.8
HLS9_354 4.73 2230 2.12 67328 30.2
HLS9_236 4.79 3730 1.28 68182 18.3
HLS9_291 4.79 1830 2.62 68182 37.3
HLS9_432 5.21 1520 3.43 74160 48.8
HLS9_F962 5.44 2070 2.63 77434 37.4
HLS9_270 6.21 610 10.28 88395 144.9
HLS9_311 6.45 1430 4.51 91811 64.2
HLS9_393 6.45 1230 5.24 91811 74.6
HLS9_322 6.87 1040 6.61 97789 94.0
HLS9_296 7.22 1300 5.55 102771 79.1
HLS9_422 7.23 677 10.68 102913 152.0
HLS9_346 8.26 1790 4.61 117575 65.7
aVmax/(1000 nmol/µmol)*(60 min/hr)*(143 mg S9 protein /g liver)*(1659 g liver)
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Table 4. Kinetics parameters for sulfonation of 1′-hydroxymethyleugenol by human individual liver S9.
Code Vmax Km
In vitro catalytic
effeciency
Scaled Vmax, in
vivoa
In vivo
catalytic
efficiency
(Vmax/Km)
(Vmax, in
vivo/Km)
(nmol/min/mg
S9 protein)
(µM)
(µL/min/mg S9
protein)
(µmol/hr) (L/hr)
HLS9_133 0.02 90 0.22 285 3.2
HLS9_120 0.014 71 0.20 199 2.8
HLS9_251 0.013 172 0.08 185 1.1
HLS9_236 0.031 102 0.30 441 4.3
HLS9_270 0.027 110 0.25 384 3.5
a Vmax/(1000 nmol/µmol)*(60 min/hr)*(143 mg S9 protein /g liver)*(1659 g liver)
Figure 6. Sensitivity of the predicted formation of 1′-sulfooxymethyleugenol to metabolic parameters at a dose of 0.217
mg/(kg bw). Vmax and Km values are the Michaelis-Menten constants for the formation of 1′-hydroxymethyleugenol
(1′HME) and methyleugenol-2′,3′-oxide (MEO) by recombinant P450 enzymes that are scaled to the average in vivo
situation, and the average Michaelis-Menten constants for oxidation of 1′-hydroxymethyleugenol (1′OME) and
sulfonation of 1′-hydroxymethyleugenol (1′HMES) as determined in incubations with individual human liver S9
fractions.
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the apparent kinetic constants for oxidation and sulfonation of 1′-hydroxymethyleugenol. This
sensitivity analysis shows that the formation of 1′-sulfooxymethyleugenol in the liver is not
affected by the kinetic constants for glucuronidation of 1′-hydroxymethyleugenol by UGT 1A9
or 2B7.
Evaluation of interindividual human variability in formation of 1′-sulfooxymethyleugenol
on population level
A Monte Carlo simulation was performed to evaluate the extent of variation in formation of
1′-sulfooxymethyleugenol in the liver that could occur in the population as a whole. In Table 5,
the parameters that were varied and the distributions assigned to these parameters are given.
Figure7 presents thepredicted frequency distributionof the formationof 1′-sulfooxymethyleugenol
in individual human livers at a dose of 0.217 mg/(kg bw). The difference between the highest
and the lowest predicted formation of 1′-sulfooxymethyleugenol in the liver is 912-fold. The
highest value amounts to 1.55 nmol/(g liver), which was predominantly due to a low level of
detoxification of methyleugenol via P450 2B6 catalyzed epoxidation. This situation occurred
once in the 10,000 simulations. The lowest value amounts to 0.0017 nmol/(g liver) and was due
to a high level of oxidation of 1′-hydroxymethyleugenol in combination with a low level of
sulfonation of 1′-hydroxymethyleugenol. This situation occurred once in the10,000 simulations.
The 50th, 95th, and 99th percentiles of the distribution of the formation of 1′-
sulfooxymethyleugenol correspond to 0.09, 0.33, and 0.52 nmol/(g liver), respectively.
With the results obtained with the Monte Carlo simulation on the variability in formation of
1′-sulfooxymethyleugenol, a so-called chemical-specific adjustment factor (CSAF) can be
derived, which can be used as replacement of the default uncertainty factor for interindividual
percentile to represent a sensitive individual and the 50th percentile to represent the average
human difference in kinetics. Based on the guidelines of the International Program on Chemical
Safety (IPCS, 2005), CSAFs can be calculated as the ratio between given percentiles (such as
95th, 97.5th, or 99th) andthecentral tendency for the wholepopulation.Using the 95th individual,
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the CSAF amounts to 3.7. Using the 99th percentile to represent a sensitive individual the CSAF
amounts to 5.8.
Discussion
The present study aimed at evaluating interindividual differences in formation of the
ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol in the human population. Insights
in the level of variation of key metabolic routes could be obtained by determining kinetic
constants for the metabolic reactions by specific isoenzymes and taking the level of variation in
activity of these enzymes in the population into account or, when specific isoenzymes were not
commercially available, by measuring the kinetic constants in incubations with a range of
individual human liver fractions.
Table 5. Distributions assigned to the parameters that were varied in the Monte Carlo simulation.
Parameter Mean CV (%) Min-max value
in the simulation
Fold variation
Vmax, 1′HME_1A2 1427
a 67 137-13027 95
Vmax, 1′HME_2C9*1 2007
a 54 267-13173 49
Vmax, 1′HME_2C19 347
a 105 12-7260 629
Vmax, 1′HME_2D6*1 92
a 61 9-596 67
Vmax, 1′HME_3A4 3466
a 114 42-65229 1551
Vmax, MEO_2B6 1115
a 39 4-30988 8068
Vmax, MEO_2E1 538
a 61 67-4797 72
Vmax, 1EU_1A2 268
a 67 21-2198 105
Vmax, 1′HMEG_1A9 171
a 49 22-885 41
Vmax, 1′HMEG_2B7 479
a 64 45-4091 90
Vmax, 1′OME 73727
a 27 25140-180466 7
Km, 1′OME 1567
b 46 247-6618 27
Vmax, 1′HMES 299
a 38 47-894 17
Km, 1′HMES 109
b 36 24-398 19
aVmax expressed at µmol/hr
bKm expressed as µmol/L
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Figure 7. Predicted frequency distribution of the formation of 1′-sulfooxymethyleugenol human livers. P50, P95, and
P99 represent the 50th, 95th, and 99th percentiles of the distribution.
The present study revealed that the first step in bioactivation of methyleugenol to the
carcinogenic metabolite 1′-hydroxymethyleugenol is predominantly catalysed by cytochrome
P450 1A2, contributing to 85% of the catalytic efficiency of this reaction when taking the
activity level of P450 1A2 in pooled human liver microsomes into account. This is in line with
what was previous observed by Jeurissen et al. (2006) who revealed that P450 1A2 contributes
to 94% of the total catalytic efficiency based on incubations with Gentest microsomes
expressing the individual cytochrome P450 enzymes to roughly average liver levels. The
involvement of P450 1A2 indicates that life-style factors such as smoking can increase the
susceptibility to the adverse effects of methyleugenol (Jeurissen et al., 2006). The isoenzymes
involved in detoxification via epoxidation of methyleugenol or O-demethylation to eugenol
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have not been identified before and were shown in the present study to be P450 2B6 and P450
1A2 respectively. The activity level of P450 2B6 can be affected by genetic polymorphisms
with the Japanese population having lower activity levels of this enzyme than Caucasians which
may affect the susceptibility to the adverse effects of methyleugenol in these populations
(Shimada et al., 1994).
Isoenzymes involved in other metabolic reactions of methyleugenol, were not identified
since the previously developed physiologically based kinetic (PBK) model for methyleugenol in
human and a sensitivity analysis of this model, revealed that formation of 1′ -sulfooxyestragole
is not affected by these metabolic parameters. This indicates that interindividual human
variation in these reactions will not significantly affect bioactivation of methyleugenol.
In case of the metabolic reactions of 1′-hydroxymethyleugenol, the present study revealed
that glucuronidation of 1′-hydroxymethyleugenol was catalysed by both UGT 1A9 and 2B7.
This is in line with what has been previously observed for glucuronidation of the 1′-hydroxy-
metabolite of the related alkenylbenzene estragole (Iyer et al., 2008). The in vivo catalytic
efficiency for glucuronidation that was predicted based on the kinetic constants for
glucuronidation by these enzymes, was observed to be 42-fold lower than the predicted in vivo
catalytic activity for oxidation of 1′-hydroxymethyleugenol. This indicates that glucuronidation
is only a minor detoxification route in humans and that formation of the ultimate carcinogenic
metabolite 1′-sulfooxymethyleugenol will not be affected by lifestyle factors and polymorphism
in UGT1A9 and 2B7. In case of oxidation and sulfonation of 1′-hydroxymethyleugenol, the
kinetic constants for these reactions by specific isoenzymes could not be determined in the
present study due to limited availability of the recombinant enzymes that are likely to be
involved in these reactions. Therefore, the variation in sulfonation and oxidation of 1′-
hydroxymethyleugenol as observed with individual human liver S9 fractions was assumed to
represent the level of variation in the population as a whole.
Based on the state-of-the-art knowledge on the probable enzymes involved in sulfonation
and oxidation of 1′-hydroxymethyleugenol an indication can be obtained whether the observed
levels of variation in these reactions are indeed relevant for the population as a whole. Recently,
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Herrmann et al. (2012) revealed that SULT1A1 and SULT1E1 are the main liver
sulfotransferease enzymes involved in sulfonation of 1′-hydromethyleugenol by measuring
mutagenicity of 1′-hydroxymethyleugenol in Salmonella typhimurium strains expressing human
sulfotransferease enzymes. The reported coefficient of variation for SULT1A1 and SULT1E1,
as determined with enzyme-selective probe substrates in human liver tissue fractions, amounts
to 34% and 47% respectively (Riches et al., 2009). The level of variation in sulfonation of 1′-
hydroxymethyleugenol observed in the present study indicates a CV of 37.6 % for the apparent
maximum sulfonation rate of 1′-hydroxymethyleugenol and a CV of 35% for the apparent Km,
values that are comparable with the levels of variation in SULT1A1 and SULT1E1 reported in
the literature (Riches et al., 2009). The isoenzymes involved in oxidation of 1′-
hydroxymethyleugenol have not been identified so far. We previously suggested that oxidation
of the related alkenylbenzene estragole may be catalyzed by 17β-hydroxysteroid dehydrogenase
type 2 (17β-HSD2) based on the subcellular localization of the reaction, which occurred mainly
in incubations with microsomes, and the enzyme specificity, with NAD+ being the preferred
cofactor. Current knowledge about 17 β -HSD2 does not give a complete insight in the level of
variation in enzyme activity that could occur in the human population. Recently, Audet-Walsh
et al. (2012) reported that genetic polymorphisms occur in the gene encoding 17β-HSD2, which
could lead to reduced 17β-HSD2 expression or function. The impact of such polymorphisms in
17β-HSD2 for its activity remains to be elucidated. The coefficients of variation in the Vmax for
oxidation of 1′-hydroxymethyleugenol, amounting to 27.1 %, and in the Km, amounting to 46
%, as observed in the present study are considered to represent an average level of variation
(Covington et al., 2007).
With the results obtained with the Monte Carlo simulation on the variability in formation of
1′-sulfooxymethyleugenol, a so-called chemical-specific adjustment factor (CSAF) could be
derived, which can be used to evaluate the appropriateness of the default factor of 3.16
generally assumed to reflect interindividual variation in kinetics within the human population
(Gentry et al., 2002; IPCS, 2005). Using the 95th percentile to represent a sensitive individual
and the 50th percentile to represent the average individual, the CSAF amounts to 3.7. This
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predicted CSAF is comparable to the default factor of 3.16 for kinetic variability and suggests
that the default uncertainty factor adequately protects 95% of the population. Using the 99th
percentile to represent a sensitive individual the CSAF amounts to 5.8 indicating that protecting
99% of the population would require a higher uncertainty factor than the default value of 3.16.
Obviously, definite conclusions on the value of the CSAF have to await further data on the
actual variation in the 17b-HSD2 and sulfotransferase activity to be expected within the human
population.
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General discussion
The alkenylbenzene methyleugenol is a natural constituent of the essential oils of various
herbs such as tarragon, basil, nutmeg, lemon grass, pay leaf, and allspices (Environmental
Canada, 2010; Smith et al., 2002). Methyleugenol is also found in edible fruits such as for
instance grapefruit, bananas as well as in some forest fruits at a level of less than 0.1 mg/kg
(TNO, 2010). Moreover, methyleugenol was recognized as a volatile flavor compound in the
juice of Kogyoku apples (Yagima et al., 1984). Dietary human exposure to methyleugenol may
occur through: (i) the consumption of fruits and vegetables containing methyleugenol or food
products derived from them, (ii) the consumption of foods and beverages flavored with these
aromatic herbs or their essential oil fractions which are added to food intentionally as flavors,
(iii) the consumption of foods and beverages which are flavored with pure methyleugenol
(Burdock, 2005; Smith et al., 2010; Smith et al., 2002), and/or iv) the use of methyleugenol
containing plant food supplements (van den Berg et al., 2011). It has been reported for example
that some brands of cookies available in the USA can contain approximately 3.3 mg/kg
methyleugenol which was added as flavor (Schecter et al., 2004), and some plant based food
supplements may contain up to 1 mg methyleugenol/g supplement (van den Berg et al., 2011).
The interest in the risk assessment of methyleugenol as a food constituent came from its
widespread use in a variety of foods and beverages as well as from its structural resemblance to
the known carcinogen safrole (Johnson et al., 2000). In addition, methyleugenol has been
reported to be carcinogenic and genotoxic, inducing malignant tumors in multiple tissues of rats
and mice as well as inducing unscheduled DNA synthesis in rat liver (Ding et al., 2011; NTP,
2000; Smith et al., 2002).
In 1965, the Expert Panel of the Flavor and Extract Manufacturers Association (FEMA)
considered that methyleugenol was GRAS (Generally Recognized As Safe) when used
intentionally at low levels as a flavoring substance in food (Hall and Oser, 1965). This
consideration of using methyleugenol as a food flavor was confirmed by the US Food and Drug
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Administration (FDA, 2004) and consequently methyleugenol is allowable for direct addition
for human consumption as a synthetic flavoring substance in the USA (FDA, 2010). The FEMA
assessment took into account: i) the various experimental data that suggest a non-linear
relationship between dose and profiles of metabolism and metabolic activation and ii) the fact
that the exposure due to use as a flavoring is relatively low (Smith et al., 2002). In another
evaluation of methyleugenol and specifically in 2000, the National Toxicology Program (NTP)
reported that methyleugenol is carcinogenic in both rats and mice (NTP, 2000). In 2001, the
FEMA Expert Panel reassessed the available data for methyleugenol and confirmed that there is
no considerable cancer risk resulting from consumption of methyleugenol as flavoring
substance and affirmed the GRAS status of methyleugenol at the low levels of use as a
flavoring substance (Smith et al., 2002). In 2001, the Scientific Committee on Food (SCF) of
the European Union published a scientific opinion on methyleugenol in which it was concluded
that methyleugenol is genotoxic and carcinogenic and that reductions in exposure and
restrictions in use levels are indicated (SCF, 2001). A more recent evaluation performed by the
Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 2008, has indicated that
although evidence of carcinogenicity to rodents given high doses of methyleugenol exists,
further research is needed to assess the potential risk to human health at relevant dietary
exposure to methyleugenol present in foods and essential oils and used as flavoring agent
(JECFA, 2008). In the EC Regulation 1334/2008 of the EU, which became effective in January
2011, addition of methyleugenol to foods was prohibited and restrictions were made on the
concentration of methyleugenol in foods that have been prepared with flavorings or food
ingredients with flavoring properties (European Commission, 2008).
The occurrence of these different risk assessments to some extent reflects the absence of
scientific agreement on the unequivocal translation of carcinogenicity data from rodent animal
experiments obtained at high levels of exposure to the risks for humans at relevant low levels of
dietary intake. Predicting the cancer risk in humans at relevant dietary intake levels requires
extrapolation of the animal carcinogenicity data taking in consideration species, dose and
interindividual variation. The present PhD project aimed at obtaining quantitative insight into
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the consequences of dose- and species- dependent effects (chapter 2 and chapter 3), matrix
effects (chapter 4) and interindividual differences (chapter 5) for the bioactivation and
detoxification of methyleugenol by using physiologically based kinetic (PBK) modeling. In
chapter 2 a physiologically based kinetic (PBK) model for methyleugenol was developed in rat
based on in vitro metabolic parameters determined using relevant tissue fractions, in silico
derived partition coefficients, and physiological parameters derived from the literature. The
model was based on the model previously developed for the related alkenylbenzene estragole
and consists of eight compartments including liver, lung, and kidney as metabolizing
compartments, and separate compartments for fat, arterial blood, venous blood, richly perfused
and slowly perfused tissues. Evaluation of the model was performed by comparing the PBK
predicted concentration of methyleugenol in the venous compartment to methyleugenol plasma
levels reported in the literature, by comparing the PBK predicted dose-dependent percentage of
the dose converted to 2-hydroxy-4,5-dimethoxyallylbenzene, 3-hydroxy-4-methoxyallylbenzene,
and 1′-hydroxymethyleugenol glucuronide to the corresponding percentage of these metabolites
excreted in urine reported in the literature, which were demonstrated to be in the same order of
magnitude. With the model obtained the relative extent of bioactivation and detoxification of
methyleugenol at different oral doses was examined. At low doses, formation of 3-(3,4-
dimethoxyphenyl)-2-propen-1-ol and methyleugenol-2′,3′-oxide leading to detoxification
appeared to be the major metabolic pathways, occurring in the liver. At high doses, the model
revealed a relative increase in the formation of the proximate carcinogenic metabolite 1′-
hydroxymethyleugenol, occurring in the liver. This relative increase in formation of 1′-
hydroxymethyleugenol leads to a relative increase in formation of 1′-hydroxymethyleugenol
glucuronide, 1′-oxomethyleugenol, and 1′-sulfooxymethyleugenol with increasing dose levels,
the latter metabolite being the ultimate carcinogenic metabolite of methyleugenol. These results
indicate that the relative importance of different metabolic pathways of methyleugenol may
vary in a dose-dependent way, leading to a relative increase in bioactiviation of methyleugenol
at higher doses. Close analysis of these data reveal that the percentage of the dose converted to
the ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol increases from 0.05% of the
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dose at 0.217 mg/(kg bw)/day, a dose level relevant for human dietary intake, to 0.07% of the
dose at a dose level of 15.3 mg/kg bw/day, the BMDL10 for tumor formation (van den Berg et
al., 2011). This reflects a change of only 1.4-fold over the dose range of interest, which is a
change that would be expected to only marginally influence the cancer risk estimate.
Furthermore this increase is so limited that a plot of the absolute amount of 1′-
sulfooxymethyleugenol formed against the dose is apparently linear over the dose range as high
as the BMD10 down to dose levels relevant for human intake (Figure 1). Thus the results of the
PBK modeling reflect that there are no relevant kinetic arguments, such as saturation of
metabolic pathways, that argue against linear extrapolation of the tumor data from high doses
used in animal experiments to low doses relevant for human dietary intake. In addition the
kinetic data also do not reveal a threshold for bioactivation. Obviously it remains to be
established whether dynamic processes following metabolic activation, would be non-linear or
leading to an apparent threshold for the ultimate tumor formation.
Figure 1. PBK model predicted dose-dependent formation of 1'-sulfooxymethyleugenol in the liver of rat (solid line)
and human (dotted line). The VSD represents the so-called virtual safe dose at which the additional cancer risk upon
life time exposure would be one in a million and is considered negligible. The BMD10 (benchmark dose 10%)
represents the dose resulting in 10% tumor incidence above background levels.
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Another argument often used against the linear extrapolation and calculation of a virtual
safe dose (VSD) based on animal tumor data is that species effects are not taken into account
since tumor data are extrapolated directly from the animal bioassay to the human situation
(EFSA, 2005). The results obtained in the present thesis also provided insight into the species
dependent effects on bioactivation of methyleugenol. In order to obtain this insight into the
species-dependent differences in kinetics of methyleugenol a PBK model for methyleugenol in
human, based on in vitro and in silico derived parameters, was developed in chapter 3. With the
model obtained bioactivation and detoxification of methyleugenol at different dose levels could
be investigated in human and compared to the results obtained with the PBK model for
methyleugenol in male rat. This comparison reveals that formation of 1′-hydroxymethyleugenol
glucuronide, a major metabolic pathway in male rat liver, appears to represent a minor
metabolic pathway in human liver whereas in human liver a significantly higher formation of
1′-oxomethyleugenol compared with male rat liver is observed. In spite of this species
dependent difference in the detoxification pathways for 1′-hydroxymethyleugenol, formation of
1′-sulfooxymethyleugenol was predicted to be similar in the liver of both human and male rat at
oral doses as low as 0.0034 up to dose levels of 300 mg/kg bw (Figure 1). Thus, despite a
significant difference in especially the metabolic pathways of the proximate carcinogenic
metabolite 1′-hydroxymethyleugenol between human and male rat, the influence of species
differences on the ultimate overall bioactivation of methyleugenol to 1′-sulfooxymethyleugenol
appeared to be limited (i.e. less than 1.06 fold). Moreover, the PBK model predicted the
formation of 1′-sulfooxymethyleugenol in the liver of human and rat to be linear from doses as
high as the benchmark dose (BMD10) down to as low as the virtual safe dose (VSD) (Figure 1).
This corroborates that kinetic data do not provide a reason to argue against linear extrapolation
from the rat tumor data to the human situation.
A third aspect that should be taken into account when extrapolating data from a rodent
bioassay to the human situation is the fact that for adequate risk estimation of food-borne
carcinogens, matrix and combination effects may have to be taken into account. Whereas
animal carcinogenicity experiments are conducted with a pure compound, human dietary
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exposure to methyleugenol will occur in a complex food matrix containing other ingredients. In
a complex food matrix, interactions can occur that can affect the bioavailability of food
components (Schilter et al., 2003). For example, a slow or incomplete release of methyleugenol
from the matrix could result in a lower bioavailability than when dosed as a pure compound by
oral gavage. The results described in chapter 3 pointed at such a possible matrix effect for the
bioavailability of methyleugenol as reported from gingersnaps served as a breakfast together
with orange juice provided as a beverage (Schecter et al., 2004). PBK modeling revealed the
predicted values would match that the experimental values when the bioavailability of
methyleugenol from the gingersnaps and orange juice food matrix would be 13.8%. The
occurrence of such a difference in the bioavailability of a compound when ingested within a
food matrix or as a pure compound has been reported for other compounds as well. Manach et
al. (2004) for example reported that the level of ferulic acid metabolites recovered in the urine
of rats amounts to only 3% of the ingested dose when ferulic acid is provided as wheat bran,
whereas recovery of the metabolites is 50% of the dose when ferulic acid is dosed as a pure
compound. Also the bioavailability of ß-carotene has been observed to be one order of
magnitude higher when provided as a pure compound added to foods than when present in
foods (van het Hofs et al., 2000).
In addition to the effect of the food matrix on the bioavailability, interactions with other
herbal ingredients might occur at the level of metabolic activation and/or detoxification. It was
for instance observed by Jeurissen et al. (2008) that a methanolic basil extract was able to
efficiently inhibit the sulfotransferase-mediated DNA adduct formation in HepG2 human
hepatoma cells exposed to 1′-hydroxyestragole.  In later work the basil ingredient responsible
for this effect on estragole bioactivation was identified as the flavonoid nevadensin (Alhusainy
et al., 2010).
To investigate whether also for methyleugenol such a matrix effect can be expected the
influence of nevadensin on the bioactivation of methyleugenol was investigated in chapter 4 of
this thesis. In this study, the effects of nevadensin on the sulfonation and the subsequent DNA
adduct formation of the proximate carcinogen 1′-hydroxymethyleugenol were studied using the
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human hepatoma cell line HepG2. Nevadensin was shown to be able to inhibit DNA adduct
formation in HepG2 cells exposed to the proximate carcinogen 1′-hydroxymethyleugenol in the
presence of this flavonoid. This inhibition was shown to occur at the level of sulfotransferase
(SULT)-mediated bioactivation of 1′-hydroxymethyleugenol. In order to investigate possible in
vivo implications the SULT inhibition by nevadensin was integrated into the male rat and
human PBK models for bioactivation and detoxification of methyleugenol. The results thus
obtained revealed that co-administration of methyleugenol with nevadensin may reduce the
levels of bioactivation of 1′-hydroxymethyleugenol to the DNA reactive metabolite, without
reducing its detoxification via glucuronidation or oxidation. This effect may be significant even
at realistic low dose human exposure levels. The results obtained point at a potential reduction
of the cancer risk when methyleugenol exposure occurs by oral intake within a relevant food
matrix containing SULT inhibitors compared to what is observed in rodent bioassays upon
exposure to pure methyleugenol dosed by gavage. Important to note is that the regular human
diet is rich in other SULT inhibitors ranging from a number of natural dietary chemicals, such
as polyphenols (Eaton et al., 1996; Morimitsu et al., 2004) to a number of food additives such
as (±)-catechin, (+)-catechin, 4-chlorobenzoic acid, aspartame, benzoic acid, erythrosine, gallic
acid, octyl gallate, p-hydroxybenzoic acid, propyl gallate, protocatechuic acid, saccharin, tannic
acid, tartrazine and vanillin which have all been shown capable of inhibiting the sulfonation of
a number of xenobiotics and endobiotics in human liver cytosol to varying extents (Bamforth et
al., 1993). These other SULT inhibitors may add to the effect since the combined effect of
several flavonoid SULT inhibitors on SULT mediated reactions has recently been shown to be
additive (Alhusainy et al., 2012).
It is also important to note that the efficiency of nevadensin in inhibiting the sulfonation of
1′-hydroxymethyleugenol and thus its potential protective effect against bioactivation of
methyleugenol to the proximate DNA reactive metabolite still needs to be established in in vivo
experiments where factors such as its bioavailability and metabolic stability will play a crucial
role. Of interest in this respect is that methylated flavones such as nevadensin have been
demonstrated to be much more metabolically stable than their non-methylated analogues which
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is reflected by their resistance to hepatic metabolism and stability in the intestinal epithelial cell
layer (Walle, 2007; Wen and Walle, 2006). Furthermore, they also have higher intestinal
absorption through Caco-2 cell monolayers (Walle, 2007; Wen and Walle, 2006). Both factors
should increase their oral bioavailability as compared to the bioavailability of non-methylated
flavones. Furthermore, recent studies in which estragole was dosed to rats in either the absence
or presence of nevadensin revealed significant reduction in the amount of estragole derived
DNA adducts formed in the liver upon co-administration of estragole with the flavonoid SULT
inhibitor nevadensin (Alhusainy et al., unpublished results), suggesting that the effects observed
in the present thesis for methyleugenol may in future also appear relevant for the in vivo
situation. In these studies nevadensin was able to significantly reduce the formation of estragole
DNA adduct (E-3'-N2-dGuo) in the liver of Sprague Dawley rats exposed to the alkenylbenzene
estragole and nevadensin simultaneously by 40%. Whether such about two-fold reduction in
DNA adduct formation would have a significant impact on the ultimate risk assessment remains
to be seen, especially given the other uncertainties in the low dose extrapolation of cancer risks
from animal data to the human situation.
A final factor of uncertainty in the risk assessment of methyleugenol that was studied in
more detail in the present thesis was the identification of the interindividual differences in its
bioactivation and detoxification. In chapter 5 of this thesis these interindividual differences
were studied in more detail by predicting the level of formation of the ultimate carcinogenic
metabolite 1′-sulfooxymethyleugenol in the human population taking the variability in key
bioactivation and detoxification reactions into account using Monte Carlo simulations. Insight
in the interindividual variation in relevant metabolic routes was obtained by determining kinetic
constants for the metabolic reactions by specific isoenzymes or by measuring the kinetic
constants in incubations with a range of individual human liver fractions. The results of the
study indicated that formation of 1′-sulfooxymethyleugenol is predominantly affected by i)
P450 1A2 catalyzed bioactivation of methyleugenol to 1′-hydroxymethyleugenol, ii) P450 2B6
catalyzed epoxidation of methyleugenol, iii) the apparent kinetic constants for detoxification of
1′-hydroxymethyleugenol via oxidation and iv) the apparent kinetic constants for bioactivation
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of 1′-hydroxymethyleugenol to 1′-sulfooxymethyleugenol. Based on the interindividual variation
in these key biotransformation steps and Monte Carlo simulations a distribution of the
interindividual variation in the level of formation of 1′-sulfooxymethyleugenol in the human
liver could be obtained. From this distribution a chemical-specific adjustment factor (CSAF)
could be derived which is defined as the 95th or 99th percentile divided by the 50th percentile
of the predicted distribution of the formation of 1′-sulfooxymethyleugenol in the liver (IPCS,
2005).  The obtained CSAF value at the 95th percentile of 3.7 indicates that the default
uncertainty factor of 3.16 for human variability in kinetics may adequately protect 95% of the
population. Protecting 99% of the population requires a larger uncertainty factor of 5.8. This
uncertainty factor is part of the margin of 10,000 suggested by EFSA to be a value for the
Margin of Exposure (MOE) for a compound that is both genotoxic and carcinogenic to be of
low priority for risk management (EFSA, 2005). The CSAF value obtained for methyleugenol
in the present thesis obviously does not present an argument to modify this value of 10,000 in
the case of methyleugenol.
Furthermore, it is of importance to note that in the present thesis especially dose-, species-
matrix- and interindividual-dependent effects on the kinetics of methyleugenol were
characterized and quantified.  The carcinogenic effects of methyleugenol will ultimately also
depend on toxicodynamic processes including processes such as the formation of DNA adducts,
DNA repair, induction of mutations and the ultimate formation and development of the tumors.
Although kinetics were shown not to provide an argument against linear extrapolation from
high doses to low doses, non-linear dose-dependent effects may still occur at one of these other
steps in the pathway leading to tumor formation. Non-linear dose response behavior could for
example occur when DNA repair becomes saturated at relatively high doses, resulting in a
relative increase in DNA adduct formation with increasing dose. Saturation of DNA repair at
increasing dose levels may be a reason why dose dependent increases in cancer incidences
should be described by non-linear rather than linear models. This could be investigated in
further detail by extending the PBK models of the present thesis into so-called physiologically
based dynamic (PBD) models in which dose levels and 1'-sulfooxymethyleugenol formation
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should be coupled to DNA adduct formation, and, ultimately, cancer incidence. With these PBD
models the level of DNA adduct formation can be predicted at different oral doses, including
doses relevant for dietary human intake. This approach allows taking into account possible
effects of DNA repair in the extrapolation from high to low dose methyleugenol for rat and
human. Since DNA adduct formation is presently considered a marker of exposure rather than a
biomarker for tumor incidence (Phillips, 2005; Sander et al., 2005), a full PBD model should
ultimately also find a way to link the predicted DNA adduct formation to tumor incidences.
Moreover, the PBK models developed in the current thesis can be used to facilitate the
prediction of carcinogenic potency of other structurally related alkenylbenzenes, for which the
toxicological database is far more limited or unavailable (van den Berg et al., 2012). Read-
across from data on methyleugenol, for which in vivo data are available, might be an efficient
approach for risk assessment of related alkenylbenzenes. Building a PBK model for the related
alkenylbenzene to predict and thus compare its bioactivation to that of methyleugenol may
provide insight in the relative potency of this related alkenylbenzene. As a first approximation
the BMDL10 for methyleugenol may then be corrected by this factor to estimate the BMDL10
for the related alkenylbenzene for which tumor data are unavailable.  On the basis of such
considerations, the specific BMDL10 value of methyleugenol (15.3-34.0 mg/(kg bw)/day) was
used to estimate a possible BMDL10 value for elemicin, using the outcomes of their PBK
models to estimate their differences in bioactivation to the corresponding 1′-sulfooxymetabolite.
PBK modeling revealed that the formation of the 1′-sulfoxymetabolite of elemicin would be 2-
fold lower, and thus the BMDL10 of elemicin was estimated by multiplying the BMDL10 values
of methyleugenol by that factor. Using the estimated BMDL10 value thus obtained, MOE values
for elemicin could be calculated based on the estimated daily intake (van den Berg et al., 2012).
The results obtained indicated that the daily exposure to elemicin resulting from the use of
spices, food, and essential oils would be of lower priority for risk management than the
exposure to the related alkenylbenzene methyleugenol resulting from these sources (van den
Berg et al., 2012). Given that the PBK models developed and used for this approach are based
especially on parameters obtained in in vitro studies, and that such a read-across would help to
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set priorities for in vivo carcinogenicity testing, this PBK model-based read-across may
contribute to the 3Rs (replacement, reduction, refinement) of animals studies.
In summary, it has been shown that integrating in vitro metabolic, physiological, and
biochemical parameters in PBK models forms a good tool to give insight into the possible dose-
dependent effects, species difference effects, matrix effects, and human variation effects on the
bioactivation of methyleugenol. The results obtained were also able to reveal the mechanisms
underlying the dose dependent effects and to show the species difference in bioactivation and
detoxification of methyleugenol. Furthermore, the outcomes of the current studies showed that
food matrix and combination effects may play a role in the ultimate bioactivation of
methyleugenol by reducing formation of the ultimate carcinogenic metabolite 1′-
sulfooxymethyleugenol. Moreover, PBK modeling gave more insights in the possible
occurrence of human variation concerning the bioactivation of methyleugenol to its ultimate
carcinogenic metabolite 1′-sulfooxymethyleugenol. Also the results obtained strengthen the
method of extrapolation of animal carcinogenicity data obtained at high doses to predict the
possible carcinogenic outcomes at low doses which are relevant to the human situation.
Additionally, the PBK models can facilitate a read-across in risk assessment from compounds
for which in vivo toxicity studies are available to a compound for which only limited toxicity
data have been described, thus contributing to development of alternatives for animal testing.
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Summary of the results
Methyleugenol, which occurs naturally in various herbs such as tarragon, basil, nutmeg and
allspice, is added to food either directly as a flavoring substance or as a constituent of added
essential oils (Smith et al., 2002). The interest in the risk of methyleugenol as a food constituent
came from its widespread use in a variety of foods and beverages as well as its structural
resemblance to the known carcinogen safrole (Johnson et al., 2000). In addition, methyleugenol
has been reported to be DNA reactive and carcinogenic, inducing malignant tumors in multiple
tissues of rats and mice as well as inducing unscheduled DNA synthesis in rat liver (Ding et al.,
2011; NTP, 2000; Smith et al., 2002). The safety of human exposure to methyleugenol at low
dietary intake levels has been assessed several times (Hall and Oser, 1965; NTP, 2000; SCF,
2001; Smith et al., 2002) without reaching a scientific agreement on how to translate  the
carcinogenicity data of rodent animal experiments obtained at high levels of exposure to the
relevant human situation. A recent evaluation, performed by the Joint FAO/WHO Expert
Committee on Food Additives (JECFA) in 2008, has indicated that although evidence of
carcinogenicity to rodents given high doses of methyleugenol exists, further research is needed
to assess the potential risk to human health at relevant dietary exposure resulting from the
presence of methyleugenol in foods and essential oils and its use as flavoring agent (JECFA,
2008).
Predicting the cancer risk in humans at relevant dietary intake levels requires extrapolation
of the animal carcinogenicity data taking in consideration dose, species, and interindividual
variation. Furthermore, it implies extrapolation from rat or mouse studies with high dose levels
of the pure compound to the human situation in which exposure at low dose levels occurs
within the context of a complex food matrix. The aim of the present PhD project was to obtain
quantitative insight into the consequences of dose- and species-dependent effects and of
interindividual differences and matrix effects for the bioactivation and detoxification of
methyleugenol by using physiologically based kinetic (PBK) modeling.
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The first chapter of this thesis presents background information to the topic. In chapter 2, a
physiologically based kinetic (PBK) model for the alkenylbenzene methyleugenol in rat was
defined based on in vitro metabolic parameters determined using relevant tissue fractions, in
silico derived partition coefficients (Payne and Kenny, 2002 and reference therin), and
physiological parameters (Brown et al., 1997) derived from the literature. The model was based
on the model previously developed for the related alkenylbenzene estragole and consists of
eight compartments including liver, lung, and kidney as metabolizing compartments, and
separate compartments for fat, arterial blood, venous blood, richly perfused and slowly perfused
tissues (Punt et al., 2008). Evaluation of the model was performed by comparing the PBK
predicted concentration of methyleugenol in the venous compartment to methyleugenol plasma
levels reported in the literature, by comparing the PBK predicted dose-dependent % of
formation of 2-hydroxy-4,5-dimethoxyallylbenzene, 3-hydroxy-4-methoxyallylbenzene, and 1′-
hydroxymethyleugenol glucuronide to the corresponding % of metabolites excreted in urine
reported in the literature, which were demonstrated to be in the same order of magnitude
(Solheim and Scheline, 1976). With the model obtained the relative extent of bioactivation and
detoxification of methyleugenol at different oral doses was examined. At low doses, formation
of3-(3,4-dimethoxyphenyl)-2-propen-1-olandmethyleugenol-2′,3′-oxideleadingto detoxification
appear to be the major metabolic pathways, occurring in the liver. At high doses, the model
reveals a relative increase in the formation of the proximate carcinogenic metabolite 1′-
hydroxymethyleugenol, occurring in the liver. This relative increase in formation of 1′-
hydroxymethyleugenol leads to a relative increase in formation of 1′-hydroxymethyleugenol
glucuronide, 1′-oxomethyleugenol, and 1′-sulfooxymethyleugenol the latter being the ultimate
carcinogenic metabolite of methyleugenol. These results indicate that the relative importance of
different metabolic pathways of methyleugenol may vary in a dose-dependent way, leading to a
relative increase in bioactiviation of methyleugenol at higher doses.
In subsequent studies described in chapter 3 a physiologically based kinetic (PBK) model
for methyleugenol in human based on in vitro and in silico derived parameters was identified
based on the model previously developed for the related alkenylbenzene estragole. The model
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consists of six compartments including liver as metabolizing compartment, and separate
compartments for fat, arterial blood, venous blood, richly perfused and slowly perfused tissues
(Punt et al., 2009). With the model obtained, bioactivation and detoxification of methyleugenol
at different dose levels could be investigated. The outcomes of this human model were
compared with those of the PBK model for methyleugenol in male rat. The results obtained
reveal that formation of 1′-hydroxymethyleugenol glucuronide, a major metabolic pathway in
male rat liver, appears to represent a minor metabolic pathway in human liver whereas in
human liver a significantly higher formation of 1′-oxomethyleugenol compared with male rat
liver is observed. Furthermore, formation of 1′-sulfooxymethyleugenol, which readily
undergoes desulfonation to a reactive carbo-cation that can form DNA or protein adducts, is
predicted to be the same in the liver of both human and male rat at oral doses of 0.0034 up to
300 mg/(kg bw).  Altogether it was concluded that despite a significant difference in especially
the metabolic pathways of the proximate carcinogenic metabolite 1′-hydroxymethyleugenol
between human and male rat, the influence of species differences on the ultimate overall
bioactivation of methyleugenol to 1′-sulfooxymethyleugenol appears to be negligible.
Moreover, the PBK model predicted the formation of 1′-sulfooxymethyleugenol in the liver of
human and rat to be linear from doses as high as the benchmark dose (BMD10) down to as low
as the virtual safe dose (VSD). This shows that kinetic data do not provide a reason to argue
against linear extrapolation from the rat tumor data to the human situation.
Another aim of the present PhD study was to study the effect of the basil constituent
nevadensin on the bioactivation and genotoxicity of herb based methyleugenol. The results
presented in chapter 4 show that nevadensin is able to inhibit DNA adduct formation in HepG2
cells exposed to the proximate carcinogen 1′-hydroxymethyleugenol in the presence of this
flavonoid. This inhibition occurs at the level of sulfotransferase (SULT)-mediated bioactivation
of 1′-hydroxymethyleugenol. In order to investigate possible in vivo implications the SULT
inhibition by nevadensin was integrated into the male rat and human PBK models for
bioactivation and detoxification of methyleugenol. The results thus obtained reveal that co-
administration of methyleugenol with nevadensin may reduce the levels of bioactivation of 1′-
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hydroxymethyleugenol to the DNA reactive metabolite, without reducing its detoxification via
glucuronidation or oxidation. This effect may be significant even at realistic low dose human
exposure levels. The results obtained point at a potential reduction of the cancer risk when
methyleugenol exposure occurs by oral intake within a relevant food matrix containing SULT
inhibitors compared to what is observed in rodent bioassays upon exposure to pure
methyleugenol dosed by gavage.
Besides dose-dependent effects, species differences effects, and matrix effects on the
bioactivation of methyleugenol the effect of interindividual variation on methyleugenol
detoxification and bioactivation was investigated in chapter 5. To this end we predicted the
level of formation of the ultimate carcinogenic metabolite 1′-sulfooxymethyleugenol in the
human population by taking the variability in key bioactivation and detoxification reactions into
account using Monte Carlo simulations. Insight in the variation in relevant metabolic routes was
obtained by determining kinetic constants for the metabolic reactions by specific isoenzymes or
by measuring the kinetic constants in incubations with a range of individual human liver
fractions. The results of the study indicate that formation of 1′-sulfooxymethyleugenol is
predominantly affected by i) P450 1A2 catalyzed bioactivation of methyleugenol to 1′-
hydroxymethyleugenol ii) P450 2B6 catalyzed epoxidation of methyleugenol and iii) the
apparent kinetic constants for detoxification of 1′-hydroxymethyleugenol via oxidation and iv)
the apparent kinetic constants for bioactivation of 1′-hydroxymethyleugenol to 1′-
sulfooxymethyleugenol. Based on the Monte Carlo simulation a chemical-specific adjustment
factor (CSAF) for intraspecies variation could be derived which is defined as the 95th or 99th
percentile divided by the 50th percentile of the predicted distribution of the formation of 1′-
sulfooxymethyleugenol in the liver.  The obtained CSAF value at the 95th percentile was 3.7
indicating that the default uncertainty factor of 3.16 for human variability in kinetics (WHO,
1999) may adequately protect 95% of the population. While protecting 99% of the population
requires a larger uncertainty factor of 5.8.
Altogether, the results shown in this thesis reveal that integrating in vitro metabolic
parameters within a framework of a PBK model provides a good method to evaluate the
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occurrence of dose-dependent effects, species differences, and human variability in
detoxification and bioactivation of a genotoxic carcinogen. Moreover, the results presented in
this thesis show the possible protective effect of the basil constituent nevadensin on SULT
catalysed bioactivation and DNA adduct formation of methyleugenol in vitro. Upon validation
of these effects in vivo, it may turn out that rodent carcinogenicity data on methyleugenol
substantially overestimate the risks posed when humans are exposed to methyleugenol within a
nevadensin containing food matrix.
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Methyleugenol, dat van nature voorkomt in verschillende kruiden zoals dragon, basilicum,
nootmuskaat en piment, wordt aan voedsel toegevoegd, hetzij als een smaakstof of als
bestanddeel van toegevoegde essentiële oliën (Smith et al., 2002). De belangstelling voor het
risico van methyleugenol als levensmiddelbestanddeel ontstond door het wijdverbreide gebruik
in een verscheidenheid van voedingsmiddelen en dranken en door de structurele gelijkenis
ervan met het bekende carcinogeen safrole (Johnson et al., 2000). Bovendien is van
methyleugenol bekend dat het DNA-reactief en carcinogeen is en zowel kwaadaardige tumoren
in verschillende weefsels van ratten en muizen veroorzaakt als DNA-adducten in rattenlever
(Ding et al.. , 2011; NTP, 2000; Smith et al., 2002). De veiligheid van menselijke blootstelling
aan methyleugenol bij lage innameniveaus is meerdere malen onderzocht (Hall en Oser, 1965;
NTP, 2000; SCF, 2001; Smith et al., 2002) zonder dat er een wetenschappelijke consensus
bereikt is over de wijze waarop de carcinogeniteitsdata van dierproeven die verkregen zijn bij
hoge blootstelling, vertaald kunnen worden naar de menselijke situatie. Een recente evaluatie,
uitgevoerd door de “Joint FAO / WHO Expert Committee on Food Additives” (JECFA) in
2008, heeft geconcludeerd dat, hoewel het bewijs bestaat van carcinogeniteit bij knaagdieren
die hoge doseringen van methyleugenol toegediend kregen, verder onderzoek nodig is om het
potentiële risico te beoordelen voor de gezondheid van de mens bij relevante blootstelling via
de voeding als gevolg van de aanwezigheid van methyleugenol in voedingsmiddelen en
essentiële oliën en het gebruik ervan als smaakstof (JECFA, 2008). Het voorspellen van het
risico op kanker bij de mens bij de relevante innameniveaus vereist extrapolatie van de
diercarcinogeniteitgegevens, daarbij rekening houdend met dosis-, soort-, en interindividuele
variatie. Bovendien houdt dit extrapolatie in van rat- of muisstudies met hoge doseringen van de
zuivere stof naar de menselijke situatie waarin blootstelling aan lage doses plaatsvindt binnen
de context van een complexe voedselmatrix. Het doel van dit PhD project was om kwantitatief
inzicht te krijgen in de gevolgen van dosis-en species-afhankelijke effecten en van
interindividuele verschillen en matrixeffecten voor de bioactivering en detoxificering van
methyleugenol op basis van het gebruik van op de fysiologie gebaseerde kinetische (PBK)
modellering.
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Het eerste hoofdstuk van dit proefschrift presenteert achtergrondinformatie bij het
onderwerp. In hoofdstuk 2 wordt een op de fysiologie gebaseerd kinetisch (PBK) model voor
methyleugenol in rat gedefinieerd op basis van in vitro metabole parameters bepaald met behulp
van incubaties met relevante weefselpreparaten, in silico verkregen verdelingscoëfficiënten
(Payne en Kenny, 2002 en de verwijzing daarnaar), en fysiologische parameters ontleend aan de
literatuur (Brown et al., 1997). Het model is gebaseerd op het eerder ontwikkelde model voor
de qua structuur vergelijkbare alkenylbenzeen estragole en bestaat uit acht compartimenten
waaronder lever, longen en nieren waarin omzetting van methyleugenol plaatsvindt, en
gescheiden compartimenten voor vet, arterieel bloed, veneus bloed, rijk doorbloed en langzaam
doorbloed weefsel (Punt et al., 2008). Evaluatie van het model werd uitgevoerd door
vergelijking van de met het PBK model voorspelde concentratie van methyleugenol in het
veneuze bloed met methyleugenol plasmaspiegels zoals vermeld in de literatuur, en door
vergelijking van het met het PBK model voorspelde percentage van de dosis omgezet naar 2-
hydroxy-4,5-dimethoxyallylbenzene, 3-hydroxy-4-methoxyallylbenzene en 1'-glucuronide
hydroxymethyleugenol met de overeenkomstige percentages van metabolieten in urine zoals
vermeld in de literatuur (Solheim en Scheline, 1976), die dezelfde orde van grootte hadden. Met
het verkregen model werd vervolgens de relatieve omvang van bioactivering en detoxificering
van methyleugenol bij verschillende orale doses onderzocht. Vorming van 3-(3,4-
dimethoxyfenyl)-2-propen-1-ol en methyleugenol-2',3'-oxide bij lage doses, leidt tot
detoxifcering en blijken belangrijke metabolische routes, die zich in de lever voordoen. Bij
hoge doses laat het model in de lever een relatieve toename zien van de vorming van de
proximale carcinogene metaboliet 1'-hydroxymethyleugenol  Deze relatieve toename in de
vorming van 1'-hydroxymethyleugenol leidt tot een relatieve toename in de vorming van 1'-
hydroxymethyleugenol glucuronide, 1'-oxomethyleugenol en 1'-sulfooxymethyleugenol,
waarbij de laatstgenoemde de uiteindelijke carcinogene metaboliet van methyleugenol blijkt te
zijn. Deze resultaten geven aan dat het relatieve belang van verschillende metabole routes van
methyleugenol kan variëren op een dosisafhankelijke manier, wat leidt tot een relatieve
toename in bioactivering van methyleugenol bij hogere doses.
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In de daaropvolgende studies, beschreven in hoofdstuk 3, werd een op de fysiologie
gebaseerd  kinetisch (PBK) model voor methyleugenol in de mens ontwikkeld gebaseerd op in
vitro en in silico bepaalde parameters en het eerder ontwikkelde model voor de gerelateerde
alkenylbenzeen estragole. Het model bestaat uit zes compartimenten waaronder lever als
metaboliserend compartiment en aparte compartimenten voor vet, arterieel bloed, veneus bloed,
rijk doorbloed en langzaam doorbloed weefsel (Punt et al., 2009). Met het verkregen model
konden bioactivering en detoxificering van methyleugenol in verschillende dosesniveaus
worden onderzocht. De resultaten van dit menselijk model werden vergeleken met die van het
PBK model voor methyleugenol in de mannelijke rat. De verkregen resultaten tonen aan dat de
vorming van 1'-hydroxymethyleugenol glucuronide een belangrijke metabole route is in de
mannelijke rat  maar een relatief onbelangrijke metabole route in de menselijke lever, terwijl in
de menselijke lever een significant hogere vorming van 1'-oxomethyleugenol is gevonden,
vergeleken met de mannelijke rattenlever. Ondanks dit verschil bleek de vorming van 1'-
sulfooxymethyleugenol, dat een reactief carbo-kation en DNA- of eiwitadducten kan vormen,
hetzelfde te zijn in de lever van de mens en de mannelijke rat bij orale doses van 0.0034 tot 300
mg/(kg lichaamsgewicht). Ten slotte werd geconcludeerd dat, ondanks een significant verschil
in vooral de metabole routes van de proximale carcinogene metaboliet 1'-
hydroxymethyleugenol tussen de mens en de mannelijke rat,  de invloed van soortverschillen op
de uiteindelijke totale bioactivering van methyleugenol naar 1'-sulfooxymethyleugenol te
verwaarlozen lijkt. Bovendien voorspelde het PBK-model  dat de vorming van 1'-
sulfooxymethyleugenol in de lever van mens en rat lineair zou zijn bij doses zo hoog als de
zogenoemde Benchmarck Dose 10 (BMD10), die 10% extra tumor incidentie geef, tot een dosis
zo laag als de virtuele veilige dosis (VSD), de dosis die leidt tot 1 extra geval van kanker op 1
miljoen bij levenslange blootstelling. Dit toont aan dat de kinetische gegevens geen argument
zijn tegen lineaire extrapolatie van de rattumorgegevens naar de menselijke situatie.
Een ander doel van het huidige promotieonderzoek was het bestuderen van het effect van
het basilicumbestanddeel nevadensin op de bioactivering en genotoxiciteit van methyleugenol.
De resultaten in hoofdstuk 4 tonen aan dat nevadensin DNA-adductvorming kan onderdrukken
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in HepG2 cellen die zijn blootgesteld aan het proximale carcinogeen 1'-hydroxymethyleugenol
en deze flavonoïde. Deze remming treedt op op het niveau van sulfotransferase (SULT)
gemedieerde bioactivering van 1'-hydroxymethyleugenol. Om mogelijke in vivo implicaties te
onderzoeken werd de SULT remming door nevadensin geïntegreerd in de mannelijke rat en
menselijke PBK modellen voor bioactivering en detoxificering van methyleugenol. De aldus
verkregen resultaten tonen aan dat gelijktijdige toediening van methyleugenol met nevadensin
de niveaus van bioactivering van 1'-hydroxymethyleugenol naar de DNA reactieve metaboliet
kunnen verminderen, zonder verminderde detoxificering via glucuronidering of oxidatie. Dit
effect kan aanzienlijk zijn, zelfs bij realistische lage dosisblootstelling bij de mens. De
resultaten wijzen op een potentiële vermindering van het risico op kanker wanneer
methyleugenol blootstelling plaatsvindt door orale inname binnen een relevante voedingsmatrix
die SULT remmers bevat in vergelijking met wat wordt gevonden in knaagdier bioassays bij
blootstelling aan pure methyleugenol toegediend door gavage.
Naast dosis-afhankelijke effecten, effecten door soortverschillen en matrixeffecten op de
bioactivering van methyleugenol, werd in hoofdstuk 5 de invloed onderzocht van inter-
individuele variatie in methyleugenol detoxificering en bioactivering. Om dat te onderzoeken
voorspelden we het niveau van vorming van de uiteindelijke kankerverwekkende metaboliet 1'-
sulfooxymethyleugenol in de menselijke populatie rekening houdend met de variabiliteit in de
belangrijkste bioactivering- en detoxificeringreacties met behulp van Monte Carlo simulaties.
Inzicht in de variatie in relevante metabole routes werd verkregen door de kinetische constanten
te bepalen voor de metabole reacties door specifieke isoenzymen of door meting van de
kinetische constanten in incubaties met een reeks individuele menselijke leverpreparaten. De
resultaten van de studie geven aan dat vorming van 1'-sulfooxymethyleugenol hoofdzakelijk
beïnvloed wordt door i) P450 1A2 gekatalyseerde bioactivering van methyleugenol naar 1'-
hydroxymethyleugenol, ii) P450 2B6 gekatalyseerde epoxidatie van methyleugenol en iii) de
schijnbare kinetische constanten voor detoxificering van 1 '-hydroxymethyleugenol via oxidatie
en iv) de schijnbare kinetische constanten voor bioactivering van 1'-hydroxymethyleugenol naar
1'-sulfooxymethyleugenol. Uit de Monte Carlo-simulatie kon een stof-specifieke correctiefactor
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(CSAF) voor intraspecies variatie worden afgeleid die wordt gedefinieerd als het 95e of 99e
percentiel gedeeld door het 50e percentiel van de voorspelde verdeling van de vorming van 1'-
sulfooxymethyleugenol in de lever. De verkregen CSAF-waarde op het 95e percentiel was 3.7,
wat aangeeft dat de standaard onzekerheidsfactor van 3.16 voor menselijke variabiliteit in
kinetiek (WHO, 1999) 95% van de bevolking afdoende kan beschermen. Voor bescherming van
99% van de bevolking is een grotere onzekerheidsfactor van 5.8 vereist.
Al met al laten de resultaten, beschreven in dit proefschrift,  zien dat de integratie van in-
vitro metabole parameters binnen een kader van een PBK-model een goede methode biedt om
het optreden van dosis-afhankelijke effecten, soortverschillen, en menselijke variabiliteit in
detoxicifiering en bioactivering van een genotoxisch carcinogeen te evalueren . Bovendien laten
de resultaten, gepresenteerd in dit proefschrift, de mogelijkheid zien van de beschermende
effecten van het basilicumbestanddeel nevadensin op SULT gekatalyseerde bioactivering en
DNA-adductvorming van methyleugenol in vitro. Bij het valideren van deze effecten in vivo,
zou kunnen blijken dat carcinogeniteitgegevens van methyleugenol verkregen in
knaagdierstudies met pure methyleugenol, de risico's bij de mens die wordt blootgesteld aan
methyleugenol binnen een voedsel matrix met nevadensin aanzienlijk overschatten.
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Abbreviations
SCF, Scientific Committee on Food
FEMA, Flavor and Extract Manufacturers Association
NTP, National Toxicology Program
PBK, physiologically based kinetic
ME, methyleugenol
1′HME, 1′-hydroxymethyleugenol
3DMPOH, 3-(3,4-dimethoxyphenyl)-2-propen-1-ol
2HDME, 2-hydroxy-4,5-dimethoxyallylbenzene
MEO, methyleugenol-2′,3′-oxide
1EU, eugenol
3HMA, 3-hydroxy-4-methoxyallylbenzene
1′HMEG, 1′ -hydroxymethyleugenol glucuronide
1′HMES, 1′-sulfooxymethyleugenol
1′OME, 1′-oxomethyleugenol
1′OME_mic, 1′-oxomethyleugenol formed by microsomal enzymes
1′OME_cyt, 1′-oxomethyleugenol formed by cytosolic enzymes
GSH, glutathione
GS-1′-oxomethyleugenol, 3′-(glutathione-S-yl)-1′ -oxo-2′-3′-dihydromethyleugenol
NEV, Nevadensin
1′ACME, 1′-acetoxymethyleugenol
ES, estragole
7HC, 7-hydroxycoumarin
7HCS, 7-hydroxycoumarin sulphate
2′dG, 2′-deoxyguanosine
15N5-2′dG,
15N5-2′-deoxyguanosine
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ME-3'-N2-dG, N2-(trans-isomethyleugenol-3′ -yl)-2′-deoxyguanosine
(15N5) ME-3'-N
2-dG, 15N5- labelled N
2-(trans-isomethyleugenol-3′-yl)-2′-deoxyguanosine
E-3′-N2-dG, N2-(trans-isoestragole-3′-yl)-2′-deoxyguanosine
NADPH, reduced β-nicotinamide adenine dinucleotide phosphate
NADP, β-nicotinamide adenine dinucleotide phosphate
NADH, reduced β-nicotinamide adenine dinucleotide
NAD, β-nicotinamide adenine dinucleotide
UDPGA, uridine 5′-diphosphoglucuronic acid
PAPS, 3′-phosphoadenosine-5′-phosphosulfate
DMSO, dimethylsulfoxide
BMD, benchmark dose;
BMDL, lower confidence bound of the benchmark dose
VSD, virtual safe dose
PCP, pentachlorophenol
SULT, sulfotransferase
NMWL, nominal molecular weight limit
L, liver
Lu, lung
K, kidney
GC, gas chromatography
LC, liquid chromatography
MS, mass spectrometry
RT, retention time
hr, hour
min, minute
bw, body weight
Ki, inhibition constant
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